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ABSTRACT 
 
Pancreas and islet transplantation are life-saving treatments for patients with type 1 
diabetes mellitus and intractable hypoglycaemia unawareness. Donated pancreata are 
predominantly derived from deceased donors, most of whom have succumbed to brain 
death. The pancreas and islets are particularly susceptible to damage during donor brain 
death, and early inflammatory changes are compounded by further damage during islet 
isolation and intraportal infusion. The growing prevalence of T1DM and scarcity of the 
organ pool necessitate the development of strategies to minimise inflammatory events 
and improve organ quality and retrieval rates. This thesis spans three separate but 
related studies: evaluating the effects of isolation and anti-inflammatory treatment on 
isolated pancreatic islets, and modulation of inflammation in pancreas from brain-dead 
donors using two different anti-inflammatory approaches, one already established in 
clinical practice and one experimental. For this purpose, we examined isolated porcine 
neonatal cell clusters islets in vitro, and established porcine and murine brain death 
models recapitulating the human condition. 
 
Porcine neonatal islet cell clusters are considered as a potential alternative to human 
islets, and they are extensively utilised in experimental models. Activated protein C is a 
serine protease with cytoprotective, anti-apoptotic and anti-coagulant properties, which 
can attenuate inflammation and potentially protect islets. We hypothesized that rHuAPC 
could exert anti-inflammatory effects on porcine islets in culture, based on the activity 
of rHuAPC on tissues from several other species, and the high level of homology 
between porcine and human protein C and its receptor, EPCR.  We studied islets from 
1-3 day old piglets after isolation during 14 days of culture, measuring inflammatory 
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gene expression. Progressively increased insulin gene expression was evident over this 
period as the NICCs matured. Expression of most proinflammatory mediators increased 
after isolation, peaking around day 4-6 and subsequently declining. The principal 
exception to this pattern occurred for the NKG2D ligands, pMIC2 and pULBP1, whose 
expression remained elevated throughout the duration of culture. Whereas we were able 
to discern an effect of rHuAPC on primary porcine aortic endothelial cells in culture, we 
did not demonstrate an effect of rHuAPC treatment in altering gene expression in 
NICCs.  
 
Cardiovascular, metabolic and inflammatory consequences of brain death impact 
negatively upon the quality of donor organs and upon the outcomes of subsequent 
transplant procedures. Novel donor management strategies are being employed to 
support donor haemodynamic status and cellular metabolism and to reduce 
inflammation in donor organs. Replacement of essential hormones including 
triiodothyronine, insulin, vasopressin and corticosteroids can maintain the physiological 
status. We tested the effects of this hormone cocktail on pancreatic function and 
inflammation in an established porcine model of brain death. Monitoring of the animals 
revealed that physiological indices such as haemodynamic status, organ perfusion and 
function were substantially improved by hormone resuscitation compared with those in 
the control group receiving conventional pressor support with noradrenaline.  
 
The pattern of gene expression for a number of inflammatory mediators was evaluated 
in whole pancreas specimens – these genes included danger signals, pattern recognition 
receptors, cytokines, chemokines and stress ligands downstream of TLR signalling, as 
well as the protective molecule A20. Expression of pro-inflammatory markers was, in 
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general, upregulated in pigs receiving noradrenaline, whereas expression of these genes 
either showed a more limited increase or was downregulated in the HR group. Insulin 
gene and protein expression levels were evaluated in the pancreas. Noradrenaline 
treatment upregulated insulin mRNA transcription, yet the islet insulin protein content 
decreased from baseline levels, HR maintained insulin content close to normal, despite 
downregulation of mRNA transcription. We used TUNEL and the activity of cleaved 
caspase-3 to evaluate the level of apoptosis in porcine pancreas after BD. The TUNEL 
technique resulted in overestimation of apoptotic cells when the outcomes were 
compared to c-casp3, indicating that TUNEL might not be an ideal technique for 
apoptosis detection in pancreas. 
 
Engagement of pattern-recognition receptors by Damage Associated Molecular Patterns 
(DAMPs or danger signals) released during brain death results in the expression of 
various proinflammatory mediators and the propagation of organ damage. esRAGE is a 
naturally-occuring soluble isoform of RAGE, which is able to attenuate inflammation 
by competitively binding to RAGE ligands such as HMGB1 and S100B, thus 
preventing ligation of their receptors TLR2, TLR4, TLR9 and RAGE and also by 
preventing the formation of RAGE homodimers at the cell surface – a prerequisite for 
RAGE signal transduction. To evaluate the effects of systemic esRAGE over-expression 
upon pancreatic function and inflammation in brain-dead mice, we transduced mice 
with an rAAV2/8 vector encoding esRAGE. esRAGE gene delivery to the mouse liver 
yielded high levels of esRAGE in the serum and transplantable organs. BD induction 
resulted in a systemic inflammatory state, characterised by increased serum levels of the 
DAMPs HMGB1 and S100B and of a number of pro-inflammatory cytokines and 
chemokines including TNFα, IL-6, MCP1 and KC. Gene expression in the pancreas 
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was also increased for these proinflammatory cytokines and chemokines, and was 
modestly reduced by esRAGE overexpression. 
 
Only the early stages of neutrophil migration into the pancreas were apparent during the 
three-hour observation period following the induction of brain death. Neutrophil 
margination was elevated in the pancreas of BD mice, and was attenuated in BD mice 
transduced with esRAGE. Expression of the stress ligand RAE-1 was increased in the 
pancreas of mice transduced with esRAGE. Whilst this may increase susceptibility of 
the pancreatic parenchyma to attack by NK cells and CD8+ T cells following 
transplantation, this tendency may be counterbalanced by the inhibitory effects of 
RAGE blockade on activated and memory T cells.  
 
Overall, the most promising of these interventions appears to be hormone resuscitation 
of the brain-dead donor, a management protocol which is already in clinical use. 
However, further evaluation of the effects of HR and of esRAGE expression after islet 
isolation and allotransplantation will be necessary to fully understand the potential of 
these treatments to improve transplant outcomes.  
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CHAPTER 1  
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
1.1 Deceased donor organ transplantation 
 
For many medical conditions, organ transplantation is the ideal, and sometimes the 
only, available treatment. In Australia, in 2013, the total number of organ donors (DBD 
and DCD) was 354. A total of 1110 organs were transplanted into 1053 recipients [1], 
comprising 607 kidneys, 230 livers, 144 lungs, 72 hearts, 38 pancreata and 4 pancreatic 
islet grafts. Nonetheless, by the end of 2012, 1605 patients remained on the waiting list. 
Some of the procured organs are deemed unsuitable for transplantation, including up to 
50% of the retrieved pancreata [2]. Strategies to improve the quality of donated organs 
are urgently needed so that this scarce resource can be fully utilised. 
 
1.2 Indications for pancreas and islet transplantation 
 
Diabetes Mellitus 
Diabetes Mellitus is a disturbance of carbohydrate metabolism induced by relative or 
absolute deficiency of insulin, or resistance to its actions, with many short-term and 
long-term complications. Diabetes mellitus and its vast medical, social and financial 
implications represent a huge and growing burden, affecting 347 million people 
worldwide [3]. High blood glucose is directly or indirectly responsible for 6% of deaths 
globally. In 2004, an estimated 3.4 million people died from consequences of diabetes 
mellitus [4, 5].  Increasing global overweight and obesity presages a global diabetes 
epidemic, with countless complications [6]. 
 
Type 1 diabetes mellitus (T1DM)  
The prevalence of type I diabetes mellitus is 0.2-0.5 % worldwide [7]. The onset is 
usually before age 30. T1DM is considered an autoimmune disease due to increased 
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frequency of auto-antibodies to islet cells. Patients usually have a lean body structure 
and are prone to ketosis caused by severe lack of insulin production. However, in 
children and young adults, obesity increases the rate of progression to T1DM in 
susceptible individuals [6, 8][9, 10] 
 
Type 2 diabetes mellitus (T2DM) 
T2DM has a prevalence of 2-4% worldwide and comprises 85-95% of all diabetes [11], 
the rest being T1DM and gestational diabetes. It is characterized by a combination of 
resistance to insulin action and inadequate compensatory insulin secretory response. 
The body build is usually overweight or obese, and patients are resistant to ketosis with 
high, normal or low levels of insulin. 
 
Complications of diabetes 
Short-term complications of diabetes and its treatment include hypoglycaemia, 
ketoacidosis, and infections. Hypoglycaemia is one of the most dangerous of these 
conditions and can result in permanent brain damage and death. Long-term 
complications (end organ damage) are divided into microvascular complications 
(retinopathy, nephropathy, peripheral and autonomic neuropathy) and macrovascular 
complications (affecting the peripheral, cerebral and cardiac vessels). 
 
Shortcomings of exogenous insulin therapy 
T1DM, a fatal disease, was transformed to a treatable condition with the introduction of 
commercially-produced insulin. Apart from a strict diet and healthy lifestyle, the 
conventional treatment for T1DM is exogenous insulin. As a result, the acute form of 
the disease is rarely lethal in those countries where exogenous insulin is accessible [4, 
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12, 13]. However, the main shortcoming of insulin treatment is that it cannot restore the 
complex balance of normal glucose homeostasis; this balance involves strict minute-to-
minute feedback between blood glucose levels and insulin secretion from the islet beta 
cells, along with other paracrine activities of islets, secreting glucagon and 
somatostatin. Therefore, despite maintaining the blood glucose level within normal 
limits, insulin therapy doesn’t react to the constant blood glucose fluctuations [12]. 
Intensive insulin therapy has been shown to improve long-term complications; 
however, a 3-fold increase in the risk of serious hypoglycaemic periods causing 
seizures and coma has been the cost of improved control [13, 14]. Additionally, the 
current insulin treatment schedules are demanding and difficult to maintain for this life-
long condition. Restoration of endogenous insulin production that responds to the 
physiologic changes in glucose levels would fundamentally change the treatment of 
diabetes. Currently, whole pancreas transplantation and isolated islet transplantation are 
the dominant sources of clinical β-cell replacement [14, 15].   
 
Pancreas and islet transplant: milestones 
The first clinical transplantation of pancreatic tissue was performed in 1893 by Watson-
Williams and Harsant. They transplanted 3 pieces of a freshly slaughtered sheep’s 
pancreas into the thigh of a young patient dying from diabetic ketoacidosis. The 
glucose level improved temporarily, but the xenograft failed within 3 days [14]. In 
1921, Best and Banting discovered insulin. Despite records of complications such as 
hypoglycaemic insulin reactions since 1923, insulin remained the only treatment for 
T1DM until the 1970s. Kelly and Lillehei at the University of Minnesota transplanted 
the first vascularized whole human pancreas in 1966 [16]. The preliminary outcomes 
and survival rates were extremely poor, but from the 1980s onwards, improvements in 
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immunosuppression, surgical techniques, infection prophylaxis and other areas of 
management brought pancreas transplantation from an experimental treatment into 
clinical practice for patients with T1DM [17-19]. Since 1970, >27,000 pancreas 
transplants in the USA and a further >15,000 pancreas transplants worldwide have been 
reported to the International Pancreas Transplant Registry (IPTR) [19, 20].  
 
Paul Lacy in 1967 first showed that the pancreas could be digested with collagenase, 
and that islets could be isolated form the pancreatic digest [21]. Then Ballinger and 
Lacy in 1972 corrected diabetes in an experimental model using islet isografts from 
normal rats implanted under the kidney capsule of streptozotocin-induced diabetic rats 
[22]. Preliminary attempts at islet autografting in humans were undertaken in 1980 
when a series of 10 patients with painful chronic pancreatitis were subjected to islet 
autotransplant [23]. Three patients reached insulin independence for 1, 9 and 38 
months. The retrieved pancreas was digested with collagenase and the digest was 
infused into the patient’s portal vein within two-and-a-half hours of recovery. 
 
Largiader et al in 1980 reported a human case of insulin independence with normal 
glucose levels in an allogenic islet cell transplant recipient 9 months post-transplant 
[24]. The subsequent outcomes of intra-portal islet infusion remained poor, 
contradictory to what was predicted, and despite using conventional 
immunosuppression, insulin independence at 1 year was less than 10% [14]. In 1992 
Pyzdrowski reported that 265,000 islets were sufficient to achieve insulin independence 
[25]. A major advance in islet cell transplantation occurred in 2000 when the Edmonton 
group successfully treated seven T1DM patients following a glucocorticoid-free 
immunosuppression protocol [26]. The recipients had hypoglycaemia unawareness and 
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received fresh islets from multiple donors infused into their portal vein. The 
immunosuppression regimen consisted of dacluzimab, sirolimus and low dose 
tacrolimus. Other specialised centers have been able to reproduce the Edmonton 
group’s results and achieve high success rates, according to reports from multicentre 
trials sponsored by the Immune Tolerance Network [20]. Approximately 1,085 patients 
have received islet transplantation at 40 international sites since the introduction of the 
Edmonton Protocol in 2000 (752 allografts, 333 autografts), as documented by the 
Collaborative Islet Transplant Registry [27]. 
 
Who should undergo pancreas/ islet transplantation?  
Selecting patients for pancreas or islet transplantation is a complex matter, and a 
variety of factors should be acknowledged in decision making. The severity of 
glycemic complications (hypoglycemia, hyperglycemia, and ketoacidosis) should be 
carefully evaluated. Pre-existence of long-term complications such as retinopathy, 
cardiovascular or renal disease can adversely affect transplant outcome [15, 19]. The 
psychosocial situation of the patient and family needs to be addressed. Severe or 
longstanding illness imposes a great burden, exhausting the patient and family both 
physically, mentally and financially [27]. Patients must fully understand and be 
aware of all the potential risks of the transplant procedure, including those related to 
the long-term immunosuppressive regimen [17, 19]. Islet or pancreas transplantation 
is proposed only when all available approaches to satisfactory diabetes management 
have failed [15].  Finally, it is absolutely crucial for the patient undergoing pancreas 
or islet transplantation to consider blood glucose control and the absence of 
hypoglycemia as their primary therapeutic goal rather than insulin independence 
[15]. 
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Pancreas transplants are performed in patients who need insulin because of T1DM, 
type 2 diabetes mellitus or a total pancreatectomy. Successful pancreas transplant is 
currently the only definitive long-term treatment for T1DM patients that restores 
glycaemic control and prevents the incidence of hypoglycaemic attacks [19, 28]. 
Three categories for pancreas allotransplantation include: simultaneous pancreas-
kidney transplantation (SPK) (the most common type), pancreas after kidney 
transplantation [29] and pancreas transplant alone [30] (mostly in brittle diabetes 
cases) [15]. Insulin-independence rates of up to 85% at one year after transplantation 
have been observed [31]. Pancreas transplantation is generally well-tolerated 
nowadays, with patient survival rates 95% to 98% at one year in all categories (SPK, 
PTA, and PAK) and graft survival rates of at one year over 80% [15, 19].  
 
SPK is defined as the “gold standard” treatment in T1DM patients with end-stage 
renal disease, in the absence of contra-indications. Malignancies, chronic infections, 
insufficient compliance, and severe cardiovascular conditions are contraindications 
for SPK transplantation [32]. 
 
Indications for pancreas transplant alone [30] have been developed by the American 
Diabetes Association: “In the absence of indications for kidney transplantation, 
pancreas transplantation should only be considered a therapy in patients who exhibit 
these three criteria: 1) a history of frequent, acute, and severe metabolic 
complications (hypoglycemia, hyperglycemia, ketoacidosis) requiring medical 
attention; 2) clinical and emotional problems with exogenous insulin therapy that are 
so severe as to be incapacitating; and 3) consistent failure of insulin-based 
management to prevent acute complications [15].” However, the risks of invasive 
surgery, along with the lifelong need for immunosuppressive therapy and its side 
effects [17] have to be considered alongside the medical risks of living with DM.  
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The indications for islet transplantation were established based on international 
agreement, and are very similar to those for pancreas transplant [15, 20]. In the table 
below [15] inclusion and exclusion criteria for islet transplant are listed (Table 1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
 
Table 1.1 Indication (inclusion and exclusion criteria) for pancreatic islet 
transplantation. Ludwig, B., et al., Current Diabetes Reports, 2010 [15]. 
 
 
Uncontrolled hypoglycemic episodes are the most common indication for islet 
transplantation alone. Islet after kidney transplantation is limited to the T1DM patients 
Inclusion criteria Exclusion criteria Relative contraindications 
Diabetes mellitus type 1 
(or complete insulin 
deficiency after 
pancreatectomy) 
Age < 18 year 
 
Age > 70 year 
Diabetes duration < 5 year 
Repeated severe 
hypoglycemic episodes, 
metabolic lability (“brittle 
diabetes”) despite optimal 
therapy 
Remaining C-peptide secretion 
(stimulated C-peptide > 0.5 ng/mL) 
 
Body mass index > 
28 kg/m² 
Malignancy (except for 
nonmelanomatous skin cancers) 
 
Relevant insulin 
resistance (insulin 
requirement > 
0.8 IE/kg body 
weight) 
 
Highly impaired quality of 
life 
 
Untreated proliferative retinopathy 
 
  
Rapid progress of 
complications 
 
Portal hypertension 
 
  
Creatinine clearance > 
40 mL/min 
 
Prohibitive cardiovascular risk 
(myocardial infarction within last 
6 month, ejection fraction < 20%, 
uncontrolled hypertension, 
significant noncorrectable coronary 
artery disease) 
 
Compliance with medical 
management 
 
  Active infections including hepatitis 
B/C, HIV, tuberculosis 
  
Alcohol/drug abuse 
Pregnancy, nursing, intention for 
pregnancy, insufficient contraception 
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with end-stage renal disease who have already undergone kidney transplantation, or 
who have rejected the pancreas after SPK transplantation. The success rate of islet 
transplantation alone depends on rigorous patient selection [15, 19, 33].   
 
1.3 Organ quality and the outcomes of pancreas and islet 
transplantation 
 
1.3.1 Donor characteristics 
 
The outcome of pancreas or islet transplant is highly dependent on donor selection [34]. 
Currently, no “donor test” can reliably foretell the outcome of transplantation; however 
scoring systems have been introduced to categorize potential donors [35]. An ideal 
donor in terms of demographic factors is described as a donation after brain death 
(DBD) donor, between 10 and 40 years of age, with a BMI less than 27.5 kg/m2 and a 
cause of brain death which is traumatic or other than cerebrovascular [36].  Reports 
from International Pancreas Transplant Registry also confirm the importance of donor 
characteristics. Due to the increasing number of extended criteria donors and 
nonrecovery (organs declined after procurement) rates, the Eurotransplant Pancreas 
Advisory Committee introduced the Pre-Procurement-Pancreas-Suitability-Score (P-
PASS), are defined according to donor parameters at the time of reporting. These 
parameters are listed as age, BMI, ICU stay, cardiac arrest, sodium, amylase, lipase, 
and catecholamine dose. Total points range from 9 to 28 [37]. Retrospective studies 
show a 3-fold increase in the chance of nonrecovery, with a score greater than 17 [2]. 
The Pancreas-Donor-Risk-Index (P-DRI) was formulated by reviewing the Scientific 
Registry of Transplant Recipients to determine which factors influencing organ quality 
are predictive for 1-year graft survival [38]. Variables such as sex, age, race, BMI, 
height, cause of death, serum creatinine and donation after circulatory death (DCD) are 
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included, as well as preservation time. The median donor has a P-DRI of 1 and is 
defined as male, 28 years of age, nonblack, BMI of 24kg/m2, with a height of 173 cm, 
DBD with a cause of death other than cerebrovascular, serum creatinine less than 2.5 
mg/dl and 12hr cold ischemia time (CIT). Age above 45 years, BMI higher than 30 
kg/m2 and DCD increase the P-DRI and contribute to higher graft failure risk [39], 
although successful organ procurement from these groups has been reported. Pancreatic 
grafts from DCD donors – currently limited to controlled DCD – have also dramatically 
increased [40]. Analysis of 1000 pancreatic grafts from the UK demonstrates no 
difference between DCD and DBD in the 1-year patient and graft survival [41]. This 
result was confirmed by other centres. Madison, Wisconsin reported 1, 3 and 10-year 
graft survival rates from DCD donors similar to those from brain-dead donors [42]. It is 
of particular importance to avoid accumulation of risk factors in one donor, for 
example a longer organ removal time should be compensated by keeping the cold 
ischemia time as short as possible [36, 43]. 
 
These factors can predict the outcomes of islet procurement as well as pancreas 
transplant. The results of islet isolation can be altered by additional variables. Islets 
from paediatric donors are reportedly more difficult to separate from the exocrine 
components of the pancreas without excessive fragmentation [20]. Higher body mass 
index (BMI) of the donor results in greater islet recovery [44] and pancreatic insulin 
content is increased in donors with an increased body surface area. A damaged-looking 
pancreas has also been correlated with reduced islet isolation rate and graft survival 
[27].  
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1.3.2 Pancreas retrieval and preservation 
 
Pancreas excision requires advanced surgical techniques to keep the organ intact and 
preserve the capsular integrity, which is important for subsequent enzymatic 
digestion [27]. Pancreas procurement in DBD donors is mainly performed using 
either of two methods: rapid dissection in the cold after flush-out [45], or warm 
dissection before cold perfusion [46]. During retrieval and before perfusion the organ 
must be evaluated to decide whether it is transplantable or not [37]. Minimal 
handling is advised to prevent pancreatitis and local injury prior to aortic cross-
clamping [47]. After dissection the pancreas is cooled rapidly with intracellular 
preservation solutions and topical ice, and then transported for whole organ 
transplant or islet isolation. Both standard solutions, University of Wisconsin (UW) 
and histidine-tryptophan-ketoglutarate (HTK) are equally suitable to protect the 
pancreas during transport for islet isolation. However UW has been shown to be 
superior to HTK for whole pancreas preservation [48, 49]. Ideally, cold ischemia 
time should be kept below 6-8 hours [27, 35, 45]. 
 
1.3.3 Ischemia-reperfusion injury 
 
The pancreas is highly sensitive to ischemia [50].  So far, no reliable early markers for 
pancreatic ischemia-reperfusion injury (IRI) have been identified. For instance, serum 
amylase, lipase and C-reactive protein levels do not reflect the severity of pancreatic 
inflammation until several days after transplantation [37]. The major feature of 
pancreatic IRI is microcirculatory impairment and venous thrombosis in the graft 
accounts for the majority of early graft failures [51-53]. Therefore, improving the 
posttransplant blood circulation in the graft has been attempted through administration 
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of nitric oxide [54] or anticoagulants [55] or by preventing neutrophil adhesion [56], 
although none of these approaches has been validated by prospective randomized trials.  
 
Remote ischaemic preconditioning, utilising short occlusion of the lower extremity 
blood flow prior to organ retrieval, has demonstrated promising results in decreasing 
IRI in pancreas grafts [57, 58].  A current randomized controlled trial is now evaluating 
this approach [59]. 
 
1.3.4 Islet isolation 
 
The total number of islets in a human pancreas has been estimated to vary between 3.6–
14.8 million, 1.3-2% of the whole pancreas. Islets vary in size; 75% of the total islet 
volume in humans comprises islets ≥ 100 µm, which constitute less than 20% of the 
total islet number. Most centres with an active clinical islet cell transplant programme 
obtain 300–600,000 islet equivalents (IEQ)/pancreas after isolation, which is about 
50% of the islet tissue content [20, 27].  
 
After retrieval, the organ is transported to the islet isolation facility [27]. Islets are 
particularly susceptible to irreversible ischemic damage. To minimise hypoxia,  
continuously oxygenated perfluorohydrocarbons (PFCs), known for their high oxygen-
solubility coefficients, are being combined with  standard University of Wisconsin 
preservation solution for pancreas which are procured for islet isolation and, this 
seemingly improves islet cell function [20].  
 
Briefly, after retrieval, the pancreas is catheterized and collagenase enzyme is infused 
into the duct to start the digestion process [27]. For human islet isolation, the pancreas 
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is cut into pieces and transferred to a Ricordi chamber along with the enzymatic 
solution, and incubated at 37 °C until the islets are freed from the surrounding exocrine 
tissue, usually for 15-30 min [60-62]. For large or small animals, the organ pieces are 
incubated with enzyme at 37 °C in a water bath [63]. After digestion and washing, the 
digest is purified using either discontinous Ficoll density-gradient centrifugation [20] or 
continuous iodixanol density-gradient centrifugation [64, 65]. The latter has been 
proven to decrease inflammation and also improve efficiency of islet isolation [66]. The 
duration of centrifugation is typically 10 min. Larger islets may be damaged during this 
process, but the medium-sized majority are recovered. Islets are then transferred to 
culture, and maintained for 24 hr before clinical transplantation; or used for further 
research purposes. Culture before use increases islet purification from exocrine tissue, 
may reduce inflammation, boost islet recovery and allow islet or donor manipulation 
[67, 68]. 
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Figure 1.1 Factors contributing to loss of islet grafts. To achieve long-term graft 
function, many aspects of the islet transplant procedure must be optimised, from donor 
management to islet intraportal infusion. Islets in the photo are stained with dithizone. 
Shapiro, J., et al., The review of diabetic studies, 2012 [27]. 
 
 
Instant Blood-Mediated Inflammatory Reaction 
 
Upon infusion into the portal vein, the islets provoke a non-specific inflammatory 
response called instant blood-mediated inflammatory reaction (IBMIR). Direct contact 
of islets with circulating blood initiates the complement and coagulation cascades [69]. 
Tissue factor, along with an array of proinflammatory mediators, including monocyte 
chemotactic protein (MCP)-1, interleukin-8, and macrophage migration inhibitory 
factor (MIF) expressed by isolated islets, activates platelets and complement. Islets 
become trapped within clot and are infiltrated with neutrophils and macrophages within 
15 min of infusion [70]. 
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The clinical success of allotransplantation is inversely correlated with the level of 
proinflammatory mediators expression by islets [71, 72]. Suppression of tissue factor or 
thrombin formation prevents islet damage in vitro [73]. However, in vivo IBMIR is not 
completely abrogated by anticoagulation and can cause portal thrombosis [70]. IBMIR 
destroys most of the infused graft and less than 50% of the islets seed in the liver after 
2 hr [72]. Various clinical reports show that only a small fraction of total infused islets 
engraft and function, causing inferior islet transplant outcomes. Reduction of the 
inflammatory status of islets at the time of intarportal infusion is thus an important 
therapeutic goal. 
 
1.4 Clinical outcomes 
 
1.4.1 What constitutes a successful transplant for the treatment of 
type 1 diabetes mellitus? 
 
A successful pancreas transplant is the only available long-term treatment for T1DM 
that can restore normoglycaemia, prevent hypoglycaemia, arrest progression of, or in 
some instances cure, the secondary complications of diabetes [19]. Developments in 
whole pancreas transplantation techniques, organ retrieval and anti-rejection strategies 
over the past 4 decades have continually improved the outcome of pancreas 
transplantation. Unadjusted patient survival rates have increased significantly to >96% 
at 1 year post-transplant and >80% at 5 years in the three categories (SPK, PTA, and 
PAK) over the last decade [12, 17, 19, 74]. Using insulin independence as the marker 
for graft survival, unadjusted graft survival rates at 1 year were 89% (SPK), 86% [29] 
and 82% [30]. 5 year survival rates are 71% (SPK), 65% [29] and 58% [12, 19, 30, 74]. 
The estimated half-life of a pancreas graft is now 7–14 years. 
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Analysis of transplant outcomes in a large cohort of patients indicates that secondary 
diabetic complications affecting many organs and systems have been improved 
significantly after transplantation [19]. Pancreas transplantation can prolong life [28, 
75], reverse established nephropathy [76] and improve quality of life [77]. 
Improvements in diabetic nephropathy, neuropathy, gastroparesis, retinopathy, 
microvascular and macrovascular disease, cardiac function and sexual function have 
generally been observed [15, 19]. Better control of the levels of HbA1c compared to 
intensive insulin therapy was also reported [78]. However, pancreas transplantation 
requires invasive surgery with considerable attendant morbidity and life-long 
immunosuppression [14, 19].  
 
Many groups believe that to gauge the success of an islet transplant, resolution of life-
threatening hypoglycaemia and HbA1c control are more appropriate outcome measures 
than simply measuring insulin-independence [12]. 
 
Islet transplantation is yet to be perfected; and until achievement of treatment from a 
single donor becomes the norm, it cannot replace pancreas transplantation [27]. 
However, fundamental developments such as refinements to donor selection criteria, 
isolation method and immunosuppression protocols have substanitially improved the 
clinical outcomes of islet transplantation.  
 
Recipients in 10 programs demonstrated graft survival and insulin independence 
comparable to multi-donor rates with single-donor islet infusion [65, 79-87]. The 
current “Edmonton protocol” results in 1-year insulin independence rates of 80%-85% 
[27]. Insulin independence rates of up to 50-70% at 5 years are now being reported 
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from 7 centres following different protocols [65, 81, 88, 89]. O’Connell et al. reported 
the following results on clinical islet transplantation in Australia from 2012 to 2013 
[90]: “islet transplantation can improve outcomes in patients with severe hypoglycemia 
and metabolic instability. Eighty two percent of recipients achieved the primary 
endpoint of absence of hypoglycemia and HbA1c <7%. Interestingly, patients who 
were C-peptide positive but required supplemental insulin had excellent control of their 
diabetes, with equivalent HbA1c to that achieved in patients who were insulin 
independent with similar improvement in hypoglycemia. These outcomes were a 
marked improvement from our originally reported single centre study where 50% of 
recipients were insulin independent and all had returned to insulin within 24 months”. 
The beneficial impact of euglycaemia is in accordance with the results from pancreas 
transplantation [27]. Islet transplantation has been shown to halt micro- and 
macroangiopathic changes, with or without insulin independence [91-93]. Islet 
transplantation slows progression of retinopathy, and improved nerve conduction 
velocity is observed [94, 95]. Further, islet grafting has been shown to arrest 
progression of diabetic nephropathy [95] and improve vascular function [96]. 
 
Nonetheless, without controlled studies to prove the effects of the islet transplantation 
on secondary complications, no definitive conclusions can be established [14, 15]. 
 
1.4.2 Current challenges  
 
Pancreas and islet transplant programmes have expanded vastly over the past two 
decades as a successful treatment for T1DM. Nevertheless, there are a number of 
challenges that should be addressed to render these treatments more accessible and 
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efficient. Overall shortage of donor pancreata and the immunologic factors relating to 
both allo- and autoimmunity are two main issues. 
 
Organ shortage 
Scarcity of donated human pancreata is limiting potential transplantation. Donor 
shortage is exacerbated by underutilization [27, 36, 97]. Identifying potential donors 
[36], improving organ retrieval rates [98] , pancreas procurement from donation-after-
cardiac-death (DCD) donors [37, 51, 98], xenotransplantation [37, 99] and derivation of 
insulin-secreting tissue form stem cells [100, 101] are all strategies which could 
improve the availability of pancreas and islet grafts. 
 
Alternative source: xenotransplantation 
Immense organ shortage necessitates the development of replaceable sources of tissue 
for transplantation. With significant ethical, logistic and safety barriers surrounding 
organ procurement from nonhuman primates, the prospect of utilizing islets from pigs 
represents one possible alternative. Porcine insulin has long been used in T1DM before 
production of recombinant human insulin; structurally they differ by only one amino 
acid. Although the first scientific attempt at pig islet transplant to a human recipient in 
1994 did not restore normoglycaemia, the porcine c-peptide was detectable for more 
than 300 days [102].   
 
Wild-type pig solid organ transplantation (rather than islets or cells) into nonhuman 
primates leads to hyperacute rejection. The naturally-occuring anti-Gal antibodies of 
human and old-world primate recipients detect the galactose-α1,3-galactose (Gal) 
oligosaccharide which is expressed by the porcine vascular endothelium, and 
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immediate activation of complement destroys the graft [103]. Foetal and neonatal 
porcine islets also express Gal, which decreases during maturation. Xenotransplant of 
wild-type porcine islets of any age into the circulation triggers a severe instant blood 
mediated immune reaction (IBMIR), destroying the graft [104]. The IBMIR response to 
islets from GAL knock-out pig appears to be milder [105]. Murine transgenic islets 
over-expressing human CD39, an ectonucleotidase that degrades the platelet agonists 
ATP; also provoked reduced IBMIR and coagulation [106]. Following IBMIR, the 
adaptive immune response to islet xenografts is T cell–mediated. Strategies for 
overcoming the primary obstacles towards islet xenotransplantation include genetic 
engineering of the donor pigs, development of immunosuppressive regimens effective 
against xenoimmunity, immunomodulation/immunoprotection (such as co-
transplantation with other donor/recipient cells) and the use of alternative anatomical 
sites for islet transplant [99, 107]. 
 
Alloimmunity  
The current immunosuppressive regimens are successfully controlling allorejection of 
pancreas or islet grafts, and are also at least partly effective in preventing recurrence of 
autoimmunity. The most encouraging graft survival rates are from regimens with 
tacrolimus and mycophenolate maintenance therapy [27, 97].  
 
This acceptance comes with the great cost of life-long immunosuppression and its 
many side effects. If pancreas or islet transplantation is to be the standard treatment for 
children, or early after diabetes is recognised, and/or xenotransplants are going to 
become reality, immune rejection most probably needs to be addressed by means other 
than pharmacologic immunosuppression.  
 20 
Reducing immunogenicity of the organ is an essential step towards optimized 
engraftment. Donor treatment strategies [51, 98, 108] immunoalteration through the 
expression of protective genes [109, 110] [111], and inflammation reduction [112, 
113], combination of these strategies with therapies aimed at tolerance induction in 
recipients [114] [115, 116] are areas where  the graft can be modulated at multiple 
levels to minimise the immune reaction. Understanding the physiology of the instant 
blood-mediated immune reaction (IBMIR) [117] after  infusion of islets into the portal 
vein, and the mechanisms underlying recurrent autoimmunity against β-cells will also 
facilitate the treatment of T1DM and secondary complications by islet or pancreas 
transplantation [110] [12].  
 
1.5 The innate immune system  
 
Also called natural or native immunity, innate immunity is present in healthy 
individuals and the first system responding to infection or injury. The major 
components of innate immunity are epithelial barriers, phagocytes (macrophages and 
neutrophils), dendritic cells, natural killer cells, the complement system and various 
cytokines and chemokines. Pattern recognition receptors permit the recognition of 
broad families of microbial ligands or endogenous “danger signals” released from 
damaged tissues. In addition to restriction and eradication of infection, innate immunity 
stimulates adaptive responses that will follow, and plays an important role in the 
initiation of tissue repair [118]. 
 
Immunosuppressive regimens have made organ transplantation a reliable effective 
treatment for many end-stage diseases. Allotransplant rejection was initially thought to 
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be entirely mediated by adaptive immunity, yet this does not explain observations such 
as the improved outcome of renal transplantation from living unrelated donors 
compared to brain dead donors, even in the absence of HLA-matching. Based on 
Matzinger’s “danger model” and reports describing immune activation of organs by 
brain-death and ischemia-reperfusion injury, the role of innate immunity in pre and 
post-transplant graft failure was recognised [119, 120]. Early events in brain death 
activate innate immunity and increase the immunogenicity of organs through pattern 
recognition receptor (PRR) signalling, upregulation of proinflammatory and adhesion 
molecules and endothelial/complement/coagulation activation. 
 
1.5.1 Components of innate immunity contributing to the 
outcomes of transplantation 
 
Pattern recognition receptors 
Pattern recognition receptors (PRRs) are essential to the function of the innate immune 
system and include C-type lectin receptors, NOD-like receptors, RIG-like receptors, 
Toll-like receptors and RAGE [121]. Among these, Toll-like receptors and RAGE have 
been implicated in transplant-associated immunity.  
 
A correlation between factors known to be related to organ quality, including brain 
death, ischemia and donor characteristics, and activation of innate immunity and 
subsequently adaptive immunity is established [122]. According to the “danger 
model” [119], various non-nspecific threats arising from pre- and peritransplant events 
(ischemia, brain death, or surgical manipulations) can trigger the innate immune system 
[123]. The molecular mechanisms linking these events with immune reaction are yet to 
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be fully understood, but numerous experimental studies provide solid evidence for the 
involvement of pattern recognition receptors [124].  
 
Toll-like Receptors 
Toll-like receptors (TLRs) are present on the cell surface and in the intracellular 
compartment where microbial components are encountered. TLRs are highly conserved 
across species from Drosophila to humans. Most species posess 10-15 TLRs which are 
expressed by a variety of cell types including epithelial cells, endothelial cells, 
leukocytes, dendritic cells and the parenchymal cells of many organs including 
pancreatic islet cells. They recognise and are activated by families of molecules called 
pathogen-associated molecular patterns (PAMPs) and danger associated molecular 
patterns (DAMPs) [125, 126] (Figure 1.2). DAMPs, alarmins or danger signals are non-
infectious endogenous molecules released by injured tissue [127], namely heat shock 
protein (HSPs), high-mobility group box 1 (HMGB1), hyaloronan, fibrinogen, 
fibronectin, heparan sulphate, surfactant protein A and minimally modified low-density 
lipoprotein (LDL) [127-129]. When engaged by their ligands, TLRs recruit adaptor 
molecules for signal propagation through their Toll/interleukin-1 receptor (TIR) 
domain. Four adaptor molecules are known, amongst these myeloid differentiation 
factor 88 (MyD88) and TIR-domain-containing adaptor inducing interferon-β (TRIF) 
predominate. Accordingly, TLRs signal through two MyD88-dependant and –
independent pathways [130]. In humans, stimulation of all TLRs except TLR3 results 
in signal transduction through the MyD88 pathway. Recruitment of MyD88 activates 
IL-1 receptor-associated kinases (IRAKs) 1, 2 and 4 as well as tumor necrosis factor 
(TNF)-receptor-associated factor 6 (TRAF6). Then, the IRAK-1/TRAF6 complex 
separates from the receptor and binds to TGF-β-activated kinase 1 (TAK1) and TAK1-
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binding proteins, TAB1 and TAB2, at the cell or compartment membrane. While 
IRAK-1 is degraded at the membrane, the complex of TRAF6, TAK1, TAB1, and 
TAB2 is released and forms a large complex with other cytosolic proteins. This 
complex catalyses the synthesis of a Lys 63-linked polyubiquitin chain of TRAF6 and 
subsequently induces TRAF6-mediated activation of TAK1 finally causing NF-κB 
translocation to the nucleus, where it induces the downstream expression of genes 
encoding cytokines, chemokines, co-stimulatory and adhesion molecules, cellular 
membrane proteins and others [130, 131].  TLRs can activate both innate and adaptive 
immunity based on the pathways they signal through, and thus are among the key 
molecular linking the two systems [132]. Depending on the cell type, downstream 
events can differ (Figures 1.3-1.5).  
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Figure 1.2 Immune activation by TLR signalling.  Donor brain death and ischemia as 
acute injuries release DAMPs that initiate TLR signalling on antigen- presenting and 
parenchymal cells. TLR activation results in production of cytokines, chemokines and 
growth factors, dendritic cell maturation and the migration of activated dendritic cells to 
the T cell zone of draining lymph nodes. These events stimulate different cell types, 
results in leukocyte recruitment and activation of the alloimmune response. Graft 
immune activation induces further alloimmunity and promotion of chronic damage and 
dysfunction. Leventhal, J.S., et al., Kidney Int, 2012 [133]. 
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Figure 1.3 Downstream effects of TLR signalling on parenchymal cells. Engagement of 
TLR4 on parenchymal cells activates the MyD88-dependant pathway, leading to production 
of chemokines and recruitment of leukocytes. Expression of stress ligands which bind to the 
activating receptor NKG2D increase the susceptibility of the parenchymal cells to killing by 
CD8+ T cells and NK cells. 
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Figure 1.4 Activation of the endothelium by TLRs and cytokines. Signalling through TLRs 
on the endothelium and on adjacent leucocytes leads to the production of chemokines which 
bind to the endothelial surface. Local expression of chemokines attracts leukocytes, and 
induces the production of cytokines such as TNFα. Adhesion molecules including P/E-
selectins and intercellular adhesion molecule-1 (ICAM-1) are expressed in response to 
cytokine stimulation of the endothelium, and facilitate 
leukocyte arrest, transmigration and tissue infiltration. 
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Figure 1.5 Monocyte and DC maturation and migration in response to TLR signalling. TLR 
engagement on dendritic cells initiates adaptive immunity by upregulating MHC class II 
and co-stimulatory molecules which are important for antigen presentation to naïve T cells , 
and by modulating the expression of chemokine receptors (decreases in CCR6 and increase 
in CCR7), thereby directing the DC to the T cell regions of peripheral lymph nodes where 
antigen presentation can occur. 
 
 
 
 
 
RAGE 
The Receptor for Advanced Glycation Endproducts (RAGE) is a member of the 
immunoglobulin superfamily, encoded in the Class III region of the major 
histocompatability complex. This receptor consists of one V type domain, two C type 
domains, a transmembrane domain, and a cytoplasmic tail. The V domain has two N-
glycosylation sites where most of the extracellular ligands bind. The cytoplasmic tail is 
critical for intracellular signalling [134].  
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This multilagand receptor was initially found to be activated by advanced glycation 
endproducts (AGEs), but other ligands including damage-associated molecular patterns 
(DAMPs) have been discovered subsequently [135]. Based on its multiligand 
recognition, RAGE is now categorised as a pattern-recognition receptor (PRR) [134]. 
 
Many tissue and cell types constitutively express RAGE at low levels; it is found in all 
transplantable organs, but mature lung type-I pneumocytes express it at significantly 
higher levels than other resting cell types. RAGE is related to the pathogenesis of many 
conditions such as cardiovascular disease, diabetic vascular disease, neuronal 
degeneration and cancer [136, 137] and is upregulated at the site of ligand 
accumulation. 
 
Ligands for RAGE are drawn from several large families including the High Mobility 
Group family proteins such as the prototypic HMGB1/amphoterin, members of the 
S100/calgranulin protein family, matrix proteins such as Collagen I and IV, amyloid-
beta peptide, and advanced glycation end products such as carboxymethyllysine (CML-
AGE) [138] [139]. 
 
RAGE shares binding affinity to HMGB1with TLRs 2, and 9. The signal transduced 
following ligation of RAGE by S100/calgranulins or HMGB1 varies depending on the 
cell type. The key mediators propagating the signal are erk1/2 (p44/p42) MAP kinases. 
p38 and SAPK/JNK MAP kinases, rho GTPases, phosphoinositol-3 kinase and the 
JAK/STAT pathway, resulting in nuclear translocation of NF-κB and downstream gene 
upregulation of pro-inflammatory and adhesion molecules [134, 140, 141] [142]. The 
unique effects of RAGE-mediated NF-κB activation can be attributed to its  prolonged 
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time course [138], therefore RAGE can act as a master switch converting a transient 
proinflammatory response into sustained cellular dysfunction, whereby this sustained  
NF-κB activation mediates the crosstalk between innate and adaptive immunity. In 
addition to the NF-κB pathway, RAGE acts as an adhesion receptor for leukocyte 
recruitment, mainly through the β2-integrin Mac-1 [143].  
 
Although the role of RAGE in adaptive immunity is less well elucidated compared to 
that in innate immunity, significant findings have been reported. RAGE-deficient T 
cells in mouse showed impaired proliferative responses in vitro to nominal and 
alloantigens, in parallel with decreased production of IFN-gamma and IL-2. Dendritic 
cells from RAGE-deficient mice did not show impairment in Ag presentation, 
maturation, or migratory capacities [144]; although other studies have suggested that 
RAGE and HMGB1 are necessary for animal and human DC maturation and homing to 
lymph nodes [145]. 
 
RAGE is expressed as a variety of isoforms. Major forms are full-length, membrane-
bound forms (fl-RAGE or mRAGE) and a soluble splice variant including the 
extracellular domain alone named endogenous secretory RAGE (esRAGE). Soluble 
RAGE (sRAGE) may also be produced by enzymatic cleavage of the transmembrane 
receptor by ADAM-10 or MMP-9 [146]. Further isoforms with no binding activity lack 
the N-terminus and the dominant negative form does not have the cytoplasmic tail 
(DN-RAGE) [137]. The various RAGE isoforms have different regulatory effects. 
esRAGE, for instance, is a naturally-occurring decoy receptor that binds to HMGB1, 
S100B as well as AGE and other RAGE ligands. esRAGE is known to mediate 
HMGB1 clearance from the circulation in healthy humans [147]. DN-RAGE 
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suppresses RAGE-mediated signalling, even in cells expressing the full-length form 
[148]. Notably, sRAGE and esRAGE both can intercept the RAGE-ligand interaction 
and thus suppress RAGE response and expression [134]. esRAGE and RAGE can also 
form heterodimers with flRAGE at the cell surface, preventing signal transduction 
which requires homodimerisation and association of the two cytoplasmic tails [149]. 
 
Danger-associated molecular patterns, endogenous danger signals or alarmins  
Danger-associated molecular patterns (DAMPs) are endogenous mediators released 
from injured cells under non-infectious conditions; they provoke leukocyte chemotaxis 
and infiltration and antigen-presenting cell activation as part of innate immune 
signalling. Some such as HMGB1 or HSP72 are stored in distinct anatomical 
compartments within cells, whilst others, including low molecular weight hyaluronic 
acid, fibronectin and byglycan, result from breakdown of extracellular matrix 
components. They can be found in leukocytes, epithelial and endothelial cells, and 
many other cell types. These immunostimulants serve as early warning signals to 
activate the innate and adaptive immune systems [150]. 
 
HMGB1 
One of the best-characterized endogenous alarmins is high mobility group box 1 
(HMGB1). It is a DNA-binding protein which modulates transcription and chromatin 
modelling and is ubiquitously found in the nuclei of all vertebrate cells. It is released 
upon cell injury or necrosis or from activated inflammatory cells, and acts as an 
extracellular immune-signalling molecule [151]. Proinflammatory activity of HMGB1 
through TLR4/TNFα signalling depends on the presence of cysteine at position 106; 
during apoptosis, this residue is oxidised, causing reduced HMGB1 binding affinity 
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with TLR4; hence only HMGB1 released during necrotic death and not apoptosis has 
proinflammatory capabilities [151]. 
 
Other molecules such as ssDNA, LPS, IL-1β and nucleosomes join HMGB1 to shape 
specific complexes which are recognised by TLR9, TLR4, IL-1R and TLR2 
respectively [152, 153]. The inflammatory response provoked by complex structures is 
significantly stronger compared to that of uncomplexed alarmins [154]. HMGB1 is 
known to bind to RAGE and induce inflammatory events. For instance, binding of 
HMGB1 to CpG DNA stimulates augmented cytokine production through joint RAGE 
and TLR9 signalling [155]. The serum level of HMGB1 increases in any severe 
inflammation such as tissue damage or sepsis and can be used as a predictor of 
morbidity in many conditions. Production of IL-1, IL-6, TNFα and macrophage 
inflammatory proteins (MIP1α and MIP1β) is directly mediated by HMGB1 [156]. 
 
S100B 
S100 calcium binding protein B or S100B belongs to the family of S100/calgranulins 
and acts as a ligand for RAGE. It is found at various levels in the cytoplasm and 
nucleus of many cells including dendritic cells, langerhans cells, and mononuclear 
phagocytes, myocardium, renal epithelium, adipocytes, melanocytes and chondrocytes; 
however astroglia of the CNS express it most abundantly [157]. Different organs can 
release S100B into circulation following damage and it is cleared by the kidney [158]. 
Acute brain injury and brain death in particular have shown to increase S100B levels in 
blood, thus it is being employed as a reliable biochemical marker to measure the 
severity and outcome of CNS damage [159, 160].  
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Intracellular S100B is involved in regulation of a number of cellular processes such as 
cell cycle progression, differentiation and cytoskeletal structure; nonetheless it can 
impose detrimental effects at high level [160, 161]. High extracellular levels of S100B 
can stimulate endothelial, vascular smooth muscle cells, monocytes, macrophages and 
T cells through RAGE and induce the production of downstream proinflammatory 
mediators [143, 162, 163], which subsequently causes migration of inflammatory cells 
to the stressed tissue as well as apoptosis [164]. Downstream events of RAGE 
signalling by S100B also include apoptosis induction by elevation of reactive oxygen 
species, cytochrome C release and activation of the caspase cascade [161]. Extensive 
studies have demonstrated the release of S100B from the injured CNS; however the 
source of the circulating S100B in brain dead individuals may include other organs 
undergoing hypoperfusion and damage due to the haemodynamic sequalae of brain 
death. 
 
Cells involved in the innate immunity 
The innate response to injury is executed by a variety of leukocyte subsets. Neutrophils, 
macrophages, natural killer cells (NK cells) and some T cells are the principal 
leukocytes migrating rapidly to the site of injury.   
 
Neutrophils are the cellular defence frontline of the innate immune response to foreign 
bodies or injury. They are recruited from the circulation or bone marrow reserve in 
response to chemoattractants. Interleukin-8, IFN-γ, C5a and leukotriene are the best 
known chemoattractants; E/P-selectin, intercellular adhesion molecule 1 (ICAM1) and 
vascular cell adhesion molecule 1 (VCAM1) expressed on injured vascular 
endothelium are the adhesion molecules that neutrophils bind to, primarily in the 
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postcapillary venules. At the site of injury, neutrophil properties include phagocytosis, 
production of reactive oxygen species (ROS), cytokine secretion, leukotriene synthesis, 
degranulation and bactericidal activity [165-167]. Neutrophils can directly phagocytose 
intruding cells, or detect “danger signals” including PAMPs or DAMPs via their pattern 
recognition receptors (PRRs) such as toll-like receptors (TLRs). Stimulation of TLRs 
initiates downstream immune reactions [168].  
 
When circulating monocytes migrate to the site of inflammation, they differentiate to 
macrophages. These phagocytic cells play an important role in removal of pathogens 
and cellular debris and display a number of functions including antigen internalisation 
and presentation, cytokine production and stimulation of other immune cells [169]. 
Phagocytosis is triggered when macrophages encounter opsonised microbes or their 
PRR recognise microbe–associated molecular patterns (MAMPs). The remnants of 
ingested pathogens are presented as peptide antigens in the context of major 
histocompatibility complex II (MHC II), inducing T cell activation, and thus 
contributing to the development of an adaptive immune response. Macrophages can 
also secrete proinflammatory cytokines and other soluble molecules when directly 
stimulated by pathogens- these include TNF, IL-1, IL-6, IL-12, nitric oxide and 
indoleamine dioxygenase [170, 171]. 
 
Natural killer (NK) cells are important effector lymphocytes which recognise 
“foreignness” by detecting the absence of self-MHC I, in association with activating 
ligands induced by infection or malignant transformation. 
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These activating ligands include UL16-binding proteins 1 (ULBP1), MHC class I 
polypeptide-related sequence A (MICA) and MHC class I polypeptide-related sequence 
B (MICB) in humans, MHC class I-related protein 2 (MIC2) and porcine ULBP1 in 
pigs and retinoic acid early transcript 1 (RAE-1), murine ULBP-Like transcript 1 
(MULT1) and histocompatibility 60 (H60) in mice. In common with macrophages, NK 
cells express Fc receptors including CD16 and CD 32 which trigger their activation and 
causing killing of target cells that have been coated with antibody (antibody-dependant 
cellular cytotoxicity). Target cells are destroyed by NK cells in two ways. The first is 
via the release of proteins called perforins, which form pores, so proteolytic enzymes 
called granzymes, pass into the target and induce apoptosis [172]. Alternatively the NK 
cell’s Fas ligand (FasL) binds to Fas on the target cell ultimately causing the activation 
of caspases leading to apoptosis [173]. 
 
Additionally, NK cells secrete a variety of mediators, including proinflammatory 
cytokines, chemokines, colony-stimulating factors, and other molecules functioning as 
regulators of body defenses. NK cells regulate the activity of other immune cells 
through cytokine production and cell-cell contact [174]. 
 
T cells are mainly considered as components of adaptive immunity; however both 
CD4+ and CD8+ T cells can amplify the activity of the innate immune system. CD4+ T 
cells mainly release proinflammatory cytokines, whereas CD8+ T cells, also known as 
cytotoxic T cells (CTL), can destroy targets by mechanisms similar to those of NK 
cells. The cytokines released by CD4+ T cells such as IFN-γ, IL-2 and IL-15 induce the 
recruitment, activation and proliferation of cytotoxic T cells, NK cells and 
macrophages [175].  
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 Dendritic cells (DCs) are critical for the presentation of cognate antigens to naïve CD4 
T cells and initiation of adaptive immune response. However, dendritic cell activation 
is dependent upon the presence of non-antigen-specific danger signals which are 
required to facilitate and amplify the subsequent adaptive response. Hypoxia and 
oxidative stress activate dendritic cell differentiation and maturation, DCs express 
hypoxia inducible factor-1  (HIF-1 ) and other downstream target genes, such as 
vascular endothelial growth factor or glucose transporter-1, along with CD40, CD80, 
CD86 and increased levels of MHC class II which initiate antigen presentation and T 
cell activation [176]. 
 
1.5.2 Inhibitors of innate immune signalling 
 
A20  
A20 is one the endogenous negative regulators of pattern recognition receptor (PRR) 
signalling. Along with MyD88s (the short form of MyD88), suppressor of cytokine 
signalling 1 (SOCS1), toll-interacting protein (TOLLIP) and cylindromatosis (CYLD), 
these suppress over-or unnecessary stimulation of PRRs including TLRs [177]. A20 
was first discovered in 1990 as a zinc finger protein that is strongly induced by TNFα, 
so called TNFAIP3 (tumor necrosis factor, alpha-induced protein 3), and is capable of 
inhibition of TNF-mediated NF-κB activation [178]. A20 is also crucial for regulation 
of TNF-independent inflammatory signalling [179]. A20 is expressed by many cell 
types, including β cells, emphasizing its potential role in regulation of TLR signalling 
within pancreatic islets. The nuclear NF-κB directly induces A20 when it binds to two 
κB binding sites in the A20 promoter, increasing transcription re-initiation rates and 
subsequent total levels of A20 mRNA [180]. Therefore, in general, by inhibiting NF-
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κB activation, A20 in turn self-regulates its expression. After production, this cysteine  
de-ubiquitinating protease exerts anti-inflammatory effects in several pathways,  
mainly by de-ubiquitination of central molecules such as TRAF6 in TLR4/IL-1 and IL-
17 signalling, RIP1 in TNFα and RIP2 in NOD2 pathways [177]. Both TLR4 ligands, 
LPS and TNF, can induce A20 expression and both MyD88-dependent and MyD88-
independent TLR-signalling pathways are inhibited by A20 activity [181]. 
Macrophages from A20 deficient mice produce considerably higher levels of 
proinflammatory cytokines when stimulated with TLR2, TLR3 and TLR9 ligands [182] 
[179].   
 
A20-deficient mice die prematurely due to spontaneous multi-organ inflammation and 
cachexia, they exhibit defects in resolving acute inflammatory responses and are unable 
to terminate TNF-induced IKK and NF-κB activation; indicating the importance of the 
negative regulatory effect of A20 to whole organism homeostasis.  
 
Studying mouse pancreatic islets revealed the crucial role of A20 activity in the islet 
response to inflammation and injury. Loss of A20 expression renders β-cells 
susceptible to apoptotic death; whereas enhancing A20 expression could improve the 
survival of islets exposed to traumatic conditions [183, 184].  
 
Activated Protein C (APC) 
Protein C which was first isolated from bovine plasma by Stenflo [185], is a serine 
proteinase synthesized by liver, endothelial cells, leukocytes, and keratinocytes. The 
most overt function of protein C is as an endogenous anti-coagulant. Severe protein C 
deficiency is characterised by massive, usually lethal, thrombotic complications 
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occurring in infancy. Adults heterozygous for protein C deficiency manifest a 
significantly increased risk for venous thrombosis [186]. When activated, APC exhibits 
a repertoire of additional physiological effects including cytoprotective (mainly through 
its receptor EPCR), anti-inflammatory, anti-apoptotic (via EPCR and protease-activated 
receptor-1, PAR-1) and pro-angiogenic functions (via matrix metalloproteinase 
activation), endothelial barrier protection (via induction of sphingosine kinase-1 
(SpK1), and upregulation of sphingosine-1-phosphate (S1P) formation via SpK1)[187-
192]. 
 
Protein C is activated by the thrombin-thrombomodulin complex when it is bound to its 
cell surface ligand, endothelial protein C receptor (EPCR). EPCR augments thrombin-
thrombomodulin- dependent PC activation by about almost 10-fold, with the same 
affinity for both PC and APC [189, 193]. This receptor mediates the pleiotropic 
cytoprotective effects of APC on cells through PAR1 signalling (Figure 1.6). EPCR has 
been detected on endothelial cells, keratinocytes, monocytes CD56+ NK cells, 
neutrophils, eosinophils,  tenocytes and other cell types [192], EPCR gene transcription 
can be upregulated by APC and inflammatory cytokines such as TNFα and IL-1β 
[194].  APC can modulate pathways of inflammation and apoptosis, with the general 
effect of down-regulation of proinflammatory and proapoptotic pathways and up-
regulation of anti-inflammatory and anti-apoptotic pathways. APC blocks expression of 
TNFα, suppresses NF-κB nuclear translocation, and subsequently the transcription of 
downstream proinflammatory genes [188, 191]. However, APC has also been observed 
to upregulate expression of the chemokines MCP1 and IL-8, and cytokine IL-6 [195, 
196].  
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Matrix metalloproteinase-2 (MMP-2) is resistant to cleavage by most enzymes, but 
APC has been shown to selectively upregulate both gene and protein expression of 
MMP-2 and directly cleave and activate the proenzyme to its mature form. Protein C 
and matrix-metalloproteinase 2 activity are thus closely linked [197]. 
 
According to in vivo studies, leukocyte recruitment can be blocked by exogenous APC 
in various inflammatory conditions [198, 199].  Recombinant human APC inhibited 
TNF-induction of cell surface adhesion molecules such as VCAM-1, ICAM-1, 
selectins, through regulatory effect on the NF-κB pathway [188]. Xue et al. 
demonstrated that APC can promote angiogenesis in human skin and wound healing in 
mice as well as the development of healing phenotype in cultured tenocytes [200, 201].   
 
Stimulation of endothelial cell proliferation and angiogenesis by APC through 
activating MAP kinase pathway mediated by EPCR and PAR-1 signalling is also 
reported in vitro and in vivo [9]. 
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Figure 1.6 Activation of protein C and activity pathways. (A) In the presence of 
thrombomodulin (TM) and endothelial cell protein C receptor (EPCR), protein C is 
activated by thrombin (IIa). The anticoagulant activity is exerted when APC is 
detached from its receptor (B). If APC remains bound to EPCR, multiple effects on 
cellular functions follow (C). (B) Anticoagulant activity is induced at cell surfaces 
by cleavage and deactivation of the activated cofactors Va (FVa) and VIIIa (FVIIIa) 
to, FVi and FVIIIi. (C) Pleiotropic cytoprotective effects of APC are transduced 
through the cellular receptors EPCR and PAR-1. These activities include modulation 
of gene expression, anti-inflammatory and anti-apoptotic activities and protection of 
endothelial barrier functions. Griffin, J. H., et al., Journal of Thrombosis and 
Haemostasis, 2007 [187]. 
 
 
1.5.3 Inflammatory pathways in warm ischemia-reperfusion injury 
 
Extensive animal model studies in heart [202], lung [203], liver [204], kidney [205] and 
pancreatic islets [206] have demonstrated a significant role for TLR4 signalling in the 
pathogenesis of warm ischemia-reperfusion injury (IRI). Although TLR4 absence has a 
general protective effect in ischemia and IRI in all organs, the extent of engagement 
and effect of TLR4 and adaptor molecules vary among tissue and organs. 
HMGB1 is released from hepatocytes after ischemic injury and induces inflammation 
through TLR4 signalling, primarily on non-parenchymal cells [207]. Both mRNA and 
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protein levels of HMGB1 are upregulated in ischemic mouse kidneys [205], but in this 
instance, signalling through TLR4 on renal parenchymal cells is the principal 
contributor to further inflammation and damage. 
 
In several experimental studies, IRI was attenuated by neutralising HMGB1 with 
antibodies. Mouse kidneys were protected from IRI by blocking HMGB1, manifested 
as less tubular damage and apoptosis, less infiltration and lower creatinine level [208]. 
In liver, administration of HMGB1 neutralising antibody led to significantly reduced 
damage after IRI, whereas recombinant HMGB1 treatment exacerbated IRI [209, 210]. 
 
1.6 Brain death 
 
Most organs for transplantation are retrieved from brain dead donors. The scarcity of 
the graft source along with the global detrimental effects of brain death on 
transplantable organs, necessitate expansion of our knowledge of the events 
surrounding brain death at a cellular and molecular level and improved management of 
potential donors.  
 
According to The American Academy of Neurology [211], brain death is the 
irreversible loss of brain and brain stem function, usually due to major haemorrhage, 
hypoxia, or metabolic dysregulation. The diagnosis is confirmed by comprehensive 
neurological evaluation. To establish absence of brain stem reflexes, and apnea under 
standardized conditions. Additional tests like electroencephalography, transcranial 
Duplex-ultrasound, or cerebral angiography, may be performed. Brain death is 
accompanied by complicated sequelae including hemodynamic, hormonal, metabolic, 
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and inflammatory consequences, which all profoundly affect the state of the patient’s 
organs. 
 
1.6.1 Physiological and hormonal changes 
 
Brain stem herniation introduces massive haemodynamic instability, starting with a 
short period of hypertension and bradycardia. These were observed in BD-induced 
Chacma baboon [212], then in small and other large animal models [213, 214]. The 
succeeding event is an explosive release of catecholamines into the circulation, called 
the “catecholamine storm”, which causes a hyperdynamic cardiovascular response 
[215]. Higher heart rate despite increased systemic and pulmonary vascular resistance 
is observed. Brain dead patients manifest increased cardiac indices and initially 
enhanced tissue oxygenation [216]. When serum catecholamines are depleted, 
peripheral vascular tone falls, cardiac output falls rapidly and this may be compounded 
by hypovolaemia. Neurogenic pulmonary oedema may supervene, and all lead to 
cardiovascular collapse [212]. Due to the erratic hemodynamic state, organ perfusion, 
particularly for abdominal organs, is disrupted [217]. The trio of hemodynamic 
changes, compromised organ perfusion and reduced oxygen levels characterize 
established brain death.  
 
BD disturbs the hypothalamic-pituitary axis. Loss of vassopresin, [anti-diuretic 
hormone (ADH)] from the posterior pituitary gland causes diabetes insipidus which 
worsens hypovolemia. Decreased Thyroid-stimulating hormone (TSH) and 
adrenocorticotropic hormone, ACTH from the anterior pituitary gland dampens 
circulating levels of thyroid hormones and corticosteroids, which contribute to 
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increased hypovolemia and acidosis, as well as triggering immune responses and 
general inflammation [215].  
 
Ischemia affects cell metabolism at different levels including disturbed cellular ionic 
gradients, increased calcium concentration and activation of numerous phospholipases, 
leading to degradation of cell membranes [219]. Depending on the intensity of damage, 
oxidative stress is induced by uncoupling of the respiratory chain in the inner 
mitochondria membrane after accumulation of free fatty acids [50]. Inhibition of 
oxidative phosphorylation can result in cell death due to ATP depletion and lack of 
energy. A shift from aerobic to anaerobic metabolism can be clinically manifested as 
high levels of circulating free fatty acids and lactate, lower insulin secretion and 
hyperglycaemia [220, 221].  
 
1.6.2 Proinflammatory states accompanying brain death 
 
Brain death constitutes a systemic inflammatory state. This state is the result of a 
complex interaction between the immune system, vascular endothelium, complement 
and coagulation systems. Preliminary studies, particularly those in small animal 
models, revealed a general increase in cytokines such as IL-6, IL-1β, TNFα and IFN-γ 
in the circulation early after BD induction [213] [In some human studies, only systemic 
IL-6 and TNFα increased in circulation [222]]. Gene expression for these molecules is 
also upregulated in the transplantable organs; with each ogan manifesting a slightly 
different pattern of gene expression [223].  
 
Activation of the vascular endothelium occurs after BD [224], with the expression of 
adhesion molecules, such as P-/E-selectins, intercellular adhesion molecule (ICAM)-1 
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and vascular cell adhesion molecule (VCAM)-1, and of chemokines such as monocyte 
chemoattractant protein (MCP)-1, and this combination results in cellular infiltration in 
all transplantable organs [225, 226]. The infiltrating leukocytes are activated, and 
secrete proinflammatory chemokines such as TNFα and IFN-γ, which induce the 
upregulation of major histocompatibility complex (MHC) class I and II on parenchymal 
cells. This event is associated with increased organ immunogenicity and affects 
transplant outcomes through the T-cell recognition process [227].  
 
The complement system is also activated as a consequence of brain death. Increase in 
complement C3 synthesis, C3a serum level, and also complement deposition were 
observed, adversely affecting the engraftment of kidney and heart transplants [228, 
229]. 
 
Coagulation pathways are triggered after BD. The extrinsic pathway is initiated by 
release of thromboplastin from tissues with promotion of fibrin clotting. Platelets are 
activated through contact with damaged endothelium and release coagulation factors 
and inflammatory molecules [230].  
 
In a porcine model, HMGB1 migration from the nucleus to cytoplasm, a precursor to 
release from the cells, expression was noted in liver early after BD induction, TLR4 but 
not TLR2 expression was upregulated in both liver and kidney [231]. 
 
Epithelial and gut barrier dysfunction is induced by elevated levels of HMGB1, leading 
to increased bacterial translocation to mesenteric lymph nodes [232]. Furthermore, 
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following endotoxaemia induced by brain death the HMGB1-LPS complex can form an 
extremely potent ligand for TLR4 signalling [233].  
 
In summary, brain death and its severe physiological and metabolic consequences can 
induce the release of proinflammatory mediators. Inflammation increases the 
immunologic activity of transplantable organs and renders tissues more detectable by 
the host’s immune system. Histological damage, inferior function, and lower 
engraftment in comparison with organs from living donors are transplant-related 
outcomes of such a catastrophe [227, 234, 235]. Variability in the extent of 
inflammatory changes has been reported in different studies- in general, greater degrees 
of haemodynamic instability are correlated with more significant increases in 
proinflammatory mediators within the transplantable organs suggesting that donor 
management protocols which optimise haemodynamic parameters could attenuate graft 
inflammation [236-239]. 
 
1.6.3 Endotoxaemia in BD donors 
 
Endotoxin is a lipopolysaccharide produced from the cell wall of Gram-negative 
bacteria. This macromolecule is normally absorbed into the portal circulation and is 
cleared by hepatocytes and/or Kupffer cells. The process of endotoxin clearance can be 
disturbed due to humoral, bacterial or host alterations. When the endotoxin is not 
cleared by the liver, it reaches the systemic circulation and causes endotoxaemia [210].   
 
It is widely known that integrity of the intestinal barrier may be compromised in 
critically ill patients, such as those exposed to trauma, burns, shock, etc. [240]. The gut 
response to a major trauma like brain death induces an intestinal cytokine response 
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[241], increased intestinal permeability [242], and translocation of intestinal bacteria 
and endotoxin [243], causing systemic inflammatory response syndrome (SIRS) and 
sepsis [244]. 
 
BD contributes to high systemic endotoxin levels through several different pathways. 
Liver damage and Kupffer cell exhaustion following BD can interrupt the clearance 
and promote endotoxaemia [245]. Moreover, the damage to gut’s structure and barrier 
function can happen early after BD induction [246] [244] and is manifested by 
upregulation of the adhesion molecules ICAM-1, VCAM-1, and E-selectin, infiltration 
of leukocytes, and apoptosis in duodenum and jejunum. As a result, inflammation 
promotes intestinal permeability, which causes bacterial translocation and accelerates 
more systemic cytokine release and cell infiltration, leading to further inflammation 
and immune activation of potential donor organs. Endotoxin is a ligand for TLR4 and 
can contribute to the activation of antigen presenting and parenchymal cells expressing 
this pattern-recognition receptor [246]. As described above, endotoxin signalling is 
amplified when endotoxin binds to the HMGB1 released from damaged tissues 
following brain death. In liver transplantation the level of endotoxaemia is inversely 
correlated with graft outcome [210]. 
 
 
 
1.6.4 Role of TLRs in experimental islet transplantation 
 
β cell death is induced by TLR4 signalling.  Islet isolation and transplantation have 
been shown to increase TLR4 expression which adversely affects transplant outcomes. 
Allogeneic islets from TLR4−/− mice injected into the renal subcapsular space 
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exhibited reduced inflammatory signals, increased presence of regulatory T cells and 
indefinite graft survival. TLR4 suppression with blocking treatments led to similar 
results [247, 248]. 
 
In other studies utilizing a mouse model of islet transplant under the kidney capsule, 
inflammation in the graft was mediated by both TLR2 and TLR4 and related to early 
graft dysfunction, the absence of TLR4, NF-kB activation and graft dysfunction were 
prevented [206].  
 
These findings were confirmed in mice receiving intraportal islet infusion. Following 
transplant of TLR4−/− islets, the immune response in liver with the engrafted islets in 
the measured by proinflammatory cytokines, HMGB1 expression, NF-κB activation, 
caspase-3 and TUNEL positive cells, was dramatically suppressed compared to the 
grafts from wild type animals, concomitant with a prolonged graft survival. HMGB1-
mediated stimulation of TLR4, TLR2 and RAGE was inhibited by administration of 
anti-HMGB1 antibody in mouse recipients. By blocking the circulating and tissue 
HMGB1, production of TNFα, L-1ß and IFN-γ (by NK cells and Gr-1+CD11b+ cells) 
were suppressed and massive early islet graft loss was halted, which led to improved 
islet graft viability [249] [250]. Reports suggest that serum HMGB1 levels can be a 
useful clinical biomarker to evaluate islet damage [251]. These studies suggest that 
inhibition of TLR4 signalling represents a novel strategy to attenuate early graft failure 
and preserve graft mass and function. 
 
Nonetheless, another model employing TLR4-KO mice exhibited conflicting outcomes. 
In vitro and in vivo stimulation of TLR4 signalling by LPS increased inflammation and 
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infiltration within the islet graft under the kidney capsule; however no evidence of graft 
survival prolongation was observed when either TLR4 deficient donor or recipient. 
Survival of the MyD88-KO islet allograft was significantly prolonged when recipients 
were treated with anti-CD40L, suggesting that a combination of treatments targeting 
innate and adaptive alloresponses can synergize to prevent graft rejection [252]. 
 
1.6.5 Brain death in clinical solid organ transplantation 
 
Extensive clinical data have demonstrated that donor BD has detrimental effects on 
organ transplant outcomes, in accordance with the findings of experimental 
procedures. In 1995, Terasaki et al. reported that kidney transplants from deceased 
donors have significantly lower survival rates than those from spousal (living 
unrelated) donors, despite the fact that the deceased donor organs were better matched 
than those from spousal donors [253]. The principal factor contributing to the reduced 
survival of kidneys from deceased donors was postulated to be damage due to peri-
mortem events. BD can increase the rate of acute rejection and delayed graft function in 
kidney transplants [254].  
 
Several studies of postreperfusion clinical kidney specimens confirmed triggering of 
inflammation and endothelial activation by BD [255] [256] [257]. Endothelial adhesion 
molecules, (E-selectin, ICAM-1, and VCAM-1) as well as proinflammatory cytokines 
and chemokines such as MCP1, TNFα, INFγ, IL-10 were significantly upregulated in 
these biopsies, comparable to those from kidneys undergoing acute rejection.  In heart 
transplant recipients, expression of IL-6 and TNFα in the graft predicted the 
development of right ventricular failure and heart malfunction [258, 259]. Release of 
sympathomimetic mediators results in increased rates of apoptosis and necrosis in 
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cardiomyocytes [260]. Furthermore, BD can promote chronic allograft vasculopathy, in 
particular explosive/traumatic BD in donors caused inferior graft survival rates and 
increased intimal coronary artery thickening [220, 261, 262].  
 
It was shown by Van Der Hoeven in 1999 that adhesion molecules ICAM-1 and 
VCAM-1 are overexpressed in liver after BD, immunologically activating the organ 
and causing increased leukocyte infiltration [224]. Upregulation of many cytokines and 
chemokines (IL-6, IL-10, macrophage inflammatory protein (MIP)-1, TNFα and IFN-γ 
as well as MHC-II) is observed in transplanted livers from BD donors [234]. Recipients 
of BD donor grafts had more acute rejection episodes compared with recipients of 
grafts from live donors [263]. Increased serum transaminases are detected after liver 
transplantation from BD donors compared with living donors [234], and these grafts are 
subject to a higher rate of primary non-function [264].  
 
1.6.6 Impact of brain death on pancreas and islet transplant 
 
Contreras et al. investigated the effect of brain death on rat pancreas [265]. These 
authors reported increased serum levels of TNFα, IL-1β and IL-6 post BD induction. 
Transcription of these molecules was upregulated in pancreas tissue. Islet recovery, 
viability and functionality (in vitro and after intraportal transplant) were significantly 
reduced in islets isolated from BD pancreatic tissue. Overall, brain death decreased islet 
yields and functionality in rats. 
 
Tissue factor (TF) and monocyte chemoattractant protein-1 (MCP1) expressed by 
isolated islets trigger the instant blood-mediated inflammatory reaction (IBMIR) 
following intraportal infusion [70, 71]. The regulators leading to expression of these 
 49 
molecules by islets are yet to be elucidated. Interestingly, in a rodent model of BD, TF 
and MCP1 gene expression in the pancreatic tissues did not change after BD compared 
to the controls, but freshly isolated islets from the BD group displayed significantly 
higher mRNA expression for these genes than islets isolated from the control group 
[266]. BD may thus be of paramount importance as an initiator of TF and MCP1 
induction in the isolated islets, and as a contributor to islet graft loss through IBMIR. 
 
In one clinical brain death study, TNFα protein levels were higher in BD than in control 
pancreas, but despite systemic inflammation and increases in serum IL-6 and TNFα, 
pancreatic levels of IFN-γ, IL-1β and IL-6 were unchanged by BD [222]. This was the 
first study to detect BD-induced damage to the pancreas before commencement of islet 
isolation and transplantation. TNFα induces apoptosis in β cells through NF-κb 
activation [183], and resultant loss of islet β cells may contribute to reduced yield from 
BD donors.   
 
Similar to findings in rodent models, whole pancreas tissue from BD donors does not 
express tissue factor [222] whereas human isolated islets do [267]. Such differences can 
be explained by the detrimental effects of cold ischemia and the isolation procedure on 
islets compounding the effects of brain death [70, 266].  
 
When islet isolation outcomes were compared in cadaveric versus living donors who 
had pancreatecomy due to trauma or lesion [268], superior results were observed from 
living donors. Islet purity, islet isolation success rate, and equivalent islet numbers 
adjusted by pancreas weight were all significantly higher in the living donors; the islet 
function in vitro was also superior in living compared to BD islets, though this 
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difference did not reach statistical significance. Analysis of human islets post isolation 
showed that they express significantly high mRNA levels of A20 compared to islets 
within the native pancreas. High expression of NF-κB-regulated A20 is consistent with 
the observation that organ preservation and or islet isolation results in activation of NF-
κB [269]. 
 
1.7 Donor management/preconditioning 
 
The great disparity between the pool of available donor organs and the demand for 
these organshas prompted endeavours to increase the organ retrieval rate through 
improved management of potential donors and broadening of the donor eligibility 
criteria [270].  
 
Goals are defined for donor management in order to reach standards. These intend to 
preserve physiology close to normal by maintaining body temperature, adequate 
oxygenation, haemodynamic stability and sufficient urinary output [271]. These 
management protocols may confer additional benefits if they can attenuate 
inflammation in transplantable organs. 
 
Based on a broad understanding of the pathophysiology of brain death, treatment with 
three hormones; T3, cortisol and insulin, was proposed in the 1980s, primarily for 
administration to BD prospective heart donors with suboptimal haemodynamic 
parameters [272]. This application led to a series of experimental and clinical studies. 
In pigs, Novitzky and Cooper showed that treatment with hormones significantly 
restores cardiac output and stroke volume compared to values in control animals [214]; 
in baboons conversion of anaerobic to aerobic metabolism was observed [221]. 21 
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consecutive BD donors were treated with hormones and compared with donors 
receiving traditional therapy including i.v. fluids, inotropes and bicarbonate. The 
treated group showed significantly improved cardiac indices and organ function after 
transplant [273]. A retrospective study of BD donors during 1 year in the United States 
had established the superiority of “hormone resuscitation”, comprising a different three 
agents, methylprednisolone, arginine vasopressin and T3 or T4. Stability of a group of 
“marginal” BD donors was significantly improved and the number of organs retrieved 
and transplanted per donor increased significantly [274]. Some protocols include a 
forth drug, adding insulin to the cocktail.  In a BD pig model case control study where 
the four-drug hormone resuscitation was compared to norepinephrine and regular fluid 
replacement [231], results showed that inotrope requirement was decreased and 
hemodynamic status was significantly improved in the treated animals, supporting HR 
application in the management of the brain-dead donor.  
 
High-dose steroid treatment in BD is now known to suppress the inflammatory 
response [275], prevent hypoxic damage [276] and improve transplant function and 
engraftment [277, 278]. 
 
Overall, hormone resuscitation has been resulted in significant augmentation of 
retrieval rates, reduction of inflammation and improved 1-year graft survival for 
pancreas, kidney, liver, heart and lung [270, 279].  
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1.8 Experimental strategies to reduce graft inflammation  
 
1.8.1 Treatments applied to the donor 
 
Blockade of IL-1 receptor 
IL-1β is highly upregulated early after injury [280] and plays a major role in mediation 
of acute inflammatory responses. Blockade of IL-1 receptor in rhesus macaque donors 
led to suppression of proinflammatory molecule production, improved islet function in 
culture, and most importantly increased engraftment and function after transplantation 
[281]. These finding are in accordance with the effects of IL-1β and TNFα combined 
blockade in in recipients in enhancing the efficacy of clinical islet transplantation and 
achieving single-donor islet transplant [82]. 
 
Anti-thymoglobulin treatment 
Antithymocyte immunoglobulin (ATG), a polyclonal rabbit IgG against human T cells, 
is generally used in recipients. ATG antibodies interrupt leukocyte-endothelium 
interaction and cell migration by modulating expression or binding of mediators such 
as ICAM1 and lymphocyte function-associated antigen 1 (LFA-1), and also by binding 
to the chemokine receptors and thereby blocking their function [282]. ATG can induce 
changes in different lymphocyte cell subsets in blood and promote regulatory T cell 
expansion [283]. Donor treatment with rATG may improve the organ quality. In a rat 
model, rabbit anti-rat thymoglobulin was administered to the brain-dead donors, and 
hearts, lungs and small bowels were harvested. Histological changes including 
neutrophil infiltration and structural damage were studied. The histological injuries 
were significantly lower in the lungs of the rATG-treated group, with a trend towards 
reduction in hearts and intestines as well [283].  
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The immunosuppressive effect of ATG has been attributed to T cell depletion, 
mediated by lymphocyte surface antigen modulation and alterations in the patterns of 
cytokine production, chemotaxis, endocytosis, stimulation, and proliferation [282]. In 
another study of BD in rates by the same group [284], acute tubular necrosis (ATN) 
was significantly attenuated in the rATG-treated group. This effect was overexpression 
of IL-10, inhibiting pro-inflammatory cytokines such as TNFα. These results pave the 
way for further application of ATG in donor cytoprotective strategies to improve organ 
viability. 
 
Antibodies against selectin 
Selectin molecules are among the inflammatory mediators induced early after brain 
injury and subsequent hypoperfusion, initiating immune activation and leukocyte 
migration. High-affinity counter-receptor for P- and E-selectin, PSGL-1, is expressed 
constitutively on cell surfaces and essential as a trigger for the diapedesis of leukocytes 
[285]. rPSGL-Ig, a recombinant soluble form of PSGL-1, abrogates the interaction of 
circulating leukocytes and platelets with activated endothelium. Administration of this 
ligand in animal models of total ischemia/reperfusion has been shown to inhibit the 
initial selectin activity and subsequent cellular and humoral events [286, 287]. Selectin 
blockade with rPSGL-Ig in rat models of kidney allograft reduced early inflammatory 
events, chronic rejection rate, improved engraftment and organ survival, although in 
conjuction with minimal dose of sirolimus and/or cyclosporin A. In these models the 
protective effects are particularly boosted when both donor and recipient are treated 
with the antibody [288, 289].  
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1.8.2 Treatment/manipulation of isolated islets 
 
Extended duration of culture alone 
After isolation, islets express several mediators with powerful biological activity, 
including IL-1β, IL-8, MIP2, MCP1, and MIF. After long-term culture (7–11 days), 
expression of these pro-inflammatory molecules considerably decreases compared to 
the islets at early stages after isolation. According to the literature, it’s certainly 
advantageous to culture islets before transplantation to reduce expression of these 
mediators. Cultured islets are more likely for successful engraftment [290]. Culturing 
would also permit enhanced expression of specific genes that may improve islet 
engraftment, e.g., protective genes (heme oxygenase-1, HO-1; A20), anti-apoptotic 
genes (Bcl-2), and immunomodulatory genes (IL-10, TGFβ).  
 
 
Islets in vitro: 
Gene transfer: A20, haemoxygenase-1, Fas Ligand 
 
TNFα-induced protein 3 (TNFAIP3), or A20, is a regulator of inflammation and a 
potent anti-apoptotic gene in many cells types including β cells. A20 is considered as a 
potential therapeutic target for intervention in conditions characteristically apoptosis 
and/or the inflammatory response, due to its activity on NF-κB and cell death [109, 
179].   
 
In mouse models of islet transplant, adenovirus-mediated gene transfer of A20 to 
donors protects the isolated islets from IL-1β/IFN-γ and Fas-induced apoptosis. A20 
expression protects functional β cell mass and promotes survival. The dual 
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antiapoptotic and antiinflammatory effect of A20 on β cells is related to abrogation of 
cytokine-induced NO production due to transcriptional blockade of iNOS induction 
[291] [183] [111]. Normoglycaemia was restored and maintained in mice with less 
number of A20-expressing islets compared to normal islets [111].  
 
Haemoxygenase-1 is an enzyme which degrades Heme to (HO-1) metabolites including 
bilirubin and biliverdin producing carbon monoxide during the process. HO-1 has anti-
inflammatory; proliferative anti apoptotic properties, there is increasing evidence of its 
efficacy in improving transplant outcomes [292]. HO-1 expression is observed in islets 
under stress conditions such as after isolation [293]. HO-1 application both 
pharmacologically or by gene transfer in donor islets protects them from stress-induced 
apoptosis in both in vitro and in vivo settings, graft function and survival and tolerance 
is also promoted [294, 295]. 
 
Exposure of rat isolated islets to Cobalt protoporphyrin and zinc protoporphyrin in 
culture induced HO-1 over-expression, when these islets were transplanted into mice,  
improved graft function and survival was observed. The protective effects of HO-1 in 
this xenotransplantation model are thought to be mediated by IL-10 as HO-1 generates 
CO, which downregulates iNOS and upregulates IL-10,  protecting the β cells [296]. 
 
Administration of bilirubin, a product of HO-1 activity, either pharmacologically or by 
gene delivery in donors and in isolated islets, induces upregulation of antiapoptotic 
molecules like Bcl-2 and hepatopoietin (HPO-1) and suppression of the proapoptotic 
and proinflammatory genes caspase-3, caspase-8, and MCP1 both in vitro and post-
transplant and promotes tolerance [297, 298]. 
 56 
 Allotransplant of FasL–engineered islet grafts in a mouse model established 
euglycaemia and limited the need for immunosuppression, inducing robust localized 
tolerance in all recipients. Tolerance was initiated and maintained by 
CD4+CD25+Foxp3+ regulatory T (Treg) cells [110]. CTLA4-Ig and TGF-β transduction 
of mouse islets prior to transplantation also prolongs graft survival [299] 
 
1.8.3  Treatment of the recipient 
 
Anti-inflammatory agents 
Anti-inflammatory agents have been incorporated within immunosuppressive regimens 
in recent clinical allogeneic islet transplant protocols [27], although no large clinical 
study has yet evaluated the impact of these interventions. TNFα inhibitors along with a 
T-cell depletion agent are being largely administered in peri-transplant 
immunosuppressive regimens, resulting in significantly higher rates of insulin 
independence and long-term graft survival than conventional immunosuppression [88, 
300]. 
 
In a human to rodent islet xenotransplant model, etanercept (an TNFα inhibitor), could 
reverse hyperglycaemia only when administered in combination with anakinra (an IL-
1β receptor antagonist) [300], suggesting that TNF inhibition alone cannot fully halt the 
inflammation. More importantly, clinical application of etanercept and anakinra in islet 
allotransplantation rendered all patients insulin-independent after a single infusion [82]. 
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In a rodent model, withaferin A, an anti-inflammatory compound and a potent NF-κB 
inhibitor abolished proinflammatory cytokines and apoptosis and significantly 
enhanced islet graft survival [301]. 
 
Several anti-inflammatory agents are under investigation and more emerging to 
optimise islet transplantation outcomes including diannexin [302], and the combination 
of JNK inhibitor SP600125 with nicotinamide and simvastatin [303].  
 
Haemoxygenase-1  
In rodent models, administration of HO-1 pharmacologically along with cobalt 
protoporphyrin (CoPP) to recipients enhances islet function and survival, along with 
promoting tolerance induction [295]. Moreover, preconditioning of only the donor, 
islets, or the recipient or combinations of such treatments with carbon monoxide (CO), 
supresses TLR4 signalling and production of proinflammatory mediators such as TNFα 
and MCP1, and decreases graft infiltration, resulting in prolonged graft survival [248, 
304]. 
 
Activated protein C 
In a “loop system” where human islets were exposed to ABO-mismatched blood, 
rHuAPC prevented IBMIR in a dose-dependent manner, significantly preserving islet 
integrity while maintaining platelet and leukocyte counts [305]. It has been 
demonstrated that APC limits IBMIR in vivo and in vitro through all the three anti-
coagulation, fibrinolysis and NF-κB inhibition pathways [117]. Administration of 
murine APC to culture media decreased TNFα production and translocation of NF-κB 
in the murine portal vein endothelial cells (PVECs) co-cultured with syngeneic islets 
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[306]. Though the treatment in this study involved the portal vein endothelial cells, 
APC actions may also have been mediated through an effect upon the islets in culture. 
 
Contreras et al. showed that following intraportal islet allotransplant into recipient mice 
treated with APC, the fibrin formation and deposition due to islet infusion was reduced 
in liver; endothelial activation, inherent to islet infusion, and measured by plasma 
levels of sICAM-1 and soluble P/E-selectin was almost abolished in the treated group. 
Cytokine production and inflammatory response of the liver (the engraftment site) was 
significantly suppressed. Islets in treated recipients showed superior engraftment and 
functionality and reduced apoptosis and immunogenicity in biopsies [306].  
 
Induction of APC generation by liposomal formulations of thrombomodulin, increased 
the engraftment of transfused islets through reduction of coagulation and inflammation 
[307]. In NOD mice, exogenous APC totally prevented development of type 1 diabetes 
by preserving β cells from apoptosis, stimulation of growth, reduction of inflammation 
and suppressing immune cell infiltration into islets [308]. It is noteworthy that plasma 
levels of PC/APC are significantly lower in T1DM patients compared to the controls 
[309]. 
Taken together these findings suggest that APC might also be able to inhibit recurrent 
anti-islet autoimmunity in islet graft recipients with type I DM. 
 
1.9  Modulation of immune responses using soluble RAGE 
 
Soluble RAGE results in an effective blockade of RAGE signalling, both in vitro and in 
vivo a range of mostly rodent animal models. In mice, sRAGE administration has been 
shown to suppress production of pro-inflammatory markers such as adhesion 
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molecules, cytokines, chemokines, matrix metalloproteinase 9 activity, tissue factor, 
and phosphorylation of p38 MAP kinase. Endothelial activation and leukocyte 
migration and infiltration are also inhibited, all leading to significantly suppressed 
innate immune activation in response to inflammatory stimuli [143, 310].  
 
In a study showing the association of RAGE activity with the development of diabetic 
angiopathy, the activity of human esRAGE in mice was documented [311].  
 
Blockade of RAGE improves outcomes after hepatic IRI in mouse, modifies the 
activity of NF-κB and AP-1 and the expression of TNFα and IL-6, and modulates the 
activation of inflammatory and proapoptotic pathways. Hepatocyte cell death is 
suppressed and regeneration is promoted [312]. It should be noted that because of the 
ability of some RAGE ligands (such as HMGB1) to change multiple pattern 
recognition receptors, soluble RAGE also has inhibitory effect on signalling through 
TLRs 2, 4 and 9. 
 
In accordance with its role in both innate and adaptive immunity, interruption of RAGE 
signalling using either soluble RAGE isoforms or small molecule inhibitors of RAGE 
promotes favourable outcomes of allotransplantation. In a lung allograft model, IRI was 
attenuated, and oxygenation, capillary leakage and tissue injury scenes all improved in 
animals pretreated with soluble RAGE [313]. RAGE blockaded by esRAGE delays 
allograft rejection in murine heart transplantation whilst small-molecule RAGE 
inhibition [314], dampened islet allograft rejection [315], highlighting the role of 
RAGE-induced donor-reactive T cell priming in acute rejection. The ability of soluble 
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RAGE to attenuate inflammation in pancreas and islets after donor brain death has not 
previously been evaluated. 
 
Here we will evaluate the ability of systemic esRAGE overexpression to reduce 
pancreatic inflammation in a murine model of brain death, alongside two other 
strategies to reduce pancreas or islet inflammation - treatment of brain-dead donor pigs 
with a hormone resuscitation cocktail and treatment of porcine neonatal islet cell 
clusters in vitro with recombinant HuAPC. 
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CHAPTER 2  
MATERIALS AND METHODS 
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2.1 Porcine neonatal islet cell cluster (pNICC) preparation 
and culture 
 
2.1.1  PNICC isolation 
 
Donor pancreata were obtained from 1-3 day old inbred Westran or outbred Large 
White neonatal piglets of either sex (Body weight: 1.2-2.5 kg, Pancreas weight: 2-4 gr). 
The pancreata were removed and digested to isolate islet clusters following a method 
modified from that described by Korbutt et al [316]. Briefly, piglets were anesthetised 
with Halothane. The chest and abdomen were opened using a parasternal incision and 
the piglets were allowed to exsaguinate. The pancreas was then removed and placed in 
cooled washing medium (4°C) containing HBSS with 1% pig serum (isolated from 
fresh adult large white pig blood). In a class II biosafety cabinet, each of the pancreata 
was chopped into ~2 mm3 fragments with long curved scissors in a 50 ml Falcon 
conical tube (BD Biosciences, San Jose, California).The tissue was left to settle under 
gravity and the supernatant was removed and replaced by fresh medium. After a further 
3 rounds of chopping and washing the tissue (by brief centrifugation at 1000rpm), 
HBSS plus Collagenase Type V (1 mg per ml of the chopped tissue), (Sigma, Castle 
Hill, NSW, Australia) was added to the finely cut pancreata. Digests were gently 
agitated in a shaking water bath at 37°C for 14-18 min, then filtered through a metal 
filter mesh and washed 4 times with washing medium to remove all the collagenase. 
The yield of pNICCs from each pancreas depends on the starting weight of the neonatal 
pig pancreas (weight in grams x 20000 = Number of pNICCs). 
 
Enough pNICC culture medium (consisting of Hams F-10 medium (Sigma) + 10% pig 
serum) was added to 150 mm x 20 mm Petri dishes to give a final volume of 35 ml in 
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each plate. The islet aggregates were then transferred into the dishes at a concentration 
of 1000 ICC/ 3 ml, which was maintained during the culture period.  
 
2.1.2 pNICC culture 
 
Dishes containing the islet aggregates were maintained in culture medium at a37°C in a 
humidified incubator with 5% CO2, 95% air. The medium and dishes were completely 
changed on the first day post isolation and then every 2nd day for 5 days by briefly 
spinning the islets in 50 ml tubes and pouring off the supernatants. During the second 
week of culture, half and full medium changes were done every 2nd day alternately 
(Table 2.1). 
 
Table 2.1 pNICC medium change schedule. 
 
 
 
 
 
Days post-
isolation 
Full medium and plate 
change 
Half medium change 
1 - 
3 - 
6 - 
- 8 
10 - 
- 12 
14 - 
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2.1.3 Preparation of pNICCs for counting and viability 
assessment 
 
Using a sterile tip and pipette, 3 x 50μl aliquots of resuspended pNICCs were taken 
from each islet preparation.  2 x 50μl were placed in two lines on a large Petri dish for 
counting purposes. The number of pNICCs in each of the lines was counted, or islet 
size according to isolated pancreatic islet equivalents (IEQ) was measured, depending 
on what was required. Results were recorded in the NICC Isolation Data Sheet.  
Prior to staining the islet clusters for viability assessment, a labelled frosted glass slide 
was marked with Dako pen (Dako, Denmark) to create a surrounding thick barrier and 
air dried. 1 x 50μl of the islet suspension was transferred into a 0.2ml tube, an equal 
amount (50μl) of Acidrine orange + Ethidium Bromide was added to this, then the 
suspension was transferred onto the marked glass slide using a transfer pipette, without 
introducing bubbles. This was then cover-slipped without pressing and left for 15 min 
to develop. The slides were examined under a mercury lamp-equipped, fluorescence 
BX60 Olympus microscope (Olympus, Tokyo, Japan). Images were taken using a 
DP72 Olympus camera mounted on the microscope (Figure 2.1). In live cells Acridine 
orange fluoresces green, and in dead cells Ethidium Bromide fluoresces orange. 
 
 
 
  
 
 
 
Figure 2.1 pNICCs post isolation in culture stained with Acridine orange + Ethidium 
Bromide. Live cells fluoresce green, dead cells fluoresce orange (x200 magnification). 
   
Day 10 Day 6 Day 3 
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2.1.4 Recombinant Human Activated Protein C preparation 
 
Xiris [Drotrecogin alfa (activated) recombinant human Activated Protein C; Eli Lilly 
Pty Ltd, West Ryde, NSW, Australia], 5mg as powder in a vial was provided by Dr 
Chris J. Jackson (Sutton Arthritis Research Laboratories at Royal North Shore Hospital, 
Sydney). 
The powder was reconstituted with double-distilled autoclaved water to make a 2μg/μl 
solution prior to use. The solution was then stored in sufficient working aliquots at -
80ºC. 
 
2.1.5 Treatment of Porcine Neonatal Islet Cell Clusters 
(pNICCs) with rHu APC 
 
Recombinant human APC [187] was added to culture medium at a concentration of 
10μg/ml from day 3 post-isolation. The dose 10μg/ml was decided based on the 
literature, majorly from the studies performed by Jackson et al [317, 318]. rHuAPC was 
applied to the treatment-receiving dishes along with every full or half change of the 
medium. 
 
2.1.6 Harvesting pNICCs  
 
ICCs were harvested days 0, 3, 4, 6, 10 and 14 for gene expression and 
immunohistochemical staining. 7,000 to 10,000 ICCs were harvested from culture by 
centrifugation at 1000 rpm for 2 minutes. After removing the supernatant, ICCs were 
directly disrupted in lysis buffer for nucleic acid extraction. Some lysates were frozen 
at -80 °C at this stage and batched for further RNA extraction. 
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For immunostaining around 1,000 ICCs were frozen in Tissue Tek freezing medium 
(Sakura Finetek, AJ Alphen aan den Rijn , The Netherlands). A thin layer of medium 
was applied to the bottom of a pre-cooled cryomold and frozen down in liquid nitrogen, 
the ICCs were placed on the frozen medium and allowed to freeze immediately, the 
cryomold was filled with Tissue Tek, which was then frozen in the vapour phase of 
liquid nitrogen and stored at -80°C. The frozen blocks were cut in a Cryotome, in 5μm 
sections. The slides were stored at -80°C for further use and were fixed in acetone at 
room temperature for 10 min immediately prior to immunostaining. 
 
2.1.7 Total RNA preparation from porcine islet cell clusters         
 
RNA extraction 
Total RNA was extracted using the Ambion RNAqueous Mini Kit (Ambion, TX) 
following a protocol modified for the manufacturer’s instructions. Approximately 7000 
ICCs were pelleted by briefly spinning them and isolating the supernatant; then 700μl 
of Lysing/Binding buffer (Ambion) was added to the tissue pellet. After homogenising 
the tissue with a T10 Basic Ultra Turrax homogeniser (IKA, Staufen, Germany), the 
solution was syringed through a 25 gauge needle to reduce the viscosity and shear the 
DNA. The following solutions were added subsequently with thorough mixing between 
additions: 70μl of 2M sodium acetate, pH 4.0 (Sigma) followed by 700 µl of RNA 
grade Phenol solution, pH 4.2 (Sigma). The mixture was vortexed and left on ice for 5 
minutes before 140μl of a 49:1chloroform : isoamyl alcohol (both BDH AnalaR, 
Kilsyth, Australia) solution was added. After vortexing for 30 seconds, the contents 
were left to cool on ice for 15 minutes. The organic and aqueous phases were separated 
at 11,000rpm for 45 minutes at 4°C in a refrigerated Eppendorf microcentrifuge. The 
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aqueous phase was then removed to a fresh 2ml Eppendorf tube; an equal volume 
(800µl) of 64% ethanol solution (Ambion) was added to this. The solution was then 
purified and washed on an RNAqueous filter cartridge (Ambion) following the 
manufacturer’s protocol. After eluting the RNA in 180µl of elution solution, 2µl of 
glycogen (Ambion), 12µl of 7.5M ammonium acetate and 390µl of 100% ethanol was 
added to the solution and left overnight to precipitate at -20°C before being centrifuged 
at 11,000rpm at 4°C for 45 min as above. The RNA pellet was then washed with 1.5ml 
of 70% ethanol, and allowed to air dry at room temperature. Dried pellets were then 
reconstituted with 20µl of DEPC-treated water before the quantity and quality of RNA 
were assessed. 
 
Assessment of RNA concentration, integrity and contamination 
The RNA concentration of each sample was determined by optical density analysis. 
The RNA content and protein contamination in 1µl of solution was estimated using a 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, MA, USA). A tester 
sample was then diluted if necessary and 1µl of this tester sample was loaded on an 
Agilent 2100 Bioanalyzer RNA chip (Agilent Technologies, CA, USA) following the 
manufacturer’s instruction and run in an Agilent 2100 Bioanalyzer (Agilent 
Technologies) to assess the precise concentration and obtain the RIN (RNA Integrity 
Number), which is calculated based on the absorbance spectrum. All the RNA samples 
from porcine NICCs show a RIN of more than 7, indicative of highly preserved total 
RNA (Figure 2.2). RNA samples to be used as templates for reverse transcription were 
then diluted with DEPC-treated water to a final concentration of 0.2µg/µl and stored in 
NUNC cryogenic vials in liquid nitrogen as three 1µg aliquots and 1 aliquot of the 
remaining RNA. 
 68 
 Figure 2.2 absorbance spectrum of total RNA generated from electrophoresis in the 
Bioanalyzer.First peak in the graphs shows distinct 18S ribosomal subunit, the second 
peak shows distinct 28S ribosomal subunit. 
 
 
2.1.8 Complementary DNA synthesis from extracted RNA 
 
cDNA was synthesised using the SuperScript III kit (Invitrogen, CA, USA). All 
samples to be compared were included in the same cDNA synthesis reaction. Minus RT 
controls (reaction prepared without reverse transcriptase enzyme), and cDNA for 
preparing standard dilution series as well as no-template-controls were included in all 
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reactions. Two cDNA samples were synthesized from each RNA sample in two 
separate procedures. 
 
1µg of total RNA was made up to 11µl with DEPC-treated water and primed with 2µl 
Oligo-dT primer (Roche diagnostics, IN, USA). The contents were mixed and heated at 
65ºC for 5 mins, then cooled on ice before adding the master mix. The master mix (7µl) 
contained 4µl of SuperScript III reaction buffer (Invitrogen), 1µl of 0.1M DTT 
(Invitrogen), 1µl of 10mM dNTP (Ultrapure dNTP set, Amersham Pharmacia, Sweden) 
and 1µl if SuperScript III enzyme (Invitrogen). In the Minus RT reaction 1µl of water 
replaced the SuperScript enzyme and for the no template control no RNA was added to 
the DEPC-treated water. The 20µl mixture was then heated at 50ºC for 60 min followed 
by 15 min at 70ºC. After the completion of the reaction, the cDNA was diluted 1:5 with 
80µl of DEPC treated water and aliquoted in 5µl portions in 0.2µl tubes or directly into 
PCR plates which were then stored at -80 ºC prior to analysis.    
 
2.1.9 Taqman primer and probe design for real-time RT-PCR 
of porcine genes 
 
Taqman primers and probes for quantitative real-time RT-PCR analysis were designed 
using sequence data obtained from NCBI,  ANGIS (Sydney Bioinformatics, NSW, 
Australia) and EnsEMBL databases using Primer Express (PE Biosystems, Foster City, 
CA) software. In order to avoid potential amplification of small amounts of 
contaminating genomic DNA in PCR, all the primer/probe sets were designed to either 
span intron/exon boundaries or to span long intronic sequences. The Taqman primer 
and probes sets were synthesized by Sigma-Aldrich (Sydney, Australia) or Applied 
Biosystems (PE Biosystems) and supplied in lyophilised form. All Taqman probes 
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were labelled with a 5’ 6-FAM reporter and a 3’ TAMRA quencher, apart from the 
probe for MMP-2, designed as an MGB (minor-groove binding) probe. The 
oligonucleotide pellets were reconstituted with DEPC-treated H2O, and the stock 
solution was stored at -70ºC. The working solution of primers was made up from a 
mixture of reverse and forward primers at a 30μM concentration of each, and the 
working solution of probe was diluted to a 20μM concentration, both working aliquots 
were stored at -20ºC. Primer/probe Sequences appear in table below (Table 2.2). 
 
 
Gene Name Sequence (5’ → 3’) 
 
GAPDH 
 
Forward CAGCAATGCCTCCTGTACCA 
Reverse GATGCCGAAGTTGTCATGGA 
Probe AACTGCTTGGCACCCCTGGCC 
 
H3 Histone 3A 
Forward CCGTGGCTCGTACAAAGCA 
Reverse TTGCGAGCGGCTTTTGTAG 
Probe CCCGCAAATCGACTGGTGGTAAAGC 
 
A20 
Forward CCCCGAAAACAGAGGTGTCA 
Reverse TTTGAGAAGTACTGGGCTGAGAAA 
Probe AGCCAGTTGTCACTCAACCCAGTCCATC 
 
MCP1 
Forward GCGGCTGATGAGCTACAGAAG 
Reverse CCGCGATGGTCTTGAAGATC 
Probe CACCAGCAGCAAGTGTCCTAAAGAAGCAG 
 
MIP1 
Forward AGCGCTCTCAGCACCAATG 
Reverse TTCCGCACGGTGTATGTGA 
Probe CAGACCCTCCCACCTCCTGCTGC 
 
MIP2 
Forward TCAAGAACATCCAGGACCTGAA 
Reverse GCTATGACTTCCGTTTGGTCACA 
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Probe TGACGTCCCCGGGACCCCA 
IL-1β 
Forward CCAAGAGGGAGCCTCAAGCT 
Reverse CTCTGCTGACTTTTCTTTCCATAGC 
Probe TGCCCCCCAGACATAGCCCAAA 
IL-6 
Forward GACAAAGCCACCACCCCTAA 
Reverse CTCGTTCTGTGACTGCAGCTTATC 
Probe CACCACAAATGCCGGCCTGCT 
 
IL-8 
Forward GGGTGGAAAGGTGTGGAATG 
Reverse GGCTGCAGTTCTGGCAAGAG 
Probe TGCACTGGCATCGAAGTTCTGCACTT 
 
Complement C3 
Forward GCGCTGCAGGAGGCTAAAG 
Reverse AGTCTGCGAGGAAGTCTCTTGC 
Probe CATCTGTGAACCACAGGTCAATAGCCTGTTG 
INF-γ 
Forward GCATGGATGTGATCAAGCAAGA 
Reverse CTGGCCTTGGAACATAGTCTGA 
Probe TGCAGATCCAGCGCAAAGCCAT 
 
HSP72 
Forward CCAGATTGAGGTGACCTTCGA 
Reverse TGCCTGTGCTCCTGTCAGT 
Probe TGTCACACTCAGGATGCCATTGGCA 
 
TLR2 
Forward CCAGGCAAGTGGATTATTGACA 
Reverse CGGAAAGCACGAAGATGGTT 
Probe ATCATCGACTCCATCGAAAAGAGCCAGA 
 
TLR4 
Forward GAGCTGAGCAAATGGTGTGTACA 
Reverse CAGGTGGCGTTCCTGAAACT 
Probe ACCTTTAGAAATGCAGGACCTGCCTGTGC 
 
HMGB1 
Forward AAGGAGAGCATCCTGGCCTATC 
Reverse TCTGCAGCGGTGTTATTCCA 
Probe ATCTCTCCCAGTTTCTTTGCAACATCACCA 
 Forward TCTGGCAAGCGTTGTTTTTGTA 
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MIC2 Reverse ACCGTGAAGTTGTACCAAAGATTG 
Probe CCCGGGTACCGTCGTTGCACA 
 
ULBP1 
Forward AGACAGCGGCATCACCAACT 
Reverse GATGGCTGCACCCTTCGA 
Probe CAGCGCCCCCCATAGCCCA 
 
EPCR 
 
Forward CCTGGAGGCTTACCTGAAGGA 
Reverse AGCGAACGATGAGAGGAAAGG 
Probe TTCCAGGGTCTGGTGCAGGTGGTG 
 
MMP-2* 
Forward CCCGGAAAAGATCGATGCT 
Reverse AGTACTCATTCCCTGCAAAGAACA 
Probe CCCCACAGGAGGAGA* 
 
IP10 
Forward TTGAAATGATTCCTGCAAGTCAA 
Reverse TTTCTCCCCATTCTTTTTCATTG 
Probe CTTGCCCACATGTTGAGATCATTGCC 
 
Insulin 
Forward AGAAGCGTGGCATCGTGG 
Reverse GGCCTAGTTGCAGTAGTTCTCCAG 
Probe TGCCCTCTGGGAGCCCAAAC 
 
Table 2.2 Taqman primer/probe sequences for porcine genes. *MGB probe: Minor 
Groove Binding Probe. 
 
 
2.1.10  Quantitative real-time RT-PCR of porcine genes 
 
The Real-Time RT-PCR was set up as follows. Each reaction contained 5μl of template 
cDNA (in duplicate), 12.5μl of 2x SensiMix buffer (Quantace Ltd, Finchley, UK), 
0.25μl of 30μM Forward+Reverse Taqman primers, 0.25μl of 20μM Taqman probe and 
7μl H2O to make up a 25μl reaction volume. To minimise pipetting errors and 
variabilities between samples, 20μl of pre-assembled Master Mix was added to 5μl of 
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cDNA template. A gene specific standard curve (comprising a 4-fold dilution series of 
a high expressing cDNA sample) was included in each assay. 
 
Thermal cycling parameters were as following: 
2 holds at 50ºC for 2 min and 95ºC for 10 min, followed by 40 cycles of 95ºC for 15 
sec (melting) and 60ºC for 1 min (annealing). The reactions were run in a Model 7700 
or 7000 Sequence DetectorTM (Applied Biosystems) or a Corbett Rotor-Gene 6000 
(Qiagen) real time RT-PCR machines. Results were analysed using ABI Prism 
Sequence Detector SoftwareTM v1.7 and Corbett Rotor-Gene 6000 Application 
Software, v1.7.  The expression level of housekeeping genes, Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and H.3 Histone 3A, was measured with gene 
specific Taqman primers and probes and the formula Gene of Interest 
ExpressionsampleX/ Housekeeping GenesampleX was used to normalise the expression of 
all cDNA samples.  
 
Analysis of Real-Time RT-PCR data 
The results were saved in Excel format (Microsoft Office); the concentration of desired 
gene amplicons were calculated by incorporating the CtsampleX of gene of interest in the 
linear regression formula obtained from the gene specific Standard Curve; the average 
concentration of the two DNA syntheses was used as final data to be analysed. To 
analyse the differential expression between individual specimens, Graphpad Prism 
version 5.0 (GraphPad Software, CA) was used. One-way or two-way ANOVA and 
Bonferroni post-hoc analyses were performed and a P value smaller than 0.05 was 
considered statistically significant. 
 
 74 
2.1.11  Amplification of full-length porcine endothelial 
protein C receptor (EPCR) by RT-PCR 
 
Primers for amplification of EPCR cDNA by PCR were designed on a porcine mRNA 
sequence (NCBI ref.: NM_001163406) using Sigma and ANGIS primer-design 
software (Table 2.3). The primer sets were obtained from Sigma in lyophilised form 
and reconstituted in DEPC-treated water; the working aliquots were stored at -20 at 
10mM concentration. 
 
Gene Name Sequence (5’ → 3’) 
 
EPCR 
Primers 
 
Forward CACCATGTTGACAACATTGCT 
Reverse CAGAGGGAGCCAGTGAGTAATTA 
 
Table 2.3 Forward and reverse primers to amplify EPCR sequence in porcine tissue. 
 
Reaction set up was performed using the KOD hot start DNA polymerase kit 
(Novagen, EMD Biosciences, Inc., Darmstadt, Germany) and following a protocol 
modified from the manufacturer’s instructions. Each 50 μl reaction contained 5 μl of 
10x buffer, 3 μl of dNTPs, 28 μl of PCR grade water, 1.5 μl of 10 μM of each of sense 
and anti-sense primers, 5 μl of template DNA and 1 μl of KOD hot start DNA 
polymerase. Thermal cycler conditions were as following:  Polymerase activation at 
95ºC for 2 min, denaturation at 95ºC for 20 sec, annealing at 63ºC for 10 sec, extension 
at 70ºC for 15 sec; steps 2-4 were repeated for 40 cycles in a Palm Cycler Gradient 
PCR Machine (Corbett, Qiagen). 
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Visualisation of PCR product 
To check the specificity of the rt-PCR reaction, PCR product size was verified by 
agarose gel electrophoresis and ethidium bromide staining, and observed under UV 
transillumination. 1% agarose gel was made as follows: 1.6 g of agarose powder 
(Promega, Madison, WI) was dissolved in 160 ml of 1x TAE buffer by heating in 
microwave oven, then 9.06µl of ethidium bromide was added and poured into a an Owl 
Gel caster (Thermo Fisher Scientifics). The PCR products were mixed with 1x TAE 
buffer to make up to 10 μl and loaded with 2 μl of 6 x DNA Loading Dye (Cat# R0611, 
Thermo Fisher Scientific) in the gel wells. 12μl of GeneRuler 1kb Plus DNA Ladder 
(Cat#SM1331/2/3, Thermo Scientific) was loaded in the ladder lane. The gel was 
electrophoresed for 1 to 2 hours at 100 V.; then visualized in a Syngene G:Box Chemi 
HR16 apparatus (Syngene, Synoptics Ltd, Cambridge, United Kingdom) under UV 
light. 
 
DNA purification from agarose gel 
Bands of the predicted size (~729bp) were cut out from the agarose gel under UV light. 
DNA was purified from the gel using the Gel-Advance Gel Extraction System 
(Viogene). Briefly, the gel slices containing PCR product were dissolved and DNA was 
purified and washed from the solution onto a filter cartridge by centrifugation. The 
DNA was then eluted from the cartridge and stored at -20ºC. The DNA quality and 
quantity was measured using a NanoDropTM 1000 spectrophotometer.  
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2.1.12  TOPO-cloning of porcine EPCR sequence and 
transfection into bacteria 
 
Using the blunt-ended pcDNA Gateway Directional TOPO expression kit (Invitrogen), 
the TOPO cloning reaction was set up following the manufacturer’s instructions. 
Briefly, PCR product, around 400ng/μl, was put into the reaction at a 1:1 volume ratio 
to the TOPO vector (i.e. 1μl PCR product plus 1μl Vector). Then the reaction was made 
up to 6μl by adding 1μl salt solution and 3μl H2O; gently mixed and incubated for 15 
min at room temaprature. 2μl of this solution was added to a freshly thawed vial of One 
Shot TOP10 chemically competent E. coli (Invitrogen, Life Technologies). Empty 
vector, as negative control, and pUC19 DNA (provided with the competent cells), as 
positive control DNA were also each added to a vial of cells. The competent cell vials 
were then incubated on ice for 15min. The vials were transferred to a 42ºC water bath 
for 30sec to transform cells with the vector by heat-shock, and returned to ice. 250μl of 
S.O.C medium (provided with the competent cells) was then added to the cell vials and 
left to shake at 200rpm for 1hr at 37ºC. 
 
Autoclaved LB-Agar was heated up to liquefy. Ampicillin was added to the liquid LB-
Agar to yield a final concentration of 100μg/ml and mixed gently. The liquid was 
poured into sterile 10cm Petri dishes in a fume hood and let set. 
 
50-200µl of the E. coli transformation suspension was added to the LB-Agar dishes and 
evenly spread by vigorous shaking with sterile glass beads. The plates were incubated 
upside-down at 37ºC overnight. Colonies appeared by the following morning, 3 
colonies from each dish were picked and each was transferred into a 15ml tissue culture 
tube containing 5ml of liquid LB-Agar+100μg/ml Ampicillin. The tubes were shaken at 
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200rpm at 37ºC for 6 hrs. The E. coli cultures were then passaged into 250ml of LB-
Agar+100μg/ml Ampicillin and shaken overnight at 200rpm at 37ºC to produce enough 
bacteria for MaxiPrep. 
 
Plasmid DNA extraction by Maxiprep 
JETSTAR 2.0 Plasmid Maxiprep kit (Astral scientific, Caringbah, NSW, Australia) 
was used to isolated the plasmid from transformed cells. E .coli cells were pelleted by 
centrifugation, the medium was removed and cells resuspended in solution E1 
(provided in the kit). Cells were then lysed by adding solution E2 and mixing gently, to 
get a homogenous lysate, incubated at RT for 5min. After adding solution E3 and 
mixing again, the lysate was centrifuged at RT and 12.000 xg for 10min. The 
supernatant was then applied to the JETSTAR column, which had been previously 
equilibrated with E4 solution, and allowed to run through the cartridge under gravity. 
The column was washed with solution E5 twice. After adding solution E6, the DNA 
pellet was precipitated pellet using isopropanol followed by centrifugation at 4 ºC and 
12.000 xg for 30 min. The plasmid pellet was washed with 70% ethanol and allowed to 
air-dry, the dried pellet was dissolved in H2O, and the quantity of the plasmid DNA 
was then measured using a NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific). Plasmid DNA was stored at -20 ºC prior to sequencing. 
 
Plasmid DNA sequencing 
An adequate amount of extracted plasmid DNA from E.coli (approx. 2μg) was 
sequenced using a forward primer binding the T7 promoter and reverse sequencing 
primers from Invitrogen. 
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2.2  Porcine Aortic Endothelial Cell isolation from piglet 
aortas 
 
Isolation of piglet thoracic aorta 
2-3-day old large white piglets, weighing 1.5-2.5 kg were sacrificed for multiple organ 
harvest. The animals were exsanguinated and 2-4 cm of the thoracic aortae were 
isolated from the surrounding organs and tissues, then transferred to cold sterile PBS. 
Using a 1ml syringe, the inside and outside of the aorta was flushed thoroughly with 
cold PBS, to remove blood clots.  
 
PAEC isolation by scraping method for RNA extraction 
Aortae were then put into 15cm Petri dishes and were cut longitudinally using a 
surgical blade. Any adhering lymph node or excess tissue was dissected away. The 
vessel was fixed using sterile plastic forceps to avoid tissue slippage. With a sterile cell 
scraper, the lumen of the aortae was gently scraped to detach the endothelium 
thoroughly. The scraper carrying the cells was then immersed into 700μl of cell lysing 
solution (Ambion) and cells were disrupted immediately by syringing up and down. 
Tissue lysates were used for RNA extraction using the RNAqueous kit (Ambion). 
 
PAEC isolation with enzymatic digestion method for culture 
After brief soaking in cold PBS, aortae were transferred to cold M199 medium, 
containing 10U/ml penicillin and 10mg/ml streptomycin and left on ice. For dissection, 
the aortae were transferred into a 10cm petri dish, with a drop of medium. The vessel 
was fixed to the plate using sterile forceps, and the adhering tissues were dissected 
using a surgical blade. The vessel was cut longitudinally, and sliced into 2-3 equal 
pieces, then transferred to a 6-well plate with the luminal side facing up. Collagenase I 
 79 
solution (0.26%) was prepared just before use. 3ml of enzyme solution was added to 
each well containing tissue, and incubated for 20 min at 37°C. 
The supernatant containing detached cells was transferred into a 15ml tube, the luminal 
surface was scraped gently, the well was washed with 10ml of medium, and this was 
added to the tube. The cells were washed by centrifugation at 220 xg for 7 min, and the 
supernatant was discarded. The cell pellet was resuspended in 6 ml of complete M199 
medium, transferred into the pre-warmed gelatine-coated T25 flask, and incubated at 
37°C in an atmosphere of 95% O2 and 5% CO2. 
 
Subculturing primary PAECs 
When the cells were reaching 80% confluence, supernatant was removed from culture 
flasks by aspiration. The pure colonies of macrovascular endothelial cells exhibit 
typical “cobblestone” morphology, the cultures with dominant fibroblast growth were 
discarded. The adherent cell monolayer was washed with PBS and dislodged from the 
flask by trypsinization. The cells were then washed with medium by spinning at 220 xg 
for 5 min. The cell pellet was resuspended in complete M199 medium; after counting, 
cells were seeded in gelatine-coated flasks and incubated at 37°C in 95% O2 and 5% 
CO2.  
 
PAECs treatment with recombinant human Activated Protein C 
Confluent cells isolated from fresh piglet aortae between passages 3 and 4 were used 
for the experiment. After counting the cells, 2 x 106 cells were transferred immediately 
into Ambion lysing/binding solution for RNA extraction as a baseline control. The 
same number of cells were allocated to each treatment group of the experiment. To the 
gelatine-coated T75 flasks, 15 ml of complete M199 medium was added, followed by 
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addition of reconstituted recombinant human activated protein C (Xiris; Eli Lilly Pty 
Ltd, West Ryde, NSW, Australia) to treatment flasks at 10 µg/ml, immediately prior to 
inoculation with 2 X 106 of cells. Half medium change and APC treatment were carried 
out after 24 hrs for 48 hr reactions. Control and treated reactions were harvested after 
24 hr and 48 hr in Ambion lysing/binding solution for further RNA extraction. 
 
2.3  Preparing tissue segments for immunohistostaining 
purposes 
 
Using a surgical blade, 5mm of the washed piglet aorta was cut horizontally, without 
pressing the lumen. 
 
Snap-freezing 
A thin layer of TissueTek freezing medium (Ted Pella, Inc. and PELCO International, 
Redding, CA) was put on the bottom of a pre-cooled cryomold and frozen down in 
liquid nitrogen. The 3mm specimen was then placed vertically on top of the frozen 
OCT, surrounded by extra freezing medium, frozen down immediately in the vapour 
phase of liquid nitrogen and stored at -80°C.  The frozen blocks were cut in a cryotome, 
in 8μm sections. The slides were stored at -80°C until further use and were fixed in 
acetone at room temperature for 10 min just prior to immunostaining. 
 
Formalin fixation and paraffin embedding 
The tissue was fixed overnight in 10% paraformaldehyde in phosphate buffer. The 
tissue segment was then subjected to serial dehydration and clearing and finally 
infiltrated with molten paraffin wax. Paraffin embedded tissues (PETs) were sectioned 
on a microtome at 5μm thickness and collected onto SuperFrost slides (Menzel-Gläser). 
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The slides were dried overnight at 42°C. Slides were deparaffinised in two changes of 
Xylene (15 min each) and hydrated through graded ethanol prior to immunostaining. 
 
2.4 Immunohistostaining methods 
 
2.4.1 Indirect immunoperoxidase staining for Endothelial 
Protein C Receptor 
 
Slides bearing fixed tissue sections were rinsed in PBS with 0.1% Triton X-100 
(Sigma). To uncover the antigens, the paraffin embedded sections were boiled in 
10mM Citric acid in water in a microwave oven for 15 mins, cooled down to room 
temperature and rinsed in PBS. All the slides were incubated in 0.5% H2O2 in 
methanol for 15 min followed by multiple washes with PBS. Sections were blocked 
with 10% normal goat serum in PBS for 20 min. After blotting dry, the specimens were 
incubated overnight at 4°C with polyclonal rabbit anti-human EPCR primary antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:100 in diluent (PBS with 0.1% 
Triton and 1.5% normal goat serum). After rinsing with PBS, incubation at room 
temperature with biotinylated goat anti-rabbit secondary antibody (Dako, Denmark), 
diluted 1:380 in diluent, was performed for 30 min before further washing. Using the 
Vectastain Avidin-Biotin ABC kit (Vector laboratories, Burlingame, CA), sections 
were incubated with the mixed buffer for 30 min at room temperature according to the 
manufacturer’s instructions. Specimens were washed again before incubation with 
chromogen DAB solution (Dako Denmark A/S) for 10 min. Slides were then rinsed 
thoroughly in water and counter-stained in Harris’ Haematoxylin, dehydrated through 
graded ethanol; mounted and coverslipped. (Note: positive, negative and isotype 
controls were included in all procedures) 
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2.4.2 Islet marker immunostaining on pancreas tissue 
 
The tissue was fixed and paraffinised as described above, serial sections were cut and 
and collected on SuperFrost slides, then subsequently dewaxed in Xylene and graded 
ethanol as described above, prior to use.  
 
The intensity of islet marker staining was to be subjected to quantitative analysis, thus, 
in order to minimise variability, Autostainer Link 48 [319] -an automated slide 
processing instrument- was utilised for the following series of staining experiments.  
Deparaffinised pancreas tissue sections were boiled in 10mM Citric Acid in water (pH 
6) for 10 min in a microwave oven, cooled down in a water bath and washed in water. 
The slides then were transferred into the Dako Autostainer; all the steps up to 
counterstaining were carried out by the Autostainer at room temperature. Sections were 
then incubated with 0.5% H2O2 in methanol for 10 min to block the endogenous 
peroxidase activity. Samples were blocked with IDetect Super Block solution (ID 
Laboratories, Ontario, Canada) for 5 min. The liquid was blown off and the following 
diluted primary antibodies were added to the sections and incubated for 30 min (Table 
2.4). 
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Primary Antibody Dilution Diluent Company 
Guinea pig anti human 
Insulin antibody 
1:100 TBS+1.5% NGS 
Invitrogen, Life 
Technologies 
Rabbit anti Glucagon 
antibody 
1:100 TBS+1.5% NGS 
Invitrogen, Life 
Technologies 
Rabbit anti 
Somatostatin antibody 
1:100 TBS+1.5% NGS 
Invitrogen, Life 
Technologies 
 
Table 2.4 List of primary antibodies against islet endocrine hormones. 
 
The sections were then washed with washing buffer, TBS with 0.1%Tween20 before 
adding IDetect SuperStain Anti-Polyvalent (ID Laboratories, Ontario, Canada) and 
incubating for 10 min. Sections were then rinsed with washing buffer, and subsequently 
incubated with IDetect SuperStain HRP (ID Laboratories, Ontario, Canada) for another 
10 min.  Following a further washing step, slides were developed with DAB 
chromogen [319] for 10 min. Slides were rinsed thoroughly in buffer, then removed 
from the instrument and counterstained with Harris’ Hematoxylin. Sections were 
dehydrated in graded ethanol, mounted with DPX and coverslipped. Isotype and 
negative controls for each antibody were included in the staining procedure. 
 
2.4.3 Dako ACIS (Automated Cellular Imaging System) 
 
Stained slides were labelled and scanned using the ACIS slide-scanner at 4 different 
magnifications in order to create digital slides. The digital slides were then saved in the 
ACIS workstation and the brown positive staining intensity (DAB-bound epitopes) was 
analysed and numerated by the ACIS software.  
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2.4.4 Insulin immunostaining intensity analysis 
 
Subsequently, a scoring system was designed to grade the numerical staining intensity 
for statistical comparison of groups of study (Table 2.5). The mean scores of each 
treatment group were compared using One-way ANOVA and Bonferroni post-hoc 
analyses and a P value of smaller than 0.05 was considered statistically significant. 
 
Staining intensity value 
acquired from ACIS 
Assigned Score 
90-129 +1 
130-149 +2 
>150 +3 
 
Table 2.5 Staining scoring system designed according to the anti-insulin 
immunostaining intensity. 
 
2.5 Brain death induction in pigs and different donor 
management protocols 
 
A porcine model of brain-death donor was set up to closely imitate the human brain-
dead donor. 16 large white pigs were used during the experiment. 
 
2.5.1 Methods of anaesthesia and ventilation 
 
Animals were sedated by an intramuscular injection of ketamine 10 mg/kg, midazolam 
1 mg/kg and atropine 0.05 mg/kg. General anaesthesia was induced using intravenous 
(IV) thiopentone 2–10 mg/kg. Pigs were then intubated and ventilated with 100% 
oxygen. Isoflurane inhalation and injection of fentanyl were administered when 
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required. Intravenous saline (0.9%) was infused from one hour post-induction of BD to 
maintain the central venous pressure (CVP) at 0–5 mmHg. Lignocaine 1 mg/kg IV was 
given for arrhythmia prophylaxis. 
 
 Monitoring of the animals included: electrocardiogram, invasive arterial blood 
pressure (via a femoral arterial catheter), CVP (via an internal mammary central venous 
catheter), pulse oximetry, end tidal expired CO2 and core temperature. Arterial blood 
gas and glucose analyses were performed at hourly intervals, and when clinically 
indicated, using an i-STAT Portable Clinical Analyzer (i-STAT Corporation, USA). 
Urine and bile production was monitored and recorded. 
 
2.5.2 Instrumentation 
 
To monitor the haemodynamic status, ultrasonic dimension transducers (Sonometrics 
Corp., Canada) were placed to measure pulmonary wedge pressure (PAWP), cardiac 
output and mean arterial pressure (MAP). 
Flow probes (Transonic Systems Inc., USA) were placed around the left renal artery, 
hepatic artery and portal vein to measure the perfusion of the organs.  
 
2.5.3 Induction of brain death 
 
Brain death was induced in animals following the protocol described by Hing et al. 
[231]. A burrhole was drilled in the right frontoparietal skull, a Foley catheter was 
inserted in the subdural space, and brain death was induced by inflating the Foley 
catheter balloon with water in 3 mL increments every 30 s to a total of 24 mL. By 
increasing the intracranial pressure an autonomic storm was induced. Brain death was 
 86 
confirmed by the typical hemodynamic changes, as well as the absence of response to 
painful stimuli, and the absence of pupillary and corneal reflexes. Anaesthesia was 
ceased when BD was confirmed. The animals were maintained for 6 hours before 
termination of the experiment. 
 
2.5.4 Donor management 
 
Brain-dead pigs were randomly assigned to two different donor management protocols, 
noradrenaline pressor support (NA) versus hormone resuscitation (HR). One hour after 
induction of brain death, either of the treatments was commenced. To the NA-receiving 
group noradrenaline (3.3µg/min) was administered and pigs in the HR group were 
given a cocktail of methylprednisolone, triiodothyronine, arginine-vasopressin and 
insulin (Table 2.6). In both groups infusions were titrated to maintain mean arterial 
pressure at 60-70 mmHg (Figure 2.3). 
 
 
Hormone Dose  
Methylprednisolone 15 mg/kg IV bolus 
Triiodothyronine 4 μg IV bolus, followed by 4 μg/h  IV infusion 
Arginine-vasopressin 0.5–4.0 units/h titrated to mean  arterial 
pressure 60–70 mmHg 
Insulin Titrated to blood sugar level 6–10  mmol/L at minimum 1 unit/h IV 
  
 
Table 2.6 Hormone-resuscitation protocol. 
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2.5.5 Organ procurement 
 
Core-needle or wedge biopsies were harvested from visceral organs including pancreas, 
kidneys, liver and intestine at baseline (0 hr) and 6 hrs post brain death. In a sterile Petri 
dish the biopsies were cut if necessary into 2x2mm and snap-frozen separately in the 
vapour phase of liquid nitrogen, then stored in NUNC cryovials in liquid nitrogen for 
molecular biology studies. Also 5x5mm tissue sections were fixed in formalin for 
further paraffinisation as previously outlined as well as snap-frozen by immersion in 
TissueTek freezing medium (Ted Pella, Inc. and PELCO International, Redding, CA) 
in cryomolds following the method described above, and stored at -80 ºC subsequently.  
The experiment was terminated 6 hours post BD, the abdominal aorta was cross-
clamped and the visceral organs were removed en-bloc, and then transferred to the 
backtable where the final specimens collected. Serum and urine samples were also 
harvested at 0 hr and 6 hr time points and frozen in liquid nitrogen. 
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 Figure 2.3 Sequences of brain death induction, treatment commencement and 
specimen collection. 
 
Collection of the pancreas from brain-dead donor pigs 
Pancreas biopsies were collected at both 0 hr and 6 hrs after brain death as described 
above. After procurement, the pancreas was freed from the surrounding tissues and 
dissected. The pieces were transferred into a sterile Petri dish and rapidly cut into 
2x2mm tissue samples that were snap-frozen separately in the vapour phase of liquid 
nitrogen and stored in liquid nitrogen for molecular biology studies. 5x5mm tissue 
sections were stored in formalin for fixation and further paraffinisation as previously 
outlined and also snap-frozen in TissueTek freezing medium. 
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 RNA extraction from pig pancreas tissue 
Total RNA was isolated from pig pancreas tissue as described above using Ambion 
RNAqueous mini kit. RNA concentration and integrity were also determined as 
described above. 
 
Complementary DNA synthesis from total RNA with Random Primers 
cDNA was synthesised using the SuperScript III kit (Invitrogen, CA, USA) following a 
protocol adapted from the manufacturer’s instructions. All samples to be compared 
were included in the same cDNA synthesis reaction. The RNA integrity number from 
all pancreatic specimens was reported suboptimal by Nanorop and Bioanalyzer. It is a 
challenging task to obtain intact RNA from a tissue that contains high amounts of 
RNase and is prone to autolysis, such as pancreas [320]. For this reason, random 
hexamers (Roche diagnostics, IN, USA) were used instead of Oligo-dT to prime the 
mRNA for cDNA synthesis. Oligo dT only binds to mRNA poly-A tail whereas 
random hexamers prime mRNA, with or without a poly-A tail, and this can be used as 
universal, non-specific primers to any site on RNA). Minus RT controls (reaction 
prepared without reverse transcriptase enzyme) and cDNA for preparing standard 
dilution series were included in all reactions. Two cDNA samples were synthesized 
from each RNA sample in two separate procedures. 
1µg of total RNA was made up to 11µl with DEPC-treated water and primed with 2µl 
Random Primers (Invitrogen). The contents were mixed and heated at 65 ºC for 5 mins, 
then cooled on ice before adding the Master Mix. The Master Mix (7µl) consisted of 
4µl of SuperScript III reaction buffer (Invitrogen), 1µl of 0.1M DTT (Invitrogen), 1µl 
of 10mM dNTP (Ultrapure dNTP set, Amersham Pharmacia, Sweden) and 1µl if 
SuperScript III enzyme (Invitrogen). In the Minus RT reaction 1µl of water replaced 
 90 
the SuperScript enzyme. The 20µl mixture was then incubated at 25 ºC for 5 min, 
followed by heating at 50ºC for 60 min and 15 min at 70 ºC. After the completion of 
the reaction, the cDNA was diluted 1:5 by adding 80µl of DEPC treated water and 
aliquoted in 5µl portions in sterile 0.2µl tubes. 
 
Quantitative real-time PCR of porcine genes 
Taqman primer /probe sets for porcine genes are described earlier. The real-time rt-
PCR reaction set up and thermal cycler conditions were as indicated above. Reactions 
were run in a Corbett Rotor-Gene 6000 (Qiagen). The expression level of housekeeping 
genes Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and H.3 Histone 3A, was 
also measured and the formula Gene ExpressionsampleX/ Maintenance GenesampleX 
was applied to normalise the expression level of all cDNA samples.  
 
Analysis of Real-Time RT-PCR data 
Analysis of the results was performed as described in section 2.1.10.  
 
2.6 Apoptosis detection Assays 
 
2.6.1 TUNEL assay 
 
Terminal deoxynucleotidyl transferase dUTP Nick End Labelling, (TUNEL), was used 
as an established method for the detection of DNA strand breaks in the pancreas 
samples. TUNEL staining was performed following the instructions provided along 
with the In Situ cell death detection POD kit (Roche Applied Sciences, 
 Penzberg, Upper Bavaria, Germany). The TUNEL staining was accompanied by anti-
insulin co-staining, to identify the islets throughout the specimen. 
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In brief, slides were deparaffinised and endogenous peroxidase was blocked using 3% 
H2O2 in methanol for 10 min. After washing in PBS, the specimens were treated with 
20ug/ml proteinase K (Roche) in PBS for 15 min at room temperature to uncover the 
antigens masked by fixation. Slides were washed in PBS again and blocked with 20% 
fetal bovine serum (Gibco) in PBS for 20 min at room temperature. 
 
Terminal deoxynucleotidyl transferase enzyme (Roche In Situ cell death detection POD 
kit) was diluted 1:3 in dilution buffer (Roche). The diluted enzyme was then mixed 
1:10 with labelled-nucleotide containing solution (provided with the kit), and sections 
were incubated with this solution for 30 min at 37 ºC in a humidified atmosphere in 
darkness. For the positive control, one section was treated with 2000U/ml DNase I 
recombinant (Invitrogen) in 50mM Tris-HCL, pH7.5, 10mM MgCl2, 1 mg/ml BSA for 
10 min at room temperature to induce DNA strand breaks prior to the labelling 
procedure. The negative control specimen was incubated with label solution only. 
 
After through washing, sections were incubated with peroxidase converter agent for 30 
min at 37ºC in a dark humidified chamber, washed, and visualised with 3,3'-
diaminobenzidine, DAB (Dako). Slides were then rinsed in water before 
counterstaining in Harris’ Hematoxylin, dehydration and coverslipping.  
 
TUNEL-Insulin Double staining 
Consecutive sections of each pancreas tissue sample were double-stained for TUNEL 
and insulin. A double-staining protocol was developed with AlkalinePhosphatase for 
anti-insulin staining, to complement the peroxidase colour development used with 
TUNEL. After Primary anti-insulin incubation, sections were incubated with 
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biotinylated anti Guinea pig IgG secondary antibody (Vectastain ABC-AP) + 10% 
normal goat serum for 30 min at RT. After washing in PBS, Vectastain ABC-AP 
Reagent was added to the specimens for 30 min at RT. Washing was followed by 
visualisation with liquid Permanent Red chromogen (Dako). After a quick wash, slides 
were briefly counterstained with Harris’ Hematoxylin, then left to dry overnight, 
mounted in DPX and coverslipped.  
 
Imaging and analysis of TUNEL-stained pancreas sections 
A minimum of 6 fields at 20x magnification, each showing at least one pancreatic islet, 
were photographed from each of the TUNEL-stained pancreas sections, using an 
Olympus BX60 microscope and Olympus DP72 mounted camera. The images were 
then transferred into the Image J image processing program (NIH, Bethesda, MD). 
Using the particle analysis plugin, TUNEL positive (dark brown) nuclei versus 
negative (hematoxylin-stained) nuclei throughout islet and acinar tissue were manually 
counted and recorded. The average counts from each specimen, including total positive 
and negative and the ratio of these two in both exocrine and endocrine tissue, was then 
subjected to statistical analysis by Mann-Whitney and One-way ANOVA tests. P 
values smaller than 0.05 were considered statistically significant. 
 
2.6.2 Anti Cleaved Caspase-3 immunostaining on pancreas 
tissue 
 
An alternative method of apoptosis detection is based on identification of the activated 
(cleaved) form of caspase-3. Cleaved caspase-3 was detected by immunohistochemical 
staining of formalin-fixed paraffin-embedded pancreas tissue sections. 
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Using a microwave oven, dewaxed and hydrated slides were brought to boil in 10mM 
sodium citrate buffer pH 6.0 and maintained at a sub-boiling temperature (i.e. 98ºC) for 
15 minutes. Slides were left to cool on the bench top for 30 minutes in the buffer. 
Slides were washed in distilled water and incubated in 3% hydrogen peroxide in 
methanol for 10 minutes. They were washed in water and 1x TBS/0.1% Tween-20 
wash buffer subsequently. Sections were blocked with 5% NGS in TBS for 30 min at 
RT, followed by incubation overnight at 4ºC with Rabbit anti cleaved caspase-3 
(Asp157) primary antibody (Cell Signaling technology, Danvers, MA, USA) diluted 
1:10000 in SignalStain Antibody Diluent.  
 
Isotype control (Rabbit Ig from Dako), blocking peptide (Cell Signalling technology) 
and negative control (diluent only) were also included in the staining process. After 
washing, detection was performed with SignalStain® Boost IHC Detection Reagent 
(Cell Signalling technology) for 30min at RT. 3,3'-diaminobenzidine DAB (Dako) was 
added to the section for 5min for colour development before the slides were rinsed in 
water. Sections were then counterstained in Harris’ hematoxylin, dehydrated, mounted 
and coverslipped. 
 
Analysis of the staining results was performed as described for the TUNEL staining 
section, above. 
 
2.6.3 Extraction of fragmented genomic DNA 
 
TACS Apoptotic DNA Laddering Kit (Cat# 4850-20-ET, Cat# 4859-20-K, 
Gaithersburg, MD) was used to isolate fragmented genomic DNA from both tissue 
specimens and cells. We used porcine and murine pancreas biopsies and murine 
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splenocytes to extract genomic DNA. For tissue samples: Around 50 mg of the tissue 
was ground using a sterile frozen mortar and pestle. The powdered tissue was then 
incubated in 200μl of Sample Buffer and 20μl of 10x Tissue Buffer from the kit for 18 
hours, before proceeding to the rest of protocol. For cells: 105 to 107 cells were 
incubated in 100μl sample buffer for 15 minutes, then 100μl of lysis solution was 
added, and mixed thoroughly by inversion. 
 
The same protocol was followed for both tissue and cells subsequently. After shaking, 
700μl of Extraction Solution 2 was added to the sample in a 2ml microcentrifuge tube. 
400μl of Extraction Buffer 3 to was added to the sample and vortexed for 10 seconds. 
The solution was centrifuged at 12,000 x g for 5 minutes. The upper layer (aqueous) 
was transferred to a new microcentrifuge tube. The darker, lower organic phase was 
discarded.  
 
The following reagents were added sequentially to the aqueous sample: 40μl (i.e. 0.1 
volume) sodium acetate and 440μl (i.e. equal volume) 2-propanol, mixed by inversion 
between additions, then centrifuged at 12,000 x g for 10 minutes at room temperature. 
The supernatant was carefully removed without disrupting the pellet. 1 ml of 70% 
ethanol was added to the pellet to wash, and centrifuged at 12,000 x g for 5 minutes at 
room temperature. The supernatant was carefully discarded; the pellet was let dry by 
inverting the tube on a laboratory tissue.  The pellet was resuspended in 20-100μl 
DNase-free Water. DNA concentration and quality was determined using a Nanodrop 
1000 spectrophotometer (Thermo Fisher Scientific, MA), and DNA was stored at -20 
ºC for further use. 
 95 
Visualisation of DNA laddering 
The extent of DNA fragmentation caused by apoptosis can be observed by horizontal 
electrophoresis of DNA in agarose gel. For this purpose, 1% agarose gel was made by 
dissolving Trevigel 500 from TACS kit in 1x TAE buffer, using microwave heat. The 
liquid was poured into a in large gel casting tray and left to set. 2 μg of the genomic 
DNA was made up to 10 μl and loaded with 2 μl of 5X Gel Loading Buffer in the gel 
wells. 12 μl of GeneRuler 1kb Plus DNA Ladder (Cat#SM1331/2/3, Thermo Scientific) 
was loaded in the ladder lane. The gel was electrophoresed for 2 hours at 100V. Before 
imaging, the gel was soaked in 0.5 μg/ml Ethidium Bromide in 1x TAE buffer for 30 
minutes. The gel was then visualized in a Syngene G:Box Chemi HR16 apparatus 
(Syngene, Synoptics Ltd, Cambridge, United Kingdom) under UV light. 
 
2.7 Splenocyte isolation from C57BL/6 mouse spleen 
 
Scissors and forceps were rinsed in 70% EtOH before use. A normal C57BL/6 mouse 
was sprayed with 70% ethanol. A vertical incision was made in the abdomen, and the 
spleen collected into 10ml of 4ºC RPMI medium (Sigma), then mashed, with a sterile 
syringe plunger, through a 100μm metal sieve into a cold 100mm Petri dish (Sigma). 
The cell suspension was collected in a 50ml conical Falcon tube (BD Biosciences). The 
sieve was washed with a further 40ml of medium (50 ml final medium). The 
suspension was centrifuged at 600 x g, 4ºC for 10 mins. Supernatant was removed 
afterwards.  
 
The cell pellet was thoroughly resuspended and 2ml of NH4Cl (red blood cell) lysis 
buffer was added with a pasteur pipette. The mixture was then incubated at room 
temperature for 2 minutes, during which the suspension changed from slightly opaque 
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to clear. The tube was filled with RPMI medium and centrifuged at 600 x g, 4ºC for 10 
mins. Supernatant was then discarded. The pellet was resuspended in ~25ml RPMI 
medium with a pipette and filtered through a 40μm cell strainer (BD Biosciences) into 
new a Falcon tube to remove residual tissue pieces and clumps. The strainer was rinsed 
through with RPMI until the tube contained 50ml of cell suspension. The tube was 
centrifuged at 600 x g, 4ºC for 10 mins. The supernatant was removed. Cells were 
made up to 20ml in RPMI medium, stained with trypan blue to determine the viability 
and counted by haemocytometer, then seeded as required. The yield is about 2-3 x 107 
cells. 
 
Induction of apoptosis in mouse splenocytes using Etoposide 
The treatment groups received Etoposide at a final concentration of 8.5μM, and were 
incubated for 2, 6 and 20 hours before harvesting. Genomic DNA was extracted from 
the cells as it was explained above using the TACS DNA laddering kit. 
 
2.8 Brain death induction in C57BL/6 mice 
 
2.8.1 Development of a brain death model in mice 
 
Induction of brain-death and maintenance of brain-dead mice prior to tissue harvesting 
was performed by Mr. Zane Wang in our laboratory. This model is adapted from the 
protocol published by Atkinson et al [229]. 
 
 Anaesthesia and Ventilation 
Mice were anaesthetised using IP injection of a mixture of Ketamine (Hospira Australia, 
VIC, Australia) (81mg/kg) and Xylazine (Troy Laboratories, NSW, Australia) 
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(9mg/kg). The depth of the sedation was monitored every few minutes and before any 
invasive procedure through the withdrawal reflex and observation of the whiskers of the 
mouse.  
 
Top-up doses of ketamine and Xylazine were administered when required. 
The Inspira advanced safety rodent ventilator (Harvard Apparatus, MA, USA) was used 
for ventilation with an FIO2 of 60%. The ventilator tubing was attached to a 22G blunt 
tipped cannula (BD Medical, MC, USA) used for insertion into the trachea. The 
ventilator auto-adjusts its ventilation settings according to the input weights of the mice. 
Pressure-controlled mechanical ventilation was substantially better than volume-
controlled ventilation at maintaining good oxygen saturation in the mice.  
 
Fluid Support 
The colloid solution we chose to use was Gelofusine (B.Braun, AG, Germany), a 
colloidal plasma volume replacement fluid based on modified fluid gelatine which has 
iso-oncotic pressure, physiological pH and a low chloride content. 
Immediately prior to induction of brain-death, mice received one bolus of 0.5ml IV 
Gelofusine and 2.0ml SC of normal saline at four sites. Following the initial bolus, 
1.5ml of normal saline was administered hourly SC divided amongst three sites. Further 
IV boluses of 0.25ml Gelofusine were given following femoral artery cannulation if the 
MAP was below 55mmHg, and then as required when the MAP dropped to 40mmHg or 
below (Figure 2.4). 
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 Figure 2.4 Typical races for the optimized model of BD with Gelofusine as fluid 
support. MAP peaked rapidly at the time of BD induction. This was accompanied by a 
permanent increase in HR, followed by a slow decline in BP over the subsequent hours. 
Gelofusine fluid support maintained blood pressure without compromising oxygen 
saturation. Temperature was kept between 37oC to 38.5oC. 
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Organ Harvesting 
Pancreas (along with other organs including kidney, heart, liver and spleen) was 
collected into formalin for paraffin embedding and sectioning,  liquid nitrogen as snap 
frozen pieces for RNA extraction and analysis and also into OCT for frozen sectioning. 
 
Invasive and non-invasive monitoring 
All procedures performed below were done on C57BL/6 male mice. Following 
anaesthesia with Ketamine and Xylazine, the left thighs of the mice were shaved in 
preparation for femoral artery cannulation. 
 
The scalp was incised vertically, and a 14G cannula stylet was used to drill a burr hole 
in the bottom left corner of the right parasagittal bone (Figure 2.5). A 2F Fogarty 
balloon catheter was then inserted into the burr hole and secured using masking tape. 
Brain death will be induced after mechanical ventilation and invasive BP monitoring 
have been established. Upon completion of the burr hole, mice were placed into the 
dorsal position. A rectal thermometer was then inserted. A vertical midline incision was 
made in the anterior neck. The two halves of the sternohyoid muscle were then 
separated and trachea exposed. A loose 5-0 silk tie was then placed around the trachea. 
The ventilator was set to pressure controlled ventilation with mouse weight entered, 
PEEP of 5cmH2O and FIO2 60%, and gas flow was started. A small transverse incision 
was then made in the sub-laryngeal area between two rings of cartilage (Figure 2.6 A). 
The 22G blunt tipped cannula attached to the ventilator tubing was then inserted into the 
trachea to a pre-determined mark, avoiding cannulation of either of main bronchus and 
ensuring ventilation of both lungs. The cannula was then secured with the loose tie. An 
 100 
additional 5-0 silk tie was then placed around the trachea and cannula to maintain a 
snug fit preventing gas leakage (Figure 2.6 B).  
 
 
Figure 2.5 Creation of burr hole.  A) Theoretical location of burr hole marked by “X”; 
B) Actual burr hole made in mice. 
 
 
 
Figure 2.6 Depiction of tracheostomy. A) The exposure and opening of trachea; B) The 
securing of the ventilator tube to the trachea. 
 
 
A  B 
 B  A 
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The last surgical procedure was the cannulation of the left femoral artery for MAP 
monitoring. An incision was made in the left inguinal area. The femoral neurovascular 
bundle was exposed using blunt dissection with cotton buds (Figure 2.7 A). The femoral 
artery was then separated from the surrounding tissues and vessels in the area between 
the abdominal wall and the superficial epigastric artery, (Figure 2.7 B). Lignocaine was 
used to help prevent artery vasospasm. Once separated, the distal end of the femoral 
artery was ligated with a 5-0 silk tie, slightly retracted with a clamp. A 5-0 silk tie was 
also placed around the proximal end of the artery, with a loose knot. This tie was also 
retracted and elevated using a clamp until the point where blood stopped running into 
the area in between the two ties (Figure 2.8 B and step 1 of Figure 2.8 A). A small 
transverse incision was made 2mm proximal to the distal tie (step 2 of figure 2.8 A). 
One tip of a micro-forceps was then inserted into the artery for 10 seconds to dilate it, 
preparing it for cannulation. A 1.2G cannula (Solomon Scientific, TX, USA) was 
inserted into the femoral artery beyond the proximal tie (step 3 of Figure 2.8 A). The 
cannula was secured by tightening the proximal and distal ties (step 4 of Figure 2.8 A). 
A pulsation within the cannula should be observed at this point as a sign of success. The 
MAP was read and recorded via the Physiomex® data recorder system.  Finally, a 
MouseOX® pulse oximeter (Starr Lifesciences Corporation, Oakmont, PA) with mouse 
tail clip was used to detect, monitor and record oxygen saturation and heart rate.  
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 Figure 2.7 Exposure of the femoral artery. A) Exposure of the femoral neurovascular 
bundle; B) Separating the artery from surrounding tissues and vessels. 
 
 
 
Figure 2.8 Depiction of femoral artery cannulation. A) Steps to performing a successful 
femoral artery cannulation. Step 1 shows the ligation of the distal end of the femoral 
artery and retraction with suture of the proximal end to prevent bleeding when the artery 
is transversely slit open in step 2. Step 3 shows the cannulation of the femoral artery and 
in step 4 the cannula is secured within the artery; B) Overview of the setting when 
doing the procedure. 
 
 
Body Temperature 
Core temperature was measured using a rectal probe (Columbus Instruments, Ohio, 
USA), and was maintained within the range of 37oC to 38.5oC (Figure 2.4) using a 
 B  A 
 103 
heating pad (Redzone Heating, Australia). Temperature was displayed on a Physiomex 
small animal physiological monitor (Columbus Instruments, Ohio, USA). 
 
Brain Death Induction 
Induction of brain death was performed in a similar manner to that described in other 
protocols for induction of brain death in rodents. The balloon of the Fogarty catheter is 
slowly inflated to progressively increase intracranial pressure leading to brain stem 
herniation and irreversible brain death. The burrhole was sited in the right parasagittal 
bone (Figure 2.5). 
 
The syringe connected to the Fogarty catheter was placed into an automated syringe 
driver (Harvard Apparatus, MA, USA) and saline was infused into the balloon at a 
constant rate of 5µl/min over 20 minutes up to a maximum of 100µl. Inflation was 
ceased at the point where mean arterial pressure (MAP) started rising rapidly (figure 
2.4). This was accompanied by a permanent increase in heart rate (HR), followed by a 
slow decline in MAP over the subsequent hours (Figure 2.4). 
 
2.8.2 Cloning and subcloning of esRAGE cDNA 
 
A cDNA encoding human esRAGE was obtained in two different ways. Firstly, 
esRAGE was amplified from normal human lung explanted in the course of resecting a 
pulmonary tumour. Amplification primers were forward 
CACCATGGCAGCCGGAACAGCAGTTGGAGC and reverse 
GCGGATATCCTTGTTGACCATCCCCCCAG. PCR products were run on 1% 
agarose gel to confirm that a band of expected size was amplified, then sequenced using 
the forward primer above as a sequencing primer (Figure 2.9). 
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In parallel, a codon-optimised cDNA sequence for esRAGE had been ordered from 
GeneArt (Life Technologies, NY, USA). 5µg of the pMA plasmid containing this 
cDNA was resuspended in 50µL of ultrapure H2O and then transformed into SURE-2 
competent E. coli (Stratagene, CA, USA) and allowed to grow on agar plates. A few 
colonies from the plate were selected for Mini-preparation and colony PCR using a 
Quick Mini-prep Kit (Invitrogen, CA, USA) to verify that plasmids contained the 
esRAGE cDNA.  Once the inserts were verified, a colony was selected for Maxi-
preparation. Plasmid DNA concentration was estimated by measuring absorbance at 
260nm on a nanodrop spectrophotometer (Thermo Scientific, MA, USA). Restriction 
enzyme digestion with NotI (New England Biolabs, MA, USA) and EcoRV (New 
England Biolabs, MA, USA) confirmed the presence of a band running at the expected 
size of 1113 base pairs (bp) on agarose gel electophresis. The esRAGE insert was 
amplified from the maxi-prepped plasmid DNA using esRAGE-specific primers as 
above, then both the GeneArt sequence and the native sequence were TOPO cloned into 
pcDNA3.2 (Invitrogen, CA, USA), a mammalian expression vector. The pcDNA3.2 
plasmids containing each of the esRAGE cDNAs were then transformed into one shot 
Top-10 E. coli. Correct sequencing was confirmed once again with Mini-preparation 
and PCR. Following this, expression of the esRAGE protein from these constructs was 
tested in vitro by transfecting the mammalian cell line HEK293D with the pcDNA 3.2-
esRAGE plasmid, collecting the supernatant at 48 and 72 hours after transfection and 
quantitating esRAGE using a commercially-available human esRAGE sandwich ELISA 
(B-Bridge International, CA, USA). Protein expression in vitro was slightly higher from 
the GeneArt than from the native construct, and so the codon-optimised GeneArt 
construct was used in all further experiments. 
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Figure 2.9 Codon-optimised nucleotide sequence of esRAGE designed by GeneART. 
 106 
Production and Packaging of an rAAV 2/8 vector encoding human esRAGE 
Packaging of recombinant rAAV 2/8 vectors requires that the packaging cell line 
HEK293D is triple-transfected with the following plasmids: pAM2AA (encoding the 
gene of interest and the inverted terminal repeats of the AAV serotype 2 genome) 
p5E18VD2/8 encoding the rep gene from AAV2 but the viral capsid protein from AAV 
serotype 8, and pXX6 (encoding adenoviral helper factors) (Figure 2.10). 
 
 
 
 
 
Figure 2.10 Triple transfection with pAM2AA, pXX6 and p5E18VD2/8, yields 
rAAV2/8 virions after purification.  
 
 
To produce complementary sticky ends and ensure rapid directional ligation, the 
template expression vector pAM2AA-eGFP and PCR fragments of esRAGE were 
simultaneously digested with EcoRV and NotI to release esRAGE fragments as well as 
to linearize the pAM2AA-eGFP vector. 
 
The digested pAM2AA and esRAGE fragments were run on a 1% agarose gel and 
extracted using a Wizard Gel Extraction Kit (Promega, WI, USA). These were the 
ligation products. The amount of PCR product used in the ligation was set at a 3:1 
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vector: insert ratio, and the ligation was performed using Quick T4 DNA Ligase (New 
England Biolabs, MA, USA) in a 5µl volume for 5 minutes at room temperature. 
 
The products of the ligation were transformed into SURE-2 Supercompetent cells 
(Stratagene, CA, USA). The transformed cells were plated onto agar plates with 
ampicillin (100µg/mL) at 2 different concentrations of 20µL and 200µL. A resistant 
colony was randomly selected for Mini-preparation and colony PCR to verify the 
sequence. Once verified, correct clones underwent Maxi-preparation and then sequence 
confirmation as described above in 13, ‘Cloning and subcloning of esRAGE cDNA’.  
 
Once the sequence was verified, p5E18 and pXX6 were used along with pAM2AA-
esRAGE for packaging. HEK293D cells were cultured at 37oC in 5% CO2 with standard 
medium: DMEM supplemented with 10% fetal calf serum (FCS). These cells were 
seeded into 40x10cm2 tissue dishes. The following day, the medium was refreshed in 
the morning and a triple transfection using calcium phosphate was performed 3 hours 
later. At 16 hours post-transfection, standard medium was replaced with DMEM + 2% 
FCS. Cells were then harvested 48 hours post-transfection and immediately stored at -
80oC.  
 
Virions were separated from the cell lysate by cesium chloride gradient purification, and 
then concentrated. Vector quantification was performed using quantitative real time 
PCR and vector was aliquotted at 5x1011 viral genome copies for use.  
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Control vectors 
A vector encoding Human serum Albumin was produced by PhD student Miriam Habib 
using an albumin cDNA cloned from explanted human liver, and was used as a control 
vector in subsequent experiments. Vector production and packaging were as outlined 
here for esRAGE, and a dose of 5x1011 VG yielded a concentration of human albumin 
of 90µg/mL in mouse serum. 
 
2.8.3 mRNA extraction, cDNA synthesis and real time RT-
PCR from mouse pancreatic tissue 
 
Total RNA extraction from snap-frozen mouse pancreas and cDNA synthesis were 
performed following the protocols outlined under section 2.1.7. Real time RT-PCR was 
set up and run using Taqman primers and probes as described above in section 2.1.10. 
 
Taqman Primer and probe sets for murine genes 
The Taqman primers and probes were either ordered as “primers on demand” from 
Applied Biosystems or designed using Primer Express and purchased from Sigma 
(Table 2.7). The sets purchased as all-in-one products from Applied Biosystems were 
(Name of the gene and accession number on Applied Biosystems website): Histone3f3a 
(Mm01612808), CXCL10 (Mm00445235), IL-10 (Mm00439616), IL-6 
(Mm00446190), IL-33 (Mm00505403), HSP2 (Mm00434069), TNFα (Mm00443258), 
TLR4 (Mm00445274), Complement Component3 (Mm00437858), A20 
(Mm00437121). The primers and probes we designed are shown in the table below 
(Table 2.7).  
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 Gene Name Sequence (5’ → 3’) 
 
GAPDH 
 
Forward TGCACCACCAACTGCTTAGC  
Reverse GGCATGGACTGTGGTCATGAG  
Probe CCTGGCCAAGGTCATCCATGACAACTT  
 
MCP1 
Forward GAGCATCCACGTGTTGGCT  
Reverse TGGTGAATGAGTAGCAGCAGGT  
Probe AGCCAGATGCAGTTAACGCCCCACT  
 
MIP2 
Forward GCCCCCAGGACCCCA  
Reverse CTTTTTGACCGCCCTTGAGA  
Probe TGCGCCCAGACAGAAGTCATAGCCA  
IL-1β 
Forward GCACACCCACCCTGCAG  
Reverse AACCGCTTTTCCATCTTCTTCTT  
Probe TGGAGAGTGTGGATCCCAAGCAATACCC  
Hyaloronan 
synthase 2 
(HAS2) 
Forward CAGCCTTCAGAGCACTGGG 
Reverse TGAGGCAGGGTCAAGCATAGT 
Probe CGAAGCGTGGATTATGTACAGGTGTGTGACTC 
 
RAGE 
Forward GGACCCTTAGCTGGCACTTAGA  
Reverse GAGTCCCGTCTCAGGGTGTCT  
Probe ATTCCCGATGGCAAAGAAACACTCGTG  
 
HMGB1 
Forward TGGGCGACTCTGTGCCTC 
Reverse GCCTCTCGGCTTTTTAGGATC 
Probe CGGAGGAAAATCAACTAAACATGGGCAAA 
 Forward TTGGTTCAGAAAATTGTCCAAAAG  
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KC Reverse CAGGTGCCATCAGAGCAGTCT  
Probe TGCTAAAAGGTGTCCCCAAGTAACGGAGAAAG  
RAE-1 
 
Forward ATGAATTCTTAAAGCAGTCCAAGGAA 
Reverse GGAAGTTGATGTAAGCTGGGTGATA 
Probe AGCCAAGATCAACCTC 
 
Insulin 
Forward CAGCAAGCACGTATTGTTT 
Reverse GGACCACAAAGATGCTGTT 
Probe TGCCCTCGGGAGCCC 
    
Table 2.7 Taqman primer/probe sequences for murine genes. 
 
 
2.8.4 Immunohistostaining on mouse pancreas 
 
Anti-insulin immunostaining was performed on paraffin-embedded mouse tissues 
following the protocols described earlier in section 2.4. 
 
2.8.5 Apoptosis detection in mouse pancreas 
 
Programmed cell death was investigated in mouse pancreas utilising TUNEL and anti 
Caspase3 immunostaining as well as genomic DNA studies as per the methods outlined 
in earlier section 2.6. 
    
2.8.6 Indirect immunoperoxidase staining for neutrophils 
 
Deparaffinised PET sections were heated in 10mM Sodium Citrate (pH 6) in the 
Decloaking Chamber (Biocare Medical, Concord, CA) for 15min for antigen retrieval 
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and then washed in TBST buffer (50mM Tris pH 7.4, 300mM NaCl, 0.05% Tween-20). 
Sections were blocked for 20 minutes in 20% normal goat serum in TBST buffer. The 
primary rat anti-mouse Ly-6B.2 (neutrophil) antibody (AbD Serotec, Raleigh, NC) was 
diluted 1:100 in 1% normal goat serum in TBST buffer; specimens were incubated with 
the primary antibody for 1hr at room temperature. After washing in TBST buffer, slides 
were incubated in 3% H2O2 in methanol for 5 minutes to block endogenous peroxidase 
activity. Slides were washed again and then incubated with the secondary biotinylated 
goat anti-rat antibody (BD Pharmingen, San Diego, CA) diluted 1:150 in 1% normal 
goat serum in TBST buffer. Following another wash, the detection solution was made 
by mixing 1:100 reagent A and 1:100 reagent B (Vector Laboratories, Peroxidase standard, 
Cat # PK 4000) in 1% normal horse serum in TBST buffer, and incubated slides with 
this solution for 30min at room temperature. Slides were washed in TBST and water, 
and incubated with DAB chromogen (DAKO) for 1min, washed in water, slide were 
then counterstained in Harris’ Hematoxylin, followed by dehydration and 
coverslipping. 
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3.1 Introduction 
 
Pancreatic islet allotransplantation is proven to successfully treat uncontrollable T1DM 
and in some instances to replace exogenous insulin therapy. However, this therapeutic 
option is limited by the low availability of islet donors compounded by the poor quality 
of many donor pancreata rendering them unsuitable for transplantation. Optimisation of 
the quality of donor organs and development of a sustainable supply of tissue for islet 
replacement are two approaches which might allow an expansion of clinical islet 
transplantation and both are being actively pursued.  
 
Procured pancreatic islets undergo sequential injuries beginning with the ischaemic and 
inflammatory consequences of donor brain death, the subsequent exposure to digestive 
enzymes and loss of interactions with extracellular matrix components which 
characterise the isolation procedure and further changes during culture, and the instant 
blood-mediated inflammatory reaction, or IBMIR, all of which accelerate inflammation 
and graft loss [14]. Islets are routinely cultured prior to infusion, and the culture period 
represents an interval during which islets can be studied to determine their response to 
various stimuli. Additionally they can be subjected to anti-inflammatory and 
immunomodulatory strategies, such as preconditioning with anti-inflammatory 
substances, gene therapy etc. Activated protein C is known for its unique cytoprotective 
properties, and has been demonstrated to protect islets, decrease IBMIR and increase 
engraftment in human and murine islet transplant studies [117, 191, 305, 306]. 
 
Human islets for research are very limited. Apart from their suitable physiology, 
porcine neonatal islet cell clusters are particularly favourable for both experimental and 
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clinical applications; they are more robust and less immunogenic than mature islets and 
can be manipulated more easily. 
 
The endothelial protein C receptor (EPCR) was initially identified on endothelium but 
has subsequently been demonstrated on a range of cell types. To our knowledge, the 
direct effect of rHuAPC on porcine neonatal islet cell clusters (pNICCs) has not been 
investigated. We aimed to evaluate the inflammatory status of pNICCs in culture and 
hypothesized that rHuAPC could exert anti-inflammatory activity on pNICCs. 
 
3.2 Porcine neonatal islet cell clusters in culture after 
isolation 
 
Porcine neonatal islet cell clusters (pNICCs) were isolated by physical and enzymatic 
procedures from the whole piglet pancreata according to the methods described in 
chapter 2 (section 2.1 and 2.2). The pNICCs were seeded in 150 mm x 20 mm Petri 
dishes containing culture medium, [Hams F-10 medium (Sigma) + 10% pig serum] at a 
concentration of 1000 ICC/ 3 ml. Medium change and culture procedures were 
performed as outlined above.  
 
Observation of the islets during the culture period showed that they were shedding most 
of the excess acinar tissue until day 6 in culture (Figure 3.1). 
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A large cluster of islets at day 0 
 
                  
Figure 3.1 A cluster of porcine neonatal islets surrounded by exocrine tissue freshly 
after isolation form pancreas. Staining is double fluorescent acridine orange/ethidium 
bromide. Dead cells stained red, live cells stained green (200x magnification). 
 
 
The integrity of the ICCs, as identified by the surrounding capsule condition, is well 
maintained until day 6 and then gradually declines until day 14. Viability of the islets is 
assessed by staining with acridine orange/ethidium bromide. Green cells are viable 
whereas red cells are not. According to the literature and our experience, smaller-sized 
islets maintain viability in vitro better than larger islets (Figure 3.2).  
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Day 3 Day 6 
  
 
Figure 3.2 pNICCs at day 3 and 6 post isolation and bright field microscopy x20. 
Images A and C show pNICCs stained with acridine orange/ethidium bromide for 
viability assessment under a fluorescence microscope. Images B and D show islets from 
the same day of culture, under a bright field microscope. In A, the surrounding acinar 
cells which are being shed at day 3, fluoresce in red; in C, increased dead cells, also in 
red, at the core of islets, are observed on day 6 (200x magnification).  
 
 
 
3.3 Gene expression profiling of porcine neonatal islet cell 
clusters in culture  
 
3.3.1 RNA extraction and CDNA synthesis from PNICCS 
 
pNICCs were harvested after various durations of culture for nucleic acid extraction as 
described in chapter 2. Total RNA was isolated and reverse-transcribed to cDNA as 
outlined above. In total, 8 islet preparations from 8 piglets in 6 independent 
experiments were collected for this study. 
 
 
A 
B 
C 
D 
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3.3.2 Real Time RT-PCR and gene expression evaluation 
 
The real time RT-PCR reaction was set up as described above. The list of Taqman 
primer and probe sets is given in chapter 2 (section 2.1). GAPDH and Histone H3 
genes were used to normalise the gene expression across all cDNA samples. The results 
were analysed using One-way ANOVA and Mann Whitney U tests. 
 
3.3.3 Histone H3 versus GAPDH as a housekeeping gene for 
pancreatic islets in culture 
 
Quantitative gene expression results are often normalized to the expression levels of 
“housekeeping” or “maintenance” genes as internal standards.  
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) is a high-expressing gene 
which is frequently used for normalisation of RT-PCR results. However, according to 
the literature [321, 322], GAPDH, as a key enzyme in metabolism, is affected by a 
number of factors including the type of tissue and nutritional variations. Particularly in 
the upper digestive tract, GAPDH expression is largely modulated by nutritional 
factors. Our results from testing GAPDH expression in pNICCs and whole pancreas at 
different time points and conditions confirmed the fluctuation of GAPDH (Figure 3.3). 
Therefore it was decided to select a more constant and preferably structural molecule as 
the maintenance gene. Studies show that Histone H3, a basic protein in chromatin 
structure, is a reliable choice [323, 324]. 
 
Real time RT-PCR was performed for both GAPDH and Histone H3 in pNICCS from 5 
piglet pancreata to compare the expression level at different times, and the results were 
analysed by One-way ANOVA.   
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Comparing the expression level of the two housekeeping genes, GAPDH and Histone 
H.3, in pNICCs by RT-PCR demonstrates significantly different patterns of expression 
on different days during culture. Histone H.3, a structural gene, maintains a steady 
expression after islet isolation throughout the culture period, whereas GPADH, a 
metabolic gene, is at its lowest level at day 0 after isolation. GAPDH expression is 
significantly upregulated between d0 and d4, followed by a modest increase until day 6. 
This difference in gene expression suggests that Histone H.3 is more suitable as the 
internal control gene for RT-PCR in pNICCs (Figure 3.3). 
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Figure 3.3 Comparison of two housekeeping genes in pNICCs is indicative of a 
significant increase in GAPDH mRNA level in pNICCs post isolation until day 4 and 6, 
whereas Histone H3 expression remains constant during the culture period. Therefore 
Histone H3 is a more reliable control for normalising RT-PCR results. Error bars refer 
to standard deviation. 
 
 
 
3.3.4 Gene expression in porcine neonatal islet cell clusters 
during the culture period 
 
We studied a panel of genes with different functions to assess the behaviour of pNICCs 
post isolation and in culture. These “biomarkers” are major indicators of islet maturity 
and function, and can predict the engraftment prognosis [112]. β cells, the major 
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endocrine population within pancreatic islets, secrete insulin; this mechanism is 
regulated in a complex and multifactorial manner [325-327]. 
 
Tissue injury caused by pancreas procurement and islet isolation leads to release of 
chemokines and cytokines such as IL-8, MCP1 and TNFα, as well as alarmins or 
DAMPs (damage-associated molecular patterns) like HMGB1 and HSP72  [113, 250, 
328] [329]. These act as endogenous ligands for PRRs (pattern recognition receptors) 
including TLRs [330]. TLR signalling contributes to production of downstream 
proinflammatory molecules particularly those related to inflammation, apoptosis, cell 
growth, and angiogenesis in islets [206, 269]. 
 
Matrix metalloproteinases are typically found in any remodelling, diseased or inflamed 
tissue [331]. MMPs play a central role in cell proliferation, migration, differentiation, 
angiogenesis, apoptosis and host defences. Matrix metalloproteinase-2 (from the 
gelatinase subgroup) degrades type IV collagen, the major structural component of 
basement membranes.  
 
MMP-2 is often constitutively expressed and expression is regulated at both 
transcriptional and post-transcriptional levels by transforming growth factor (TGF) β. 
[332, 333]. Activated protein C acts via its receptor EPCR to increase gene and protein 
expression of MMP-2, and is able to directly cleave and activate the MMP-2 
proenzyme [334]. EPCR expression can be upregulated by the presence of activated 
protein C (APC) and EPCR has been found to be present on endothelial cells, 
keratinocytes, monocytes, CD56+ NK cells, neutrophils, eosinophils, tenocytes, etc 
[192]. 
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The following results are RT qPCR data normalised to Histone H.3 values and analysed 
with One-way ANOVA and Mann Whitney U tests. Error bars are representative of 
standard error of the mean. 
 
Insulin gene expression: 
As the β cells within the neonatal islet cell clusters mature, they acquire the ability to 
secrete insulin and this is reflected in a progressive increase of insulin mRNA 
expression from d4 to 14 post-isolation (Figure 3.4). 
 
 
Figure 3.4 Insulin gene expression, as a key marker of islet function, demonstrates a 
significant gradual rise from d0 to d14. This is expected as neonatal islet cell clusters 
gradually mature during this period. 
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Toll-like receptors: 
The temporal pattern of gene expression differs between Toll-like receptor (TLR) 2 and 
Toll-like receptor (TLR) 4. TLR2 expression is highest immediately post isolation and 
falls steadily during the culture period to reach a minimum by d10. Conversely, mRNA 
expression for TLR4 is initially low, reaches a peak between day 3 and 6 post-isolation 
with a subsequent decline, though at day 14 levels remain above baseline (Figure 3.5). 
 
 
Figure 3.5 Toll-like Receptors 2 and 4 follow different patterns of expression. TLR4 is 
at its minimum just after isolation, increases significantly until day 6 and declines again 
by day 14. TLR2 on the other hand is most highly expressed at day 0, and after some 
fluctuations decreases significantly towards end of culture until d14. 
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Danger-associated molecular pattern molecules: 
Danger signals or damage-associated molecular pattern molecules (DAMPs) are 
expressed by pNICCs immediately post-isolation. Both HMGB1 and HSP72 exhibit 
some fluctuations from day to day during culture (Figure 3.6). 
 
 
 
Figure 3.6 Alarmins HSP72 and HMGB1, are expressed immediately after isolation 
and levels fluctuate until day 14 of culture. 
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Chemokines: 
Different chemokines manifested very different patterns of expression - this may in part 
reflect the evolution of cell types in the neonatal islet cell clusters during the culture 
period, with loss of vascular remnants and exocrine tissue. Expression of both MIP1 
and IP10 (CXCL10) fell precipitously from the day of isolation. MIP2 levels increased 
only modestly to d4, declining thereafter, whilst a more robust rise in the expression of 
IL-8 and MCP1 was noted with peak levels attained between d4 and d6 pot-isolation, 
followed by a return to levels approaching baseline by d14 (Figure 3.7). 
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Figure 3.7 The chemokines examined in this study demonstrate different patterns of 
gene expression. MIP1 and IP10 are at their highest at day 0, and fall dramatically from 
day 3 onwards. MIP2 increases modestly to day 4 followed by a decline until day 14. 
IL-8 expression rises significantly from baseline to day 6, declining thereafter.  MCP1 
is significantly upregulated by day 4 falling subsequently until day 14. 
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Activated protein C-induced molecules: 
EPCR gene expression in pNICCs decreases significantly from d0 to d3. This event is 
most likely due to loss of vascular remnants during the first days of culture. A modest 
increase in gene expression is observed on d4 and is maintained until d6. 
 
mRNA transcription of MMP-2 is at its lowest levels just after isolation, but increases 
significantly by day 4, remaining at this level until d6 then declining towards the end of 
culture (Figure 3.8). MMP expressed in islets at this time may be involved in 
remodelling of the basement membrane and restoration of the islet structure. 
 
 
Figure 3.8 EPCR is expressed by pNICCs.  Expression is at its highest immediately 
after isolation, decreasing significantly thereafter. This probably reflects the loss of 
vascular remnants from the pNICCs during culture. 
Gene expression of MMP-2 increases significantly until d6, before declining again 
towards the end of culture. 
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NKG2D Ligands: 
Ligands for the activating receptor NKG2D can be induced on parenchymal cells under 
conditions of cellular stress and the expression of these ligands renders tissues 
susceptible to killing by both NK cells and CD8+ cytotoxic T cells. Human NKG2D can 
recognise porcine ULBP1, and potentially other porcine ligands as well [335]. Thus 
expression of NKG2D ligands on pNICCs may have deleterious consequences 
following islet grafting into human recipients. Of the two known porcine ligands, 
pMIC2 was already maximally upregulated by d3 after isolation, with levels remaining 
elevated thereafter. pULBP1 steadily increases to reach a peak by d6 post-isolation. 
Again, levels remain elevated through d14 (Figure 3.9). 
 
 
Figure 3.9 The pattern of expression of stress-induced ligands pULBP1 and MIC2, 
which bind to the receptor NKG2D, differs. pULBP1 increases gradually to reach a 
peak on d6 of culture. MIC2 is elevated more rapidly, and is already maximally 
upregulated by d3. Thereafter levels remain constant. 
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Protective molecule A20: 
A20 is a protective molecule which acts to prevent NF-κB translocation into the 
nucleus and thus prevents transcription of pro-inflammatory cytokines and chemokines. 
Since NF-κB is an important mediator of signalling downstream of Toll-like receptor 
engagement, A20 can be considered as an inhibitor of TLR-mediated effects. 
A20 mRNA levels peaked between d4-6 post-isolation declining thereafter to levels 
approximating baseline values (Figure 3.10). 
 
 
Figure 3.10 Expression of A20, known to moderate inflammation by abolishing TNF-
induced NF-kappa B signalling, is greatest on d 4-6 post isolation and returns to 
baseline levels by the end of culture. 
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3.4 Activated protein C and the endothelial protein c receptor 
 
Protein C is a serine proteinase made by the liver. When activated, it has multiple 
properties including: anti-coagulant, cytoprotective (mainly through its receptor 
EPCR), anti-inflammatory, anti-apoptotic (via EPCR and protease-activated receptor-1, 
PAR-1), pro-angiogenic (via matrix metalloproteinase activation), and endothelial 
barrier protection (via induction of sphingosine kinase-1, SpK1, and up-regulation of 
sphingosine-1-phosphate [187, 188, 194, 201, 318].  
 
Protein C is activated by the thrombin-thrombomodulin complex when it is bound to its 
cell surface receptor, endothelial protein C receptor (EPCR). It mediates the pleiotropic 
cytoprotective effects of activated protein C (APC) on cells through PAR1 signalling, 
(PARs are members of the G-protein-coupled receptor superfamily whose cellular 
activation is propagated through various G-protein and non-G-protein pathways, 
resulting in a diverse array of physiologic outputs) [336]. Activated protein C can 
modulate the expression of some critical proinflammatory and proapoptotic pathway 
genes resulting in downregulation of these pathways and reciprocal up-regulation of 
anti-inflammatory and anti-apoptotic pathways. Activated protein C suppresses NFκB 
nuclear translocation and blocks expression of TNFα and other downstream genes 
[188]; APC also upregulates expression of chemokines MCP1 and IL-8, and cytokines 
such as IL-6 [195, 196]. Matrix metalloproteinase-2 (MMP-2) unlike other MMPs, is 
resistant to cleavage by most enzymes, but APC has been shown to selectively 
upregulate gene and protein expression of MMP-2 and directly cleave and activate the 
proenzyme [197]. Modulation of MMP-2 expression is mediated by EPCR, blocking 
EPCR prevents APC-induced MMP-2 synthesis and proliferation [201]. 
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Endothelial protein C receptor is engaged by Factor VII/VIIa, as well as binding 
activated protein C [193]. It is a type I transmembrane protein which is similar to the 
major histocompatibility class 1/CD1 family of proteins. EPCR is essential for the 
limitation of endotoxin-induced innate immune responses [337, 338] and is expressed 
on endothelial cells as well as a number of other cell types including islet cells [308]. 
EPCR is expressed at significantly higher levels on the endothelium of large vessels 
than on the microvascular endothelium of most organs.  It mediates activation of 
protein C by thrombin, as well as the cytoprotective and anti-inflammatory effects of 
protein C. Activated protein C upregulates expression of EPCR, while thrombin and 
IL-1β are also known to increase EPCR gene expression [339]. 
 
EPCR is shed from the cell surface into the circulation upon proteolytic cleavage by 
ADAM (A disintegrin and metalloproteinase) 17, also known as tumor necrosis factor 
(TNF)-α converting enzyme (TACE), resulting in truncation of the cytoprotective 
effects of protein C. Increased shedding is observed during severe inflammation, due to 
high local levels of IL-1β, TNF α, and thrombin [339]. 
 
3.4.1 Application of rhuAPC in islet transplantation 
 
According to published reports, application of rhuAPC can reduce inflammation, 
apoptosis and immunogenicity of islets prior to transplant [192, 306]. It also decreases 
IBMIR through NFkB inhibition [117] and promotes angiogenesis and engraftment [9, 
200]. Therefore we hypothesized that rHuAPC could ameliorate inflammation in 
pNICCs in culture. 
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3.4.2 Preliminary data suggesting possible rHuAPC 
effectiveness on pig tissue 
 
Human Protein C mRNA is 83% homologous to pig protein C mRNA. Human and 
porcine APC proteins are 74% identical and the thrombin cleavage site on protein C is 
100% homologous in pig and human (Figures 3.11 and  3.12). 
 
The sequence of porcine EPCR had been established by the group of Associate 
Professor Peter Cowan. These investigators kindly gave us access to the data prior to 
deposition. The cDNA sequence was subsequently assigned the accession number 
NM_001163406 (Table 3.1). 
 
 Human Pig 
Protein C mRNA NM_000312 NM_213918.1 
Protein C preprotein NP_000303 NP_999083.1 
EPCR mRNA NM_006404 NM_001163406 
EPCR protein NP_006395 NP_001156878 
 
 
Table 3.1 List of accession numbers for human and porcine protein C and endothelial 
protein C receptor mRNA and proteins. 
  
 
Alignment of the human and porcine EPCR  (protein sequences translated in silico 
from the cDNA) demonstrate that 7/10 of the residues important for APC binding were 
identical between pig and human while the remaining 3 residues were from similar 
families (Figure 3.13 and Table 3.2). These findings suggest that rHuAPC may be 
effective in engaging EPCR on porcine tissue. 
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 Figure 3.11 Alignment between human (Query) and porcine (Subject) protein C 
mRNA. The two sequences are 83% homologous in human and pig. 
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 Figure 3.12 Human (Query) and porcine (Subject) protein C preproprotein sequences 
alignment. The proteins are 74% identical, the cleavage site by thrombin (highlighted 
in blue) is 100% homologous in human and pig. 
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 Figure 3.13 Human (Query) and porcine (Subject) EPCR proteins alignment. In the 
binding sites (highlighted in blue) in the picture above, 7 residues out of 10 are 
identical in human and pig proteins, 3 other residues are from the same amino acid 
families (i.e. conservative substitutions).  
 
 
 
 
Human EPCR Pig EPCR Amino Acid family 
R (Arginine) Q (Glutamine) Amid 
L (Leucine) V (Valine) Hydrophobic 
F (Phenylalanine) Y (Tyrosine) Aromatic 
 
Table 3.2 EPCR binding site residues in human and pig. There is 100% protein 
similarity and 72% identity between porcine and human activated protein C binding 
sites of EPCR proteins. 
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3.5 Obtaining full length EPCR from porcine neonatal islet 
cell clusters and other cell types 
 
3.5.1 Amplification of EPCR from pNICCs, PAECs and 
PIECs by rt-PCR 
 
To investigate the expression of EPCR by pNICCs, we attempted to amplify the full 
length EPCR coding sequence (CDS, 729 bp) from pNICCs along with porcine aortic 
endothelial cells (PAECs) and porcine intestinal endothelial cells (PIECs) as positive 
controls. As described earlier in the methods chapter, extracted RNA from these cells 
was used as a template to set up conventional PCR using a KOD hot start DNA 
polymerase kit (Novagen, EMD Biosciences, Inc., Merck KGaA, Darmstadt, Germany) 
in a Palm Cycler Gradient PCR Machine (Corbett, Qiagen). The PCR products were 
loaded onto a 1% agarose gel at the maximum possible volume (e.g. 50 μl). After 
electrophoresis, the bands were visualized using a Syngene G:Box Chemi HR16 
apparatus under UV light. In the picture below, the presence of a PCR product of the 
expected size, 729 bp can be seen in the gel (Figure 3.14).  
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 Figure 3.14 Agarose gel under UV illumination showing that a PCR product of the 
expected size (729 bp) can be amplified from PAEC, PIEC and NICCs. 
 
  
 
The bands were cut out of the gel and DNA was extracted following the method 
explained in chapter two (section 2.1.11). DNA was quantified by absorption using a 
Nanodrop spectrophotometer. The yield from PCR was relatively low in repeated 
experiments, suggesting that the template was not present at high concentration (Figure 
3.15). 
 
 
 
Figure 3.15 PCR product quantification by nanodrop after isolation from gel. 
 
 
PAEC 1 PAEC 2 PAEC 3 PIEC 1 PIEC 2 NICC 1 NICC 2 Ladder 
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The DNAs were sent for sequencing along with EPCR forward and reverse sequencing 
primers (chapter 2, section 2.1.12). The full length EPCR CDS sequence was only 
obtained from PAECs. The PIECs and pNICCs failed to yield a result in repeated 
experiments. The Table below shows the alignment between the PCR product 
sequencing report and pig EPCR CDS. This sequencing report was blasted against the 
GenBank database and aligned with the pig EPCR CDS with 99% identity (Figure 
3.16). 
 
   
 
Figure 3.16 Alignment between PCR product sequencing result from PAECs (Query) 
and pig EPCR CDS (Subject). 
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Since we were unable to obtain reliable sequence data from directly PCR products, the 
products were cloned into a plasmid vector for large scale DNA preparation prior to 
repeated attempts at sequencing. 
 
3.5.2 Cloning the porcine EPCR sequence 
 
The porcine EPCR sequence from pNICCs and the positive control cell line PAEC were 
amplified again by rt-PCR (Figure 3.17). The blunt-ended DNA amplicons were then 
cloned into the pcDNA/3.2/V5/GW/TOPO vector. Next, chemically competent E.Coli 
were transformed by the plasmid containing the EPCR insert. Bacterial colonies were 
cultured; subsequently the plasmid of interest was purified from the competent cells as 
above. The extracted DNA was quantitated and sequenced using EPCR forward and 
reverse primers (Figures 3.18 and 3.19). The procedure is described in chapter 2 
(section 2.1.12) 
 
 
 
Figure 3.17 Nanodrop estimation of the quantity of DNA amplicons to be used for 
TOPO-cloning into vector and transformation of chemically competent bacteria.  
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Figure 3.18 Gel electrophoresis of the PCR product shows the band of interest at the 
expected size (729 bp). After that the amplicons are cloned into vectors, chemically 
competent E. Coli are transformed with the vector and cultured, subsequently plasmid 
containing the EPCR sequence are purified from the bacteria. 
 
 
 
 
 
Figure 3.19 Nanodrop quantification of the plasmid purified from the bacterial 
colonies. The plasmid containing the EPCR sequence is tested for quantity and quality, 
and sent for sequencing. 
PAEC  NICC d4 Ladder NICC d10 
 139 
 Figure 3.20 Chromatogram for cloned EPCR from PAECs. 
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 Figure 3.21 Chromatogram for cloned EPCR from pNICCs day 4 post-isolation. 
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 Figure 3.22 Chromatogram for cloned EPCR from pNICCs day 10 post-isolation. 
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 Figure 3.23 Alignment between the cloned sequence from pNICC at day 4 post-
isolation and porcine EPCR mRNA. The sequences are 99% homologous. 
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 Figure 3.24 Alignment between the cloned sequence from pNICCs at day 10 post-
isolation and porcine EPCR mRNA. The sequences are 98% homologous. 
 
 
Sequencing of cloned PCR products demonstrates that full-length EPCR is transcribed 
in pNICCs day 4 and day 10 post-isolation, as well as in the positive control cell line 
PAEC (Figures 3.20-3.24). Hence rHuAPC could potentially render its effects through 
its receptor EPCR in pNICCs, assuming that that protein expression by the cells reflects 
gene transcription. 
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3.6 Porcine aortic endothelial Cell (PAEC) treatment with 
rHuAPC 
 
To examine the efficacy of our protein of interest on porcine tissue, it was decided to 
test it on a primary porcine cell line which strongly expresses EPCR.  
PAECs were isolated from piglet thoracic aortas as described in the methods chapter. 
The primary cells were isolated by enzymatic digestion then cultured and treated with 
rHuAPC at a 10μg/ml concentration for 24 or 48 hours. The treatment and control 
wells, as well as freshly isolated cells (baseline) were harvested for mRNA extraction 
and cDNA synthesis. This experiment was repeated 3 times. A panel of genes were 
studied by real time q-PCR. RT-PCR results are normalised to Histone H.3 values. 
Data are analysed using One-way ANOVA and t tests. 
 
During culture of PAECs, gene expression for EPCR is increased significantly within 
24 hours and returns to baseline levels after 48 hrs. Although the mRNA level is lower 
in the non-treated group compared to the treated one at 24hr, no significant effect of 
APC on EPCR gene expression is observed in this experiment (Figure 3.25).  
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Endothelial Protein C receptor: 
 
Figure 3.25 EPCR is known to be upregulated by the presence of activated protein C 
and downregulated by cytokines and inflammatory mediators. A) EPCR expression 
level increases significantly within 24 hours then declines towards baseline by 48 
hours. B) Despite a modest increase in mRNA level in the APC-treated group after 24 
hour, no significant difference of EPCR gene expression following APC treatment 
observed. 
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Matrix Metalloproteinase 2: 
Endothelial cells express matrix metalloproteinase (MMP)-2 in response to stimulation. 
Activated protein C induces gene expression of this multi-effect enzyme and directly 
activates the protein. Expression of MMP-2 decreases significantly compared to the 
baseline level after 24 hrs in culture, and remains low until 48 hours. APC did not 
change the expression of MMP-2 in this experiment (Figure 3.26). 
 
 
Figure 3.26 MMP-2 is known to be upregulated by APC. A) A dramatic decline in 
MMP-2 mRNA expression is observed within 24 hours of culture. B) MMP-2 gene 
expression is not affected by the APC treatment. 
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Toll-Like Receptors: 
Toll-like receptor expression can be upregulated by inflammatory mediators, further 
amplifying downstream proinflammatory signalling. Endothelial cells express TLRs. 
During 48 hours of culture, expression of both TLR2 and TLR4 are significantly 
decreased in PAECs. TLR2 is downregulated by APC at 48 hours, but the extent of 
change in TLR4 expression in the presence of APC was much less (Figure 3.27). 
 
 
 
  
 
Figure 3.27 APC is expected to inhibit the expression of these inflammatory-response 
mediators. A) The expression of both TLR2 and 4 significantly declines during culture. 
B) Activated protein C-treated cells express decreased levels TLR2 after 48 hours, but 
little difference in the expression of TLR4 is detected. 
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Danger-associated molecular pattern molecules: 
Heat shock protein 72, a DAMP, can be released during tissue injury and activate TLR 
signalling. PAECs can release HSP72 under stress. APC treatment does not alter the 
expression profile of this molecule during culture (Figure 3.28). 
 
 
Figure 3.28 Danger-signal HSP72 stimulates Toll-like receptor signalling during 
inflammation. A) PAECs show fluctuations in gene expression for HSP72 during the 
culture period. B) APC does not change the HSP72 expression pattern in PAECs in 
culture. 
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Cytokines and chemokines: 
The anti-inflammatory effects of activated protein C are partly rendered thorough 
blocking of TNFα expression and suppression of NF-κB nuclear translocation with 
subsequent downregulation of downstream proinflammatory gene transcription. APC is 
known to suppress the expression of various chemokines and adhesion molecules, but 
has been shown to upregulate MCP1 and IL-8. We did not observe a specific effect of 
APC treatment on the expression of TNFα by PAECs, although the expression level 
declined significantly within 48 hours of culture. MCP1 and IL-8 gene expression, as 
expected, were significantly elevated within 24 hours of culture in the APC treated 
cells, when compared to the baseline values. The levels returned to baseline after 48 
hours in both treated and non-treated cells. MIP1, MIP2 and IP10 levels were decreased 
dramatically during the 48 hours of culture, APC treatment did not alter MIP1 and 
MIP2 expression, although a modest increase in the level of IP10 was detected after 
treatment for 48 hrs (Figures 3.29 and 3.30). 
 
Tumour necrosis factor: 
 
Figure 3.29 A) TNFα expression by PAEC decreases significantly within 48 hours in 
culture. B) Treatment with APC does not affect the TNFα mRNA levels.  
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Chemokines: 
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Figure 3.30 Gene expression of chemokines MCP1, IL-8, MIP1, MIP2 and IP10 was 
evaluated. MCP1 and IL-8 exhibit different patterns of expression compared to the 
other chemokines. A) mRNA levels for MCP1 and IL-8 are significantly increased after 
24 hrs, but return to baseline by the end of culture. MIP1, MIP2 and IP10 mRNA 
expression falls dramatically during the experiment period. B) Treatment with APC, as 
expected, significantly elevated MCP1 and IL-8 expression at 24hr, but not at the later 
timepoints. MIP1 and MIP2 did not change noticeably with APC, although IP10 was 
modestly increased in the treated cells after 48 hours. 
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NKG2D ligands: 
Ligands for NKG2D are stress-induced molecules causing immune activation of cells. 
TLR signalling and cytokine stimulation increase the expression of these ligands. They 
are also expressed by primary cell lines in culture during proliferation. Activated 
protein C might downregulate the expression of these molecules by suppressing 
inflammatory pathways. pULBP1 is decreased in PAECs after 24 hours and remains 
low, without responding to APC treatment. However, MIC2 rises significantly within 
24 hours of culture. Similar to the pULBP1, MIC2 levels are not altered by the 
presence of APC (Figure 3.31). 
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Figure 3.31 A) Expression of pULBP1 and MIC2 follows different patterns in PAECs 
during culture. pULBP1 gene expression decreases significantly during 48 hrs, whereas 
MIC2 expression is elevated within 24 hrs and remains elevated. B) Neither of these 
genes is affected by the presence of activated protein C. 
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Protective molecule A20: 
An endogenous regulator of pattern recognition receptor signalling, A20 is strongly 
induced by TLR signalling and TNFα. Activated protein C can upregulate A20 
expression mainly through PAR1 signalling. PAECs expressed A20 in culture, 
although the levels decreased significantly after 24 hrs and remained low. Treatment of 
these cells with activated protein C did not change A20 mRNA levels during the 
culture period (Figure 3.32). 
 
 
Figure 3.32 A) A20 mRNA level in PAECs is reduced significantly after 24 hrs in 
culture. B) A20 expression is higher in the APC-treated group after 24 hrs, but falls to a 
lower level compared to the non-treated group within 48 hrs. 
 
Of the genes investigated, some, but not all, changed expression as expected in 
response to APC treatment. Expression of the chemokines MCP1 and IL-8 was 
significantly increased in response to APC treatment within 24 hours of culture, in 
accordance with the known effects of APC.  Expression of other genes such as EPCR, 
A20 and TLR4, was modestly induced within 24hrs, whilst IP10 expression was 
augmented in treated cells after 48hrs. Expression of MMP-2 was unaltered, contrary to 
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expectations. In general the effects of culture overshadowed the effects of APC 
treatment.  
 
3.7 Antibody against human EPCR is active on porcine tissue 
but EPCR protein was not detected in islets 
 
To confirm the functionality of the polyclonal rabbit anti-human EPCR primary 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) on a porcine tissue, HRP 
immunostaining was performed on human and porcine carotid arteries as a positive 
control. If this antibody is able to stain porcine endothelial tissue, it can be assumed 
that it is active on other porcine tissues and therefore useful as a reagent to determine 
the presence of EPCR protein in pNICCs 
 
3.7.1 Anti-EPCR staining of human carotid artery 
 
Immunostaining of paraffin-embedded human carotid artery sections for EPCR was 
performed following the protocol described in chapter two (section 2.4). 
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 Figure 3.34 Anti-EPCR staining on human carotid. To verify the activity of the 
primary antibody on a positive control tissue, human carotid section was stained with 
anti-EPCR antibody. The endothelium of the vessel is disrupted; nevertheless, the vasa 
vasorum endothelial layer shows positive staining. 
 
 
The endothelium of the lumen of the artery appears to be compromised in most areas 
throughout these specimens. However, focusing on the vasa vasorum in the tunica 
adventitia shows some intact endothelium staining positive for EPCR. The primary 
antibody is active on the human tissue (Figure 3.34).  
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 3.7.2 Anti-EPCR staining of piglet thoracic artery 
 
Next, we proceeded to staining piglet aorta for EPCR to detect the activity of the 
antibody on porcine tissue (Figure 3.35). 
 
Figure 3.35 Anti-EPCR staining on piglet thoracic aorta. The antibody is active on 
porcine tissue, staining the EPCR protein in different layers of this tissue where 
endothelial elements are found. 
 
 
Similar to the staining pattern from human carotid, a loose layer of endothelium is 
present lining the lumen. The endothelium of vasa vasorum is strongly positive for 
EPCR. The anti-EPCR primary antibody is active on porcine tissue. 
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3.7.3 Anti-EPCR staining of porcine neonatal islet cell clusters 
 
According to the previous tests on human and porcine tissues, expression of EPCR 
protein in pNICCs should be able to be determined using this method. Immunostaining 
was performed as described in chapter two, on both paraffin-embedded formalin-fixed 
and frozen porcine neonatal islet cell clusters from day 6 and day 10 post-isolation in 
culture. 
 
 
Figure 3.36 Anti-EPCR immunostaining on pNICCs from day 6 and day 10 post-
isolation. The positive staining surrounding the islets is related to chormogen 
entrapment or tissue necrosis rather than positive antigen detection (200x 
magnification). 
 
In the previous experiments it was shown that anti-EPCR antibody can detect EPCR 
protein in both human and porcine tissues. However when investigating the presence of 
this protein in pNICCs – from both paraffin-embedded and frozen sections - there 
appears to be false positive staining surrounding the islets but no true positivity, 
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according to examination by islet experts. This can be explained by various factors 
such necrosis of the islet rim or trapping of the chromogen under the specimen edges.  
 
3.8 Treatment of pNICCs with recombinant human activated 
protein C 
 
3.8.1 Effectiveness of APC on porcine tissue 
 
Earlier in this chapter, and in chapter one, we proposed that rHuAPC could be active on 
porcine tissue, in the presence of endothelial protein C receptor. A dose of rHuAPC 
which had been previously shown to be effective in vitro on a variety of cell types from 
different species was chosen [308, 340] [200] and treatment of positive control primary 
porcine endothelial cells (PAEC) yielded some changes in gene expression consistent 
with APC activity on these cells. Whereas we had been able to isolate full-length 
cDNA transcripts for EPCR from pNICC at both d4 and d10 following isolation, we 
were unable to detect the presence of EPCR protein on the surface of pNICCs. We 
could not exclude the possibility that EPCR protein had been present in NICCs in 
culture but had been removed by enzymatic cleavage during sample collection or 
preparation; it was decided to investigate the effect of rHuAPC on pNICCs in culture. 
This series of experiments was repeated 3 times with islets from 8 animals in total. 
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3.8.2 Treatment, harvest and analysis 
 
pNICCs isolation, culture and treatment with rHuAPC was performed as described in 
chapter two. The amount of serum was maintained at 10% in the media, and rHuAPC 
was applied at 10μg/ml concentration (since in vivo investigation of rHuAPC action on 
islets was not feasible, this concentration was determined based on the literature and 
previous works with rHuAPC on various cell and tissue types). pNICCs were harvested 
for different analyses including gene expression and immunohistochemistry. The 
analysis below shows gene expression results from quantitative rt-PCR, the values are 
normalised to histone H.3 and analysed by One-way ANOVA and t test (Figures 3.37-
3.43).  
 
The baseline values for gene expression from day 0 and day 3 are shown earlier in this 
chapter (section 3.3.4). The figures below represent only the groups included in the 
rHuAPC-treatment experiment. 
 
Islet marker: 
 
Figure 3.37 mRNA transcription of insulin increases during culture, as previously 
observed. APC can potentially exert protective effects, maximising the β cell mass of 
islets, however the insulin gene expression is not altered by treatment with this agent. 
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APC-induced molecules: 
 
 
Figure 3.38 Both EPCR and MMP-2 are known to be upregulated at the gene level in 
the presence of APC. Porcine neonatal islets do express these molecules; nonetheless 
we did not observe an effect of APC on the mRNA levels for these genes.  
 
 
 
Toll-Like Receptors: 
 
 
Figure 3.39 Toll-like receptor 2 and 4 expression decreases from day 3 in culture. No 
significant result of APC-treatment is detected here.  
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Danger-associated molecular pattern molecules: 
 
Figure 3.40 HSP72 transcription appeared reduced on d14 of culture in pNICCs treated 
with APC, but in other respects, gene expression of DAMP molecules HSP72 and 
HMGB1 did not alter in response to APC treatment. 
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Chemokines: 
 
 
 
 
 
Figure 3.41 (To be continued in next page) 
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Figure 3.41 Expression of all five chemokines, MIP1, MIP2, MCP1, IL-8 and IP10 
gradually decreased in culture from day 6. Gene expression of MCP1 and IL-8 are 
known to be upregulated by APC, and whilst their expression was increased in PAEC 
treated with rHuAPC, we did not observe an effect of this anti-inflammatory agent in 
pNICCs. 
 
 
 
 
NKG2D ligands: 
 
 
Figure 3.42 Gene expression of stress-induced ligands pULBP1 and MIC2 remains 
elevated change between day 6 and day 14 of culture. Expression of pULBP1 appeared 
reduced in APC-treated islets on d14, in other regards the expression is not influenced 
by addition of APC to the culture medium. 
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Protective molecule A20: 
 
 
Figure 3.43 A20 expression in cultured pNICCs is not stimulated by APC treatment. 
 
 
Gene expression of 15 molecules in porcine neonatal islet cell clusters in response to 
addition of recombinant human activated protein C to the culture medium was 
evaluated by RT-PCR. The experiment commenced at day 6 post-isolation, when most 
of the proinflammatory genes had reached their maximum level of transcription. We 
did not detect any particular pattern of rHuAPC effect on gene expression within 
pNICCs. Although we had demonstrated some effect of rHuAPC treatment on freshly-
isolated porcine aortic endothelial cells, relative lack of effect on pNICCs may relate to 
inability of the rHuAPC to penetrate the islet cell mass, or lack of expression of EPCR 
on the cells of the islet cluster.  
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3.9 Discussion 
 
Human islets are only available for research purposes if they have been deemed 
unsuitable for transplantation, and as such, these islets may not be typical or 
representative of isolated islets as a whole. Porcine neonatal islet clusters are isolated 
from pigs without prior brain death, but in other regards are subjected to similar 
stressful events as human islets procured for transplantation. 
 
Porcine neonatal islet cell clusters are isolated from the pancreas using enzymatic 
digestion, and maintained in culture for up to several weeks. During this time the islets 
mature, shedding exocrine tissue and acquiring the ability to secrete insulin and other 
hormones involved in glucose homeostasis. We studied the pattern of expression of a 
number of genes involved in inflammation within isolated islets – these include danger 
signals, the pattern recognition receptors thorough which they act, cytokines, 
chemokines and stress ligands downstream of TLR signalling, and finally the protective 
molecule A20. 
 
Expression of these contributors to inflammatory processes peaked at different times 
post-isolation, such that it was difficult to determine unequivocally a time when 
inflammation was at its minimum (and thus the most favourable time for intraportal 
infusion). 
 
Levels of most proinflammatory cytokines and chemokines had declined by d14 and 
this was coincident with robust expression of insulin by ICCs. Although from this 
standpoint d14 would appear to be a favourable time for transfer, expression of the 
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NKG2D ligands pMIC2 and pULBP1 remained high at this time, possibly exposing 
ICCs to heightened cell-mediated cytotoxicity by NK cells and CD8+ T cells. 
 
Treating murine islets in culture with recombinant APC had been reported to reduce 
inflammation, prevent islet apoptosis and prevent IBMIR [306]. We hypothesized that 
rHuAPC could have beneficial activity on porcine NICCs. Similarities between the 
sequences of human and porcine EPCR suggested likely cross-species reactivity and we 
were able to isolate full-length transcripts for EPCR from NICCs at both d4 and day 10 
of culture. However, immunostaining failed to provide evidence of the presence of 
EPCR at a protein level in porcine ICCs. In accordance with this, we were unable to 
demonstrate changes in gene expression for molecules such as IL-8 and MCP1which 
are known to be affected by APC signalling through EPCR. Conversely, treatment of 
the positive control cell type porcine aortic endothelial cells did result in a modest 
increase in the expression of these genes and in a reduction in TLR4 expression. In 
these studies, whilst we did not perform a dose response experiment, we used a dose 
which had been effective in vitro with a variety of cell types from different species 
[200, 308, 318] [201]. The inconsistent effects of APC on the expression of different 
genes could partly be accounted for by loss of activity of APC during the culture 
period. APC has a half-life of 20-30 minutes in circulation due to inactivation by serum 
components. Nonetheless, its biological effect has a much longer duration: twice-
weekly dosing with rHuAPC protected NOD mice from the development of 
autoimmune diabetes over a 10 week period [308]. Other possible arguments for our 
observations include lack of penetration of rHuAPC into ICCs as well as overpowering 
of EPCR-PAR1 signalling by other pathways. 
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Based on these findings we decided not to pursue the strategy of treating NICCs in 
culture with rHuAPC further, and instead to address the ability of a clinically relevant 
protocol for hormone resuscitation of the brain-dead donor to reduce inflammation and 
improve function of the pancreas and islets in the setting of donor brain death. The 
results of these experiments will be described in chapter 4. 
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CHAPTER 4  
HORMONE RESUSCITATION OF THE 
BRAIN-DEAD DONOR AND ITS EFFECT 
ON PANCREATIC INFLAMMATION AND 
FUNCTION 
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4.1 Introduction 
 
Brain death results in a series of haemodynamic, neurohormonal and pro-inflammatory 
perturbations, all of which contribute to donor organ dysfunction, and pancreatic islets 
are particularly susceptible to damage during brain death and its sequelae.  
 
Observations of pituitary hormone depletion after brain death (BD) prompted the use of 
hormone replacement (HR) treatment protocols, which may ameliorate some of the 
metabolic consequences of brain death, and improve the quality of donor organs.  
 
Hormone resuscitation allows the salvage of some hearts that would otherwise be 
deemed unsuitable for transplantation, but it has not been determined whether the 
benefits of hormone resuscitation extend to other organs such as pancreas [231, 270]. A 
large animal model study is desirable to establish the effect of HR versus standard 
noradrenaline-based resuscitation protocols on pancreas quality. 
 
The aim of this study is to utilise a well-characterised pig model of brain death to 
compare the effects of hormone resuscitation and standard noradrenaline treatment on 
hemodynamic parameters, and markers of pancreatic function and inflammation. 
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4.2 Physiological changes in BD pig 
 
4.2.1 Haemodynamic status and pancreatic enzyme release 
 
Inflation of an intracranial Foley catheter was accompanied by a typical Cushing 
response, with hypertension and tachycardia. One hour after the induction of brain 
death, animals were commenced on either noradrenaline infusion titrated to maintain a 
mean arterial pressure 60-70 mmHg or a hormone-resuscitation cocktail comprising 
Methylprednisolone, triiodothyronine, insulin and arginine-vasopressin titrated to 
maintain MAP as above. Heart rate was significantly greater in noradrenaline-treated 
pigs than in those receiving the hormone cocktail at all times between 2 and 6 hours 
post brain-death (Figure 4.1a). 
 
For evaluation of haemodynamic status, data from 9 pigs in each group was analysed. 
Mean arterial pressure was better maintained in HR pigs (64±5 vs. 36±14 mmHg at 6 
hrs post BD induction, p<0.05) (Figure 4.1b). Cardiac output and stroke work were also 
better preserved in pigs receiving hormone resuscitation (Figure 4.1c and d). 
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Figure 4.1 Monitoring of haemodynamic status in brain dead pigs. a) tachycardia is 
less pronounced in HR. b) Mean arterial pressure is better-maintained with HR. c) 
Cardiac output increases with hormone treatment. d) Improved stoke work is observed 
in the HR group. 
 
 
PaO2/FiO2 ratio was higher in HR than in NA pigs (470±95 cf. 345±106, p<0.05), and 
alveolar-arterial gradient was elevated in NA pigs (311±101 vs. 192±91 mmHg, 
p<0.05) implying worse lung function in the latter group.  
 
Renal arterial flow was greater in HR than in noradrenaline-treated animals, and 
accordingly the HR pigs had higher creatinine clearance during the 6 hours following 
brain-death (Figure 4.2). There were no differences in hepatic arterial or portal venous 
flow, and no differences in AST, ALT, bilirubin or bile production between groups.  
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 Figure 4.2 Renal artery flow and creatinine clearance are improved in pigs receiving 
hormone resuscitation compared to those receiving noradrenaline treatment. 
 
Perfusion of the pancreas was not directly measured but levels of the pancreatic 
enzymes amylase and lipase did not change significantly during the observation period 
nor differ between treatment groups (Figure 4.3). 
 
 
Figure 4.3 Pancreatic enzyme release was measured during the maintenance period 
following induction of brain death. The level of amylase and lipase in serum did not 
change after 6 hours. There was no difference between two treatment methods. 
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4.2.2 Histological appearance of pancreas from brain-dead 
pigs 
 
H&E stained sections of paraffin embedded formalin-fixed pancreas were examined by 
an experienced transplant pathologist, blinded to the treatment group and scored 
according to the matrix below (Table 4.1). 
 
 
Grade Necrosis 
 
Perivascular 
neutrophils 
 
Interstitial 
neutrophils 
1 Single cell necrosis 
Mild, focal vessels 
only 
Mild, focal 
2 
Clusters of necrotic 
cells 
Mild, most vessels 
Mild, general OR 
moderate, focal 
3 
Confluent  necrosis 
>10% 
Moderate (> 1 cell 
thick) most vessels 
Moderate or marked, 
general 
 
Table 4.1 Sections were stained with H&E and scored based on this matrix by an 
experienced transplant pathologist blinded to the treatment groups. 
 
 
Whereas the appearance of pancreas samples from HR pigs at 6 hours post BD 
induction remained normal, pancreas samples from NA pigs displayed focal necrotic 
areas with nuclear debris and neutrophil infiltration (Figures 4.4 and 4.5).  
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Figure 4.4 Haematoxylin and Eosin-stained sections from the pancreas of pigs in the 
hormone (HR) and noradrenaline (NA) treatment groups at 6 hrs post brain death. The 
appearance of the pancreas in the HR group remained normal (A), whereas the 
pancreas from NA animals showed areas of focal necrosis (B). The arrows in image B 
are pointing at focal necrotic areas. 
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Figure 4.5 The histological damage caused by brain death within 6hrs in pig pancreas 
was examined by an experienced transplant pathologist and scored according to the 
matrix shown in table 4.1. Pancreata from noradrenaline-treated (NA) animals 
exhibited significantly more cellular necrosis than those from hormone resuscitated 
(HR) pigs. The total damage to the tissue was also higher in NA group; this difference 
did not reach statistical significance. 
 
A B 
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4.3 Gene expression in pancreas from brain-dead pigs 
 
4.3.1 Pancreas yields RNA of relatively low integrity 
 
1μg of total extracted RNA from frozen pancreas specimens was transcribed to 
complementary DNA using reverse transcriptase. However, as determined by 
Bioanalyzer measurements, the integrity of RNA from all the pancreatic samples was 
suboptimal after repeated attempts at RNA extraction (Figures 4.6 and 4.7). Thus, 
random hexamers were used instead of Oligo-dT primer to prime the mRNA for 
subsequent cDNA synthesis. Oligo-dT only binds to the mRNA poly A tail, whereas 
random hexamers bind to a variety of different sites on the mRNA and initiate DNA 
strand elongation. Random hexamers can thus be used as universal, non-specific 
primers for cDNA synthesis, even from fragmented RNA. 
 
 
 
Figure 4.6 Absorbance spectra of total RNA generated from electrophoresis in the 
Bioanalyzer. (A) A poor quality RNA spectrum versus a good quality RNA spectrum 
(B), both from BD pig pancreas.  
 
 
 
 
A B 
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 Figure 4.7 Absorbance data for RNA from brain-dead pig pancreas. The 260/280 ratio 
indicating the purity of RNA should be 1.8 or more. 
 
 
The real time RT-PCR reaction was set up as described in chapter two. Results were 
normalised to GAPDH and Histone H3 values. Statistical analysis was performed using 
Mann Whitney U and One-way ANOVA tests. 
 
 
4.3.2 Evaluating inflammation by determining gene 
expression for inflammatory mediators in BD pig 
pancreas 
 
Signalling through pattern-recognition receptors such as TLR4 has been implicated in 
the inflammatory consequences of brain-death. 
 
Here, we used RT-PCR to analyse gene expression for two prominent danger signals 
HSP72 and HMGB1 which are released from cells during injury, as well as pattern-
recognition receptors (TLR 2 and 4) and downstream genes in the TLR signalling 
pathway, including cytokines, chemokines and NKG2D ligands. Additionally, we 
examined the expression of the protective molecule A20, which acts to terminate NF-
κB- mediated gene transcription, and of insulin, as a measure of islet activity and 
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function. The following figures display mRNA expression as fold-change between 
baseline and termination of the experiment at 6 hr post BD, the values are normalised 
to the Histone H3 housekeeping gene. Each individual data point represents an animal,  
with the median indicated. 
 
Damage-associated molecular pattern molecules: 
Expression of two DAMPs (damage-associated molecular pattern molecules) or 
endogenous danger signals HMGB1 (high mobility group box 1) and HSP72 (heat-
shock protein 72) were evaluated by RT-PCR. They act as extracellular immune-
signalling molecules. Hormone- resuscitation downregulates mRNA levels of HMGB1 
and HSP72 compared to noradrenaline treatment; however, the difference between 
groups is not statistically significant (Figure 4.8). 
 
 
Figure 4.8 Expression of both danger signals HMGB1 and HSP-72 is elevated in the 
noradrenaline-treated group compared to the hormone-treated animals after 6 hours of 
brain death, although no significant difference is observed.  
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Toll-Like Receptor 4: 
Gene expression of TLR4, a pattern recognition receptor (PRR) which is activated 
during innate immune responses was evaluated by RT-PCR. Expression of this receptor 
was upregulated in the pancreas of animals receiving Noradrenaline treatment within 6 
hrs of brain death, but not in that of pigs treated with hormone resuscitation, (Figure 
4.9).  
 
 
Figure 4.9 Expression of TLR4, a pattern recognition receptor (PRR) that can be 
activated by danger signals, is upregulated in the pancreas of pigs treated with 
noradrenaline, but not in the pancreas of those receiving hormone resuscitation during 6 
hours post BD. 
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Chemokines: 
Expression of four chemokines was evaluated; MCP1 (recruiting macrophages), MIP1 
(activating granulocytes/neutrophils), IP10 or CXCL10 (recruiting NK cells, DCs, 
macrophages and T cells) and IL-8 (recruiting neutrophils and other target cells). 
Pancreatic expression of all these chemokines was downregulated in hormone 
resuscitation pigs, whilst in pigs receiving noradrenaline treatment, levels increased or 
remained stable during the six hours following BD induction. The increase in MCP1 
gene expression over baseline was significantly greater in noradrenaline-treated pigs 
than in animals receiving HR (Figure 4.10). 
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Figure 4.10 Gene expression of MCP1, MIP1, IP10 and IL-8 were measured by RT-
PCR. In the hormone-receiving groups, pancreatic chemokine expression was 
downregulated, whereas chemokine expression increased or remained stable in the 
noradrenaline-treated group during the 6 hours after BD induction. The increase in 
MCP1 gene expression over baseline was significantly greater in the noradrenaline-
treated pigs than in the animals receiving hormone resuscitation. 
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Cytokines: 
The expression level of two pro-inflammatory cytokines was measured by RT-PCR. 
Both IL-1β and IL-6 play an important role in immune response mediation, cell 
activation and proliferation. The expression of IL-6 in the pancreas was increased in 
noradrenaline-treated pigs (median 1.74 at baseline, 12.97 at 6 hours post BD 
induction), whilst in the hormone-resuscitation animals, IL-6 expression declined over 
the same period (median 2.22 at baseline and 0.61 at 6 hours). IL-1β gene expression 
remained stable in noradrenaline-treated pigs but was significantly downregulated by 
hormone-resuscitation (median 4.75 at baseline decreasing to 2.32 after 6 hours)(Figure 
4.11). 
 
 
Figure 4.11 Gene expression of IL-6 was upregulated within 6 hours of brain death in 
the pancreas of pigs receiving noradrenaline pressor support. In contrast, IL-6 
expression declined in HR pigs over the same interval. IL-1β expression level is 
downregulated in the hormone-treated group during this period. 
 
 
 
 
 
 183 
NKG2D Ligands: 
Expression levels of two NKG2D ligands, stress-induced molecules MIC2 and 
pULBP1 were evaluated by RT-PCR. pULBP1 did not amplify despite multiple 
attempts. Brain death induction increases the mRNA levels of MIC2 in pancreas 
compared to the baseline levels, in the noradrenaline-treated group (mean 0.64±0.14 at 
baseline, 1.97±0.4 after 6 hours, P=0.046) but not in pigs receiving hormone 
resuscitation (0.69±0.13 at baseline and 0.76±0.17 at 6 hours, P = NS) (Figure 4.12). 
 
 
Figure 4.12 Gene expression of the stress-induced protein MIC2, a ligand for NKG2D, 
can be induced by brain death in porcine pancreas. Noradrenaline treated pigs manifest 
a significant increase in MIC2 expression in the pancreas at 6 hours after BD induction, 
which was not observed in HR pigs. pULBP1 did not amplify from pig pancreas 
despite multiple attempts. 
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Protective molecule A20: 
Gene expression of A20, a protective immune regulator which is induced by NF-κB 
activators was increased in HR pancreas in comparison to the pancreas of 
noradrenaline-treated pigs (Figure 4.13). 
 
 
Figure 4.13 mRNA expression of A20 is maintained in HR animals at 6hr post BD 
when compared to baseline, whereas A20 expression declines in noradrenaline-treated 
pigs.  
 
 
Complement Component-3 gene expression: 
The central component of the complement system is the C3 molecule, Cleavage of C3 
into C3b and C3a is a pivotal step in the complement activation cascade. C3 functions 
include opsonization and phagocytosis of pathogens/apoptotic cells, clearance of 
immune complexes and chemotaxis. Although 90% of C3 synthesis is in the liver, its 
synthesis has been shown in many other tissues and cell types including pancreas, 
brain, kidney, monocytes, B lymphocytes and several tumor cell lines. C3 synthesis is 
elevated in conditions such as pancreatic cancer, acute pancreatitis, pancreas rejection 
and IBMIR (instant blood mediated inflammatory reaction) following islet transfusion 
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[27, 229]. Here we measured the gene expression level of C3 in the snap frozen 
pancreas samples from the different groups of brain-dead pigs. The results were 
analyzed using t test (Figure 4.14).  
 
According to the analysis, the expression of complement component-3 in pancreas is 
upregulated in the animals receiving noradrenaline by 6hr post brain-death (mean 
0.81±0.22 at baseline and 2.26±0.28 at 6 hours, P=0.004), whereas hormone 
resuscitation-treated pigs manifest a lesser degree of C3 mRNA upregulation 
(0.82±0.39 at baseline and 1.65±0.67 at 6 hours, P=0.04).  
 
 
Figure 4.14 Complement Component-3 gene expression in pancreas from 
noradrenaline-treated or HR pigs. mRNA is increased more in the group receiving 
noradrenaline compared to the hormone-resuscitated animals; the difference is not 
statistically significant. 
 
 
4.4 Measurement of insulin production in pancreatic islets 
 
Insulin production, as a significant biomarker for pancreas and islet function, was 
evaluated in brain-dead pigs treated with either hormone resuscitation or noradrenaline. 
Both gene expression and islet insulin content were determined.  
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4.4.1 Insulin gene expression   
Real-time RT-PCR was used to measure insulin gene expression. The values were 
normalized to Histone H3 expression. Insulin gene expression is tightly regulated. 
Nonetheless, insulin mRNA levels were downregulated at 6 hours after the induction of 
brain death compared to baseline values in BD pigs receiving hormone resuscitation 
(which includes exogenous insulin)(mean 2.6±0.6 at baseline and 1.3±0.2 at 6 hours, 
P=0.04). Conversely, insulin mRNA levels were increased at 6 hours compared to 
baseline in BD pigs maintained with noradrenaline (mean 1.3± 0.3 at baseline and 1.7± 
0.3 at 6 hours) (Figure 4.15).  
 
 
Figure 4.15 Evaluation of insulin gene expression in the pancreas of brain dead pigs 
after 6 hours indicates a significant reduction in insulin gene transcription in pigs 
treated with hormone resuscitation, whereas insulin mRNA levels increased over the 
same interval in the noradrenaline-treated group. 
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4.4.2 Insulin protein measurement  
 
Immunohistostaining of paraffin-embedded formalin-fixed sections from different 
groups of BD pigs was performed following the protocol previously described (Figure 
4.16).  
             
                                            
Figure 4.16 Insulin immunostaining scoring based on intensity (200x magnification). 
 
After staining, slides were scanned in a Dako ACIS (Automated Cellular Imaging 
System), and staining intensity (DAB-bound epitopes) of the tissue sections was 
analysed and numerated using the ACIS software. A scoring system was developed as 
described in chapter two (section 2.4.4) to allow us to compare the mean score of each 
treatment group using One-way ANOVA and Bonferroni post-hoc analyses (Figure 
4.17).  
   
   
Score +3 Score +2 Score +1 
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Figure 4.17 Comparing insulin content between the two treatment groups using 
immunohistostaining. There is a reduction in the protein content during 6hrs after brain 
death in the noradrenaline- treated group, compared to physiological levels (p<0.05). In 
contrast, the hormone-resuscitation management protocol maintains the insulin content 
close to the physiological level. Error bars represent SD.  
 
 
Overall, insulin protein content is better preserved in the hormone resuscitation group; 
conversely, noradrenaline increases the mRNA level, a seeming paradox. A possible 
mechanism to explain these changes is that noradrenaline induces glycogenolysis in the 
liver and subsequently raises blood glucose levels [341]. Insulin secretion increases in 
response to glucose level; which causes enhanced insulin transcription and protein 
secretion in the noradrenaline receiving group. On the other hand, the exogenous 
insulin component in the hormone cocktail may have controlled the blood glucose 
level, rectified the potential brain death-induced hyperglycemia, and caused insulin 
retention and mRNA downregulation in the group receiving hormone resuscitation. 
Prevention of islet overload and exhaustion by maintenance of glucose homeostasis is 
crucial in islet graft recovery post-transplantation outcomes [270, 341, 342], and 
hormone resuscitation would seem to offer an advantage over noradrenaline treatment 
in this regard. 
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4.5 Detection of apoptosis in pancreas tissue from brain-dead 
pigs 
 
Tissue injury and trauma can trigger two main types of cell death: necrosis and 
apoptosis. Necrosis is a form of cell death which starts with the loss of cell membrane 
integrity and damage to the ion pump. This results in cell swelling, lysis, and release of 
intracellular enzymes, followed by neutrophil migration, inflammation, and oedema. 
Another form of cell death, apoptosis, is in fact a programmed cell death which is 
morphologically distinguished by overall cellular condensation, shrinkage, and plasma 
membrane blebbing. Activation of a cascade of reactions, such as activation of caspase 
enzymes leads to digestion of cell structures as well as damage to nuclei characterized 
by chromatin degradation and DNA fragmentation. Eventually, the apoptotic cell is 
broken up into smaller membrane-wrapped apoptotic bodies that are usually taken up 
by phagocytic cells. An important morphologic difference from necrosis is that 
programmed cell death lacks inflammation [343]. 
 
Different methods detect events which occur at different stages during the complex 
process of apoptosis. These include TUNEL assay, DNA fragmentation detection and 
staining for the active (cleaved) form of caspase-3. 
 
4.5.1 TUNEL ASSAY (Terminal deoxynucleotidyl transferase 
dUTP Nick End Labelling) 
 
This method is used to detect apoptosis (programmed cell death) in situ at the single 
cell level. Cleavage of genomic DNA resulting in single strand breaks (nicks) occurs 
during apoptosis or severe damage and the TUNEL method is based on labelling the 
free 3’-OH ends with biotin-conjugated dUTPs using the enzyme terminal 
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deoxynucleotidyl transferase. The procedure was performed as outlined in chapter 2 
(section 2.6.1). 
 
 
4.5.2   TUNEL-Insulin double staining assay 
 
To differentiate the islets from the surrounding acinar tissue, the original TUNEL and 
anti-insulin staining protocols were modified as described in chapter 2 (section 2.6.1) 
into a two-step conjoint horseradish peroxidase and alkaline phosphatase method. 
Subsequently two serial slide sections from each specimen were subjected to 
immunostaining, the first with TUNEL and anti-Insulin and the second with TUNEL 
assay only. Slides were then examined and photographed using an Olympus BX60 
microscope and Olympus DP72 mounted camera and the double-stained sections were 
used to localise the islets on the second slide. A minimum of 6 islets per pancreas with 
the surrounding exocrine tissue were photographed and subjected to further analysis 
(Figures 4.18 and 4.19). 
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 Figure 4.18 TUNEL assay and localisation of islets in a normal pig pancreas. Image A 
shows an islet stained red for insulin, and TUNEL-positive nuclei in brown. Image B is 
the same islet in the consecutive section stained only for TUNEL. The brown-positive 
nuclei are surprisingly abundant (200x magnification). 
 
 
 
 
Figure 4.19 TUNEL assay on control pig pancreas at 0hr and 6hr post BD; there are a 
significant number of positively-stained nuclei in exocrine and endocrine tissue in both 
specimens (200x magnification). 
 
TUNEL at 0hr TUNEL at 6hr post BD 
Exocrine 
pancreas 
Exocrine 
pancreas 
Islets Islet 
TUNEL+insulin TUNEL 
A B 100 µm 
100 µm 
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Quantification of apoptosis by TUNEL assay 
Following imaging of the islets, several tools were evaluated for the quantitation and 
interpretation of TUNEL staining results in the pancreas, including the KS400 software 
package (Kontron Elektronik GmbH, Munich, Germany), Metamorph (Molecular 
Devices, CA) and ACIS (Dako, Glostrup, Denmark). Eventually ImageJ (National 
Institute of Health) was chosen to analyse the TUNEL assay results. t-test was used to 
analyse the results, the bars are showing the mean (Figure 4.20). 
 
 
 
Figure 4.20 TUNEL assay analysis in brain-dead pig pancreas. 6 hrs of brain-death 
increases the TUNEL positivity in all animals, regardless of the treatment type. 
 
Induction of brain death in pigs can increase the rate of TUNEL positive nuclei to up to 
fourfold in the islets, although not statistically significant (data not shown, p=0.2 for 
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baseline to 6hr in NA group; p=0.3 for baseline to 6hr in HR group). However, the 
extent of this increase is not affected by the type of treatment received by the animals 
(NA compared to HR, p=0.8). 
 
More importantly, the overall frequency of TUNEL positive nuclei in all tissue sections 
from normal and brain-dead pig pancreas ranged between 25 and 50%, an improbably 
high number. This result raised the question of whether TUNEL assay is a suitable 
method to detect apoptosis in pancreas. According to the literature, high levels of false 
positive TUNEL staining can occur in tissues with high rates of protein synthesis and 
are ascribed to DNA strand breaks happening during RNA transcription. Moreover, the 
exocrine pancreas contains deoxyribonucleases which could induce strand breaks in 
tissue samples between collection and analysis. TUNEL assay should be accompanied 
and verified by other parallel detection methods including Annexin V, Caspase activity, 
single strand DNA, mitochondrial membrane potential and Cytochrome C release [344, 
345]. 
 
Among these, detection of caspase activity is a well-established and reliable technique 
which can detect apoptosis from its early to late stages in situ in formalin-fixed tissues. 
 
 
4.5.3 Comparison of TUNEL and Cleaved Caspase-3 activity 
in          mouse thymus 
 
To verify the specifity and sensitivity of TUNEL and determine the quality of our 
TUNEL technique, TUNEL assay and anti-Cleaved Caspase-3 immunostaining were 
performed on C57BL/6 mouse thymus tissue as a positive control tissue. Thymus is one 
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of the sites in the body with a very high rate of lymphocyte apoptosis during normal T 
cell development. Assays were carried out following the protocols described in chapter 
2 (section 2.6.2). Anti Cleaved Caspase-3 staining was performed using rabbit anti 
human cleaved caspase-3 (ASP175) (Cell Signaling), counterstaining was done with 
Harris Haematoxylin. This antibody detects endogenous levels of the large fragment 
(17/19 kDa) of activated caspase-3 resulting from cleavage adjacent to Asp175 and 
does not recognize full-length caspase-3 (Figure 4.21). 
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Figure 4.21 TUNEL assay versus cleaved caspase-3 activity in normal mouse thymus. 
Figure A shows the immmunostaining result (200x magnification), figure B illustrates 
the analysis with no difference between assays (+/- SEM).  
 
Comparable numbers of apoptotic cells were detected in normal mouse thymus using 
either method (29 cell/HPF for TUNEL vs. 28 cells/HPF for CC3). 
 
It can be concluded from this experiment that the very high rate of TUNEL-positive 
nuclei in pig pancreas is likely to be due to a factor intrinsic to this tissue, and not to 
more widespread technical problems with the way in which the assay was performed. 
A 
B 
100 µm 100 µm 
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4.5.4 Comparison of TUNEL and Cleaved Caspase-3 activity 
in pig and mouse pancreatic tissue 
 
According to the previous results, possible factors accounting for the high rate of 
TUNEL positivity in pig pancreas could include degradation of genomic DNA by 
pancreatic deoxyribonucleases active after sample collection causing false positive 
identification of cells by the TUNEL method. To obtain information about apoptosis 
which was independent of the DNA integrity, we stained pig and mouse pancreas tissue 
for Cleaved caspase-3 in addition to TUNEL. 
 
Baseline pancreatic biopsies were obtained from pigs which were instrumented and 
anaesthetised for brain-death studies. Normal pancreas from C57BL/6 mice was also 
harvested. Paraffin-embedded biopsies were subjected to TUNEL and anti Cleaved-
Caspase-3 immunostaining. An even a higher percentage of TUNEL positive nuclei 
was observed in mouse islets compared with porcine islets (Figure 4.22). 
 
The proportion of apoptotic cells detected by immunostaining for cleaved caspase-3 is 
approximately fivefold lower, in both pig and mouse than that detected by TUNEL. 
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Figure 4.22 TUNEL versus anti C. Casp-3 staining in pig and mouse pancreatic islets. 
Significantly more TUNEL positive cells than cleaved-Caspase-3-positive cells are 
detected in pancreatic islets from either normal pigs or normal mice (Error bars are +/- 
SEM).  
 
 
These outcomes confirm our hypothesis that TUNEL assay on pancreas samples is 
subject to high levels of false positive staining. Thus another reliable method, such as 
anti-cleaved caspase-3 immunostaining, must be implemented for apoptosis detection. 
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4.5.5 Cleaved Caspase activity in BD pigs treated according to 
different resuscitation protocols 
 
 
Islet in BD pig pancreas stained for cleaved caspase-3 
  
 
Figure 4.23 Anti cleaved caspase-3 staining on paraffin-embedded tissue sections from 
brain-dead pig pancreas. A) An islet containing positively stained cells. B) The positive 
(stained brown) and negative cells within islets were counted (negative cells marked 
green and positive marked red here). Both images are shown with 400x magnification. 
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Figure 4.24 Cleaved Caspase-3 staining analysis in brain-dead pig pancreas. Caspase-3 
activity does not change during the 6 hours following brain death in the pancreas of 
animals receiving noradrenaline or hormone resuscitation treatments. 
counted A B 
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 According to the analyses, induction of brain death does not increase the level of 
Cleaved Caspase-3 activity within 6 hours in the pancreas of the tested animals. No 
significant difference between cleaved caspase-3 level in pancreatic islets from pigs 
receiving either treatment was detected (Figures 4.23 and 4.24).  
 
4.5.6 Genomic DNA studies 
 
Irreversible fragmentation of genomic DNA is one of the hallmarks of later stages of 
apoptosis. This event is initiated by the activation of endogenous endonucleases called 
Caspase activated DNase or DNA Fragmentation Factor (DFF40), which subsequently 
cleave chromatin DNA into a ladder of monomers (180-200 bp) and multimers. This 
effect can be used to detect apoptosis via the DNA laddering assay. DNA fragments are 
visualised by electrophoresis on agarose gel followed by ethidium bromide staining. 
 
Induction of apoptosis in mouse splenocytes using etoposide 
To achieve fragmented genomic DNA as a positive control for apoptosis detection, 
DNA strand breaks and programmed cell death were induced in mouse splenocytes by 
addition of the cytoctoxic drug Etoposide to the culture medium. Splenocytes were 
obtained from normal C57BL/6 mouse spleen following the protocol outlined in 
chapter 2 (section 2.7). Cells were cultured in RPMI (Sigma). The treatment groups 
received Etoposide at a final concentration of 8.5 μM, and were incubated for 2, 6 and 
20 hours before harvesting. Total genomic DNA was extracted from the cells using the 
TACS DNA laddering kit, as explained in chapter two (Figure 4.25).  
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Figure 4.25 Genomic DNA from mouse splenocytes measured by Nanodrop. 
 
 
Genomic DNA extraction and analysis from brain-dead pig pancreas 
The extracted genomic DNA from pig tissues was used to study fragmentation by gel 
electrophoresis (Figure 4.26). 
 
 
Figure 4.26 Genomic DNA from BD pig pancreas measured by Nanodrop. 
 
 
Visualisation of DNA laddering 
We used horizontal electrophoresis of DNA in agarose gel to visualise apoptosis-
induced DNA fragmentation in pancreatic specimens from brain dead pig and mouse, 
as well as mouse splenocytes as controls (Figure 4.27 and 4.28). 
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1 DNA Ladder 
2 BD pig pan. No.14/0hr 9 BD p. pan. 24/6hr 
3 BD pig pan. No.14/6hr 10 30min BD mouse pan.  
4 BD pig pan. No.16/0hr 11 3hr BD mouse pan. 
5 BD pig pan. No.16/6hr 12 M. Splenocyte/ Etoposide 2hr/I 
6 BD pig pan. No.22/0hr 13 M. Splenocyte/ Etoposide 2hr/II 
7 BD pig pan. No.22/6hr 14 M. Splenocyte/ Etoposide 6hr 
8 BD pig pan. No.24/0hr 15 M. Splenocyte/ Etoposide 20hr 
 
 
Figure 4.27 A) Genomic DNA electrophoresis of pig and mouse pancreas and mouse 
splenocytes visualised on agarose gel. B) The table indicates the corresponding 
specimens. Lanes 2-9 and 11 (from pancreas) look like a smear of completely degraded 
DNA. This can be correlated to the pancreas high content of ribonucleases and 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
A 
B 
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deoxyribonucleases as well as proteases - thus autodigestion of the biopsies cannot be 
ruled out. A ladder pattern of DNA fragmentation is evident in splenocytes. 
 
 
Figure 4.28 Example of fragmented genomic DNA due to apoptosis. M is ladder, 1 is 
control, 2-4 are genomic DNA from an apoptotic mammalian cell line.  
 
 
Genomic DNA laddering, a hallmark of the late stages of programmed cell death, was 
observed in the mouse splenocytes treated with etoposide as positive controls. All of 
the pancreas biopsies from BD pigs and one from the BD mouse exhibit a smear of 
DNA that is most likely fully degraded DNA. This observation can be related to the 
presence of ribonucleases, deoxyribonucleases and proteases within the pancreas and 
autodigestion of the tissue upon injury. 
 
4.6 Discussion 
 
Detrimental effects of donor brain death on transplantable organs are inevitable; 
however the inflammatory responses in the organs can be ameliorated to a great extent 
by optimised management of the donor. Prevention of hypoperfusion, maintenance of 
cellular metabolism and inhibition of immune activity are the essentials of these 
optimised management protocols. Pancreas, highly in demand for T1DM treatment, is 
particularly vulnerable to ischemia and manipulation, and thus the outcomes of 
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pancreas and islet transplantation stand to gain much from the optimisation of donor 
pancreas quality.   
 
In this study we developed a brain death model in pigs mimicking the human condition, 
and examined the effects of two different management protocols, traditional pressor 
support with noradrenaline and hormone replacement therapy, on pancreatic function 
and inflammation. 
 
Management of the donor with hormone resuscitation was able to maintain 
hemodynamic status and organ perfusion significantly better than treatment with 
noradrenaline during the 6 hours following induction of BD. In assessing the status of 
the transplantable abdominal organs, we measured a number of different parameters. 
HR pigs had improved renal function and creatinine clearance was improved by HR. 
Serum levels of pancreatic enzymes amylase and lipase, and liver function tests were 
similar were similar between pigs treated with either protocol. Pancreatic tissue 
integrity (evaluated by the presence of cellular necrosis) was better preserved with HR. 
 
The pattern of gene expression for a number of inflammatory mediators was evaluated 
in whole pancreas specimens – these genes included danger signals, pattern recognition 
receptors, cytokines, chemokines and stress ligands downstream of TLR signalling, as 
well as the protective molecule A20. Expression of pro-inflammatory markers was, in 
general, upregulated in pigs receiving noradrenaline, whereas expression of these genes 
either showed a more limited increase or was downregulated in the HR group.  
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Activation of the complement cascade contributes to inflammatory events following 
brain death and helps to trigger adaptive immune responses against the graft. The C3 
mRNA level in pancreas was measured by RT-PCR, showing reduced gene expression 
in pigs treated with hormone resuscitation compared with noradrenaline-treated 
animals. This result is in accordance with the overall reduction in proinflammatory 
gene expression in the pancreas of HR pigs. 
 
Based on this analysis, we came to the conclusion that administration of the hormone 
resuscitation cocktail can modulate the general inflammatory status within the 
pancreatic tissue. The possible explanations for these observations are discussed below. 
 
− The hormone resuscitation treatment cocktail, comprising methylprednisolone, 
triiodothyronine, insulin and arginine-vasopressin maintains hemodynamic 
instability and perfusion of the transplantable organs better than noradrenaline, 
which results in less tissue damage, less release of DAMPs/danger signals and 
less inflammation. There are emerging data on the protective effects of 
combination of hormones on donor management, organ quality and transplant 
outcomes. Protocols using hormone resuscitation have been shown to improve 
systemic perfusion, preserve homeostasis and cellular function; and thus 
diminish inflammation and immune activation in all the organs studied [279]. 
− Inflammation in the organ is induced by both endogenous and exogenous 
catecholamine sources in this model.  Increase in intracranial pressure releases 
catecholamines into circulation; in addition to this catecholamine storm, 
noradrenaline is infused from one hour post-induction of BD.  Adrenaline and 
noradrenaline have been revealed to directly upregulate the synthesis and release 
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of TNFα, principally through engagement of alpha(2)-adrenergic receptors. 
Translocation of NF-κB, production of downstream proinflammatory molecules 
including IL-8, IL-1β, IL-6, and augmentation of inflammatory responses also 
occur. Pre-transplant exposure to noradrenaline (for hemodynamic maintenance) 
is related to cytokine release after reperfusion in human liver graft recipients 
[217, 346, 347]. 
− Methylprednisolone directly inhibits the transcription of many proinflammatory 
molecules. Administration of methylprednisolone to BD donors has recently 
been shown to improve hemodynamic stability, perfusion and increase organ 
procurement rate [348]. Antiinflammatory effects of glucocorticoids are 
mediated through binding to receptors (GR), translocation into the nucleus and 
binding to steroid-sensitive genes. This complex inhibits the downstream 
proinflammatory activity of NF-κB signalling by trans-repression (suppression 
of co-activator molecules), and trans-activation (induction of anti-inflammatory 
genes such as NF-κB inhibitor, MAP kinase-1)[349, 350]. The downregulation 
of proinflammatory mediators such as MCP1, IL-8, IL-1β, MIC2 could thus be 
related to suppression of NF-κB signalling by methylprednisolone in this model. 
− Methylprenisolone upregulates the expression of A20, a key inhibitor for 
termination of canonical NF-κB activation. This immune regulator is induced by 
a number of NF-κB activators, such as TNFα, TLR4/IL-1, IL-17 etc.; and 
suppresses NF-κB upstream signalling through deubiquination of several 
mediators including RIP1, RIP2, and TRAF6 [177]. Our observations show that 
HR downregulates multiple proinflammatory regulators (all involved NF-κB 
signalling) but increases A20 at the same time. This selective effect of 
methylprednisolone can be related to the recent findings that corticosteroids 
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selectively spare the expression of anti-inflammatory targets of TNF through 
context-dependent cooperation between GR and NF-κB [350].  
 
Insulin gene and protein expression levels were evaluated in the pancreas. 
Noradrenaline treatment upregulated insulin mRNA transcription, yet the islet insulin 
protein content decreased from baseline levels, HR maintained insulin content close to 
normal, despite downregulation of mRNA transcription. The pattern of insulin 
expression in the two treatment groups could be related to multiple factors. One 
possibility is that noradrenaline increases blood glucose levels by inducing 
glycogenolysis in the liver. Insulin secretion increases in response to the glucose level, 
and subsequently insulin transcription and protein secretion are upregulated in the 
noradrenaline receiving group [341].  
 
Another potential mechanism may be due to correction of brain death-induced low 
circulating insulin and hyperglycaemia by exogenous insulin in the hormone cocktail 
[270]. Controlled glucose levels prevent islet overload and exhaustion, resulting in 
preserved insulin content and lower gene expression in the pancreas from HR animals 
compared to NA-treated group. Islet exhaustion has been implicated in inferior islet 
graft outcome and survival, while improved clinical transplant success rates are reported 
following peritransplant exogenous insulin administration and prevention of islet 
exhaustion [342]. These findings can be correlated to the outcomes from clinical islet 
transplant, where dead cells within the islets release excessive insulin/C-peptide in the 
first 24 hours after stressful events of transfusion [89]. 
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We used TUNEL and the activity of cleaved caspase-3 to evaluate the level of apoptosis 
in porcine pancreas after BD. The TUNEL technique resulted in overestimation of 
apoptotic cells when the outcomes were compared to c-casp3, indicating that TUNEL 
might not be an ideal technique for apoptosis detection in pancreas. TUNEL may yield 
false positive results due to the high prevalence of single-strand breaks in DNA in 
metabolically active tissues [344], and/or degradation of genomic DNA by tissue 
deoxyribonuclease activity. The extent of apoptosis was evaluated by a third method, 
detection of the typical cleavage pattern of genomic DNA by endonucleases happening 
during programmed cell death upon agarose gel electrophoresis. Our attempts however 
yielded only smears of degraded DNA from pancreas samples, where the typical ladder 
pattern was observed in mouse splenocytes treated with etoposide. The exocrine 
pancreas contains high amounts of nucleases and proteases and degradation of genomic 
DNA by these enzymes during the extraction process is likely, making this technique 
unreliable for the detection of apoptosis in pancreas. 
 
The hormone resuscitation protocol demonstrated several advantages over traditional 
pressor support with noradrenaline; improved hemodynamic maintenance of the donor, 
restriction of immune activation and inflammation in pancreatic tissue, and reduction in 
islet stress. Donor modulation can be expanded to interventions such as transfer of 
protective genes. For this purpose we decided to evaluate a strategy to attenuate TLR 
and RAGE signalling in the BD donor using gene-delivery of a naturally-occurring anti-
inflammatory molecule - esRAGE. Evaluation of the effects of systematic esRAGE 
overexpression on the pancreas in a mouse model of brain death is discussed in chapter 
5. 
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CHAPTER 5  
SYSTEMATIC OVEREXPRESSION OF 
esRAGE AND ITS EFFECTS ON THE 
PANCREAS AND ISLETS IN BRAIN-DEAD 
MICE 
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5.1 Introduction 
 
Perimortem events in the donor can substantially alter the graft microenvironment, and 
can influence the success or failure of subsequent therapeutic interventions. To 
optimise transplant outcomes, immunological interventions must address the effects of 
these donor and procurement factors in addition to the recipient immune response.  
 
One of the key initiators of innate immunity following brain death is signalling through 
pattern recognition receptors (PRRs) including toll-like receptors (TLRs) and the 
receptor for advanced glycation end-products (RAGE), resulting in a systemic 
inflammatory response in the donor, and increased expression of inflammatory 
mediators within transplantable organs. TLR engagement is linked with immune 
activation, cellular infiltration, ischemia-reperfusion injury and poor transplant 
outcomes [204, 351]. Stimulation of RAGE by its various ligands such as alarmins 
HMGB1 and S100B also contributes to release of inflammatory mediators, promoting 
IRI and inferior engraftment [134, 313]. Blockade of TLR4 and/or RAGE has been 
shown to protect against IRI and improve transplant results [143, 205, 313].  
 
Endogenous secretory (es) RAGE is a naturally-occurring soluble isoform of RAGE. It 
functions as a decoy receptor that binds to HMGB1, S100B as well as other RAGE 
ligands, preventing them engaging PRRs including RAGE, TLR2, TLR4 and TLR9. 
Moreover, esRAGE can form heterodimers at the cell surface with full-length 
transmembrane RAGE, thus blocking the homodimerisation of the RAGE receptor 
which is necessary for signal transduction [149]. Administration of esRAGE in a mouse 
model of hepatic IRI blocked RAGE and TLR4 from binding to their ligands, inhibited 
NF-κB signalling and protected against lethal hepatic ischemia-reperfusion injury 
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[312]. Knowing that human esRAGE is active in mice [311], we developed a liver-
specific rAAV 2/8 vector to allow us to express high levels of esRAGE systemically in 
C57BL/6 mice. Using this technology, esRAGE is produced by the liver and secreted 
into body fluids – concentrations of esRAGE many thousand-fold above physiological 
levels can be detected in the serum and within organs such as kidney, heart or spleen. 
Mice transduced with this vector were used to investigate the immunoprotective effects 
of esRAGE over-expression on early events following brain death induction in 
pancreas. The ultimate aim of this work is to further evaluate the effects of esRAGE 
expression in donor and/or recipient on transplantation and tolerance-induction 
outcomes. 
 
5.2 Expression of esRAGE in vivo after inoculation with 
rAAV esRAGE  
 
5.2.1 In-vivo expression of esRAGE 
 
Following the packaging of rAAV-esRAGE, we performed a dose-response experiment 
to determine the most appropriate vector dose. Male C57BL/6 mice 8-10 weeks-old 
received doses of rAAV-esRAGE of 1x1010, 5x1010, 1x1011, and 5x1011 vector 
genomes via intraperitoneal injection (IP). The concentration of esRAGE was then 
measured in the serum of the injected mice at 10 days post-injection using a sandwich 
ELISA (B-Bridge). Systemic expression of esRAGE was dose-dependent, and the dose 
of 5x1011 VG resulted in the highest esRAGE serum level (Figure 5.1). This vector 
dose did not result in liver inflammation as measured by serum ALT concentration or 
the presence of an inflammatory infiltrate upon H and E staining of the liver (Figure 5.2 
A and B), and was therefore chosen for use in later experiments. 
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We next conducted a time-course experiment using 5x1011 VG intraperitoneally (IP) to 
determine the kinetics of rAAV2/8-mediated esRAGE expression. Murine esRAGE is 
undetectable in serum, and physiological concentrations of esRAGE in humans are in 
the range 0.1-1 ng/mL. By d2 following IP injection, levels around 5000-fold greater 
than physiological concentrations in human’s serum had already been achieved in 
injected mice. esRAGE levels continued to increase until d42 post-injection, then 
started to decline. Nonetheless, durable high-level expression was demonstrable 
throughout 100 days after injection. For practical reasons, it was determined that 
sufficient levels of esRAGE for our experimental purposes were reached by 7 days 
after IP injection. Brain-death induction was therefore performed 7 days post-
inoculation. 
 
 
 
Figure 5.1 Dose-response curve for rAAV-esRAGE. Mice were injected IP with 
esRAGE at doses ranging from 1x1010 to 5x1011 VG. Levels of esRAGE measured in 
serum by ELISA were dose-dependent and many thousand-fold greater than 
physiological concentration in humans (0.1-1 ng/mL). 
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Figure 5.2 Administration of rAAV-esRAGE does not result in liver inflammation. 
Neither serum ALT levels (A) nor the appearances of liver on H and E staining (B) 
suggested liver inflammation with the highest dose of 5 x 1011 VG rAAV-esRAGE 
(200x magnification). The increase in ALT level at day 10 was observed in only one 
mouse; however considering the fact that this rise was still well below pathological 
levels correlated with inflammation, along with absence of any accompanied 
histological changes, this observation was not concerned abnormal.  
 
 
Finally, to verify our assumption that esRAGE secreted by the liver would be 
distributed throughout the body, and would appear in high concentration within 
transplantable organs, we collected liver, spleen, kidney and heart from two C57BL/6 
mice at 5 days following IP injection with 5x1011 VG rAAV-esRAGE, and measured 
the concentration of esRAGE per gram of total protein in tissue lysates (Figure 5.3). Not 
surprisingly, the highest levels were detected in liver, where esRAGE is produced, 
followed by kidney where esRAGE is reabsorbed from the urine. Spleen and heart 
contained lower, but still substantial levels of esRAGE (Figure 5.4). No human 
esRAGE was detected in organs from control C57BL/6 mice. Regarding the pancreas, 
according to a study by our group using an analogous vector, this viral construct does 
not infect the pancreas [218]. Although the concentration of esRAGE was not directly 
measured in these mice pancreatic tissue, as it was mentioned above the secreted 
esRAGE circulating in serum is supposedly delivered to this organ as well. 
 
 
 
B A 
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 Figure 5.3 Kinetics of expression for rAAV-esRAGE injected intraperitoneally (IP) at 
5x1011 VG. Serum esRAGE expression was already substantial by d2, and reached a 
peak at day 42 followed by a slow decline. 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Levels of esRAGE in various organs. Concentrations of esRAGE in relation 
to total protein in tissue lysates were greatest for liver and kidney, and less, though still 
substantial for spleen and heart. No human esRAGE was detected in organs from 
control C57BL/6 mice. 
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5.3 Physiological changes and systematic inflammatory 
response in brain dead mice 
 
Animals were monitored for physiological parameters before, during and after the brain 
death procedure. Typical recordings of blood pressure, heart rate, and oxygen 
saturation were presented in chapter 2 where the model was described. The serum 
protein levels of danger signals, chemokines and cytokines were measured by ELISA 
and Luminex techniques. 
 
In response to brain death and consequent tissue ischemia, both danger-associated 
molecular pattern molecules HMGB1 and S100B (Figure 5.5), and an array of 
chemokines and cytokines are released into the circulation. We observed a dramatic 
increase in HMGB1 and S100B within 3 hours of brain death induction. Serum levels 
of MCP1, KC, MIP2, IP10, TNFα, IFN-γ, IL-10 and IL-1β reached very high levels 
during first hour after BD (Figure 5.6). These values are indicative of the systemic 
proinflammatory state resulting from brain death.  
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Figure 5.5 Serum protein levels of danger-associated molecular patterns HMGB1 and 
S100. These danger –associated molecules are increased dramatically following brain 
death, with a peak occurring at 3 hours after brain death induction. 
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Figure 5.6 Serum protein levels of various cytokines and chemokines were measured. 
Within 60 min of brain death very high levels of these proinflammatory mediators were 
attained. 
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5.4  Investigation of inflammation in the pancreas post brain 
death 
 
Pancreatic specimens were collected from normal animals, mice anaesthetised and 
ventilated for 3 hours, brain-dead animals at 1 and 3 hrs following induction of brain 
death, mice previously transduced with rAAV 2/8 vectors expressing either esRAGE or 
the control protein human serum albumin (HSA) at 3 hours following induction of 
brain death, and esRAGE or HSA-expressing animals 1 week after inoculation with the 
vector (but not ventilated or subjected to brain-death). There were 4 animals included 
in each study group. 
 
5.4.1  RNA extraction and cDNA synthesis from brain-dead 
mouse pancreas 
 
Total RNA was extracted from the snap-frozen pancreas harvested from brain-dead and 
control animals following the instructions described before. One μg of RNA was used 
to synthesize complementary DNA as per protocol in chapter 2. This cDNA was used 
as template in RT-PCR studies. 
 
5.4.2  Investigation of gene expression by Real Time RT-PCR 
  
Real time RT-PCR was set up for various genes as described in chapter 2, using 
Taqman primers and probes. Values were normalized to Histone H3 values. Results 
were analysed with One-way ANOVA and t-test. 
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Danger Signals: 
Gene Expression of three danger molecules HMGB1, Hyaluronan synthase 1 (HAS1) 
and HSPa2 was evaluated by RT-PCR. These are known to initiate pattern recognition 
receptor (PRR) signalling. Although HMGB1 protein was released rapidly into the 
circulation following the induction of brain-death, no increase in mRNA transcription 
in the pancreas was detected within three hours, except in the mice which were 
maintained ventilated without the induction of brain death. esRAGE or HSA expression 
alone in animals without any surgical manipulations did not alter HMGB1 mRNA 
levels, and the mRNA levels were comparable between brain dead mice expressing 
either esRAGE or HSA (Figure 5.7 ).  
 
Hyaluronan synthase 1 (HAS1) is the enzyme responsible for synthesis of the low 
molecular weight form of hyaluronan, a ligand for TLR4. HAS1 expression is elevated 
in mouse pancreas at 3 hours after BD induction. esRAGE expression did not alter the 
gene expression of hyaluronan synthase 1 compared to the baseline values in 
unmanipulated animals, nor did levels of HAS1 differ between BD mice transduced 
with either esRAGE or HSA (Figure 5.8). 
 
Heat shock-related 70 kDa protein 2 (HSPa2), the murine counterpart of HSP70 in 
humans, is a molecular chaperone responsible for re-folding damaged proteins. At the 
intracellular level, HSPa2 has a protective effect. When released into the extracellular 
milieu, HSPa2 can function as a ligand for TLR4. Pancreatic HSPa2 gene expression 
was increased after three hours of anaesthesia and mechanical ventilation, regardless of 
whether brain death had been induced or not. esRAGE expression did not influence 
levels of HSPa2 in either BD or unmanipulated animals (Figure 5.9). 
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Figure 5.7 A) Gene expression of HMGB1 in pancreas remains close to baseline after 
1 and 3 hours post BD, whilst a modest increase is observed in the ventilated animals.  
B) esRAGE or  HSA-transduction alone does not influence HMGB1 gene expression in 
mouse pancreas at d7 post-inoculation. C) HMGB1 gene expression is comparable in 
mice transduced with either esRAGE or HSA at 3 hours post-induction of BD.  
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 Figure 5.8 A) Hyaluronan Synthase 1 expression was increased in mouse pancreas at 3 
hours after BD induction. B) Transduction of unmanipulated mice with either esRAGE 
or HSA does not alter levels of hyaluronan synthase 1 at d7 post-inoculation. C) 
Similarly esRAGE does not influence HAS1 gene expression after brain death. 
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 Figure 5.9 A) After 3 hours of anaesthesia and instrumentation, levels of the chaperone 
and DAMP HSPa2 were increased in the pancreas of both ventilated and brain-dead 
animals. Gene expression for HSPa2 was not affected by esRAGE transduction, either 
at baseline (B) or following brain death (C).  
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Receptors: 
Expression of the pattern recognition receptors toll-like receptor 4 and receptor for 
advanced glycation endproducts (RAGE) was examined in the pancreas of brain-dead 
mice and ventilated controls. Similar to findings for HSPa2, TLR4 expression increased 
in both BD and ventilated mice after three hours of anaesthesia and instrumentation. 
Transduction with esRAGE or HSA did not influence the level of TLR4 expression, 
either in steady state at d7 post-inoculation or at 3 hours after BD induction. Although 
it has been reported that the presence of soluble RAGE and resultant sequestration of 
RAGE ligands causes a downregulation in transcription of the full-length 
transmembrane isoform of RAGE, we did not observe any changes in RAGE mRNA 
expression during any of the conditions during the period of study  (Figures 5.10 and 
5.11). 
 
 222 
 Figure 5.10  A) Some elevation in the pancreatic gene expression of TLR4 is observed 
after three hours of maintenance in both the brain-dead and ventilated control mice. B) 
Treatment with rAAV-HSA or rAAV-esRAGE does not change the mRNA levels 
compared to the normal. C) Although the levels increase modestly in the pancreas of 
BD mice, there are no differences between the treated and control groups. 
 
 223 
 Figure 5.11 A-C) Gene expression of RAGE in mouse pancreas did not change in 
brain-dead or ventilated control mice during the period of observation, nor were 
changes detected at d7 after transduction in unmanipulated mice. 
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Chemokines: 
Through its ability to block signalling block through TLRs and RAGE, esRAGE can 
suppress the downstream production of chemokines such MCP1, MIP2, KC and IP10. 
We studied the gene expression of these four chemokines in pancreas by RT-PCR. 
Normal mouse pancreas expresses very low levels of these chemokines, and no changes 
in expression resulted when mice were transduced with esRAGE or HSA vectors but 
not otherwise exposed to any surgical procedures. Expression of all four chemokine 
genes was substantially upregulated in mice subjected to brain death, or to ventilation 
alone (MCP1 normal 0.3±0.08 v/s peak 9.4 ±3.1, P=0.02; MIP2 normal 0.17±0.03 v/s 
peak 7.6 ±2.8, P=0.02; IP10 normal 0.3±0.05 v/s peak 78 ±77, P=0.2; KC normal 
0.05±0.01 v/s peak 8.6±7.2, P=0.02). At 3 hours after the induction of brain-death, 
modest suppression of the pancreatic expression of all four chemokines is evident in the 
esRAGE-expressing group compared to HSA and other controls; however, this 
difference did not reach statistical significance. IP10 is significantly higher in the HSA-
treated group compared to normal values after 3 hours of BD (Figures 5.12-15). 
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Figure 5.12 A) MCP1 gene expression in mouse pancreas reaches a peak at 3 hours 
after the induction of BD. B) MCP1 gene expression changed little in mice transduced 
with vectors encoding esRAGE or HSA, but at three hours after the induction of BD, 
MCP1 mRNA levels were reduced in the esRAGE treated mice, compared with the 
HSA controls, though this difference did not reach statistical significance (C).  
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Figure 5.13 A) Prolonged mechanical ventilation or brain death upregulates gene 
expression of MIP2 in this model. B) Transcription of this chemokine is not changed 
following esRAGE overexpression. C) Expression of MIP2 is modestly decreased in 
the pancreas of BD mice transduced with esRAGE, compared with that of HSA 
controls. 
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 Figure 5.14 A) Brain death induction or anaesthesia/ventilation each increase IP10 
gene expression in pancreas. B) IP10 gene expression is not altered when animals are 
transduced with HSA or esRAGE vectors. C) Following BD, IP10 expression in the 
HSA control group is significantly greater than that in the normal controls, whereas 
esRAGE-expressing animals exhibit a lower increase in IP10 mRNA, closer to that of 
ventilated-only controls.  
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Figure 5.15 A) KC gene expression in mouse pancreas is substantially upregulated by 
either BD induction or instrumentation and sustained mechanical ventilation. B) HSA 
or esRAGE overexpression per se does not affect the expression of KC. C) Following 
brain death, pancreatic KC expression level is reduced in the esRAGE group in 
comparison to the HSA-treated mice. 
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Cytokines: 
Gene expression of 5 cytokines (IL-1β, TNFα, IL-6, IL-10 and IL-33) was evaluated by 
RT-PCR. Transcription of these cytokines is known to be activated by TLR and/or 
RAGE signalling. These cytokines were expressed at very low levels in the pancreas of 
normal mice. mRNA transcription was increased by brain death and generally also 
increased by instrumentation and prolonged mechanical ventilation. (IL-1β normal 
0.21±0.03 v/s peak 8.1±3.8, P=0.02; TNFα normal 19±8.0 v/s peak  164±83, P=0.2; IL-
6 normal 0.01±0.007 v/s peak  93±78, P=0.02, IL-10 normal 1.2±0.4 v/s peak 5±2.7, 
P=0.05, IL-33 normal 0.46±0.27 v/s peak 1.5±0.7, P=0.2). For IL-1β, IL-6 and IL-10, 
gene expression in mouse pancreas at 3 hours after induction of brain death was 
considerably greater than that in ventilated controls, whereas for TNFα and IL-33, 
either brain death or ventilation alone resulted in upregulation. Transduction alone, in 
the absence of other manipulations, did not cause any particular change in the 
expression of these cytokines. There was a modest trend towards reduction of TNFα, 
IL-6 and IL-10 mRNA in BD mice treated with esRAGE compared with HSA controls. 
IL-1β mRNA expression was unaffected by esRAGE overexpression, whilst gene 
expression of IL-33 was, if anything, increased in mice receiving esRAGE (Figures 
5.16-5.20).   
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Figure 5.16 A) There is a noticeable increase in the expression of cytokine IL-1β after 
3 hrs of BD compared to the baseline values. B) When mice are transduced with 
esRAGE or HSA vectors, pancreatic expression of IL-1β does not change. C) The 
pancreas shows similar levels of IL-1β mRNA in both esRAGE and HSA-treated 
animals at 3 hours after the induction of brain death. 
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 Figure 5.17 A) Both ventilation/anaesthesia and BD induction can induce gene 
expression of TNFα in pancreas. B) Expression of this cytokine is similar in the 
pancreas of otherwise unmanipulated mice transduced with esRAGE or control vector. 
C) At 3 hours following the induction of brain death, there is a modest reduction in 
TNFα expression in the esRAGE-treated animals compared to the HSA controls.  
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 Figure 5.18 A) In contrast to the other cytokines studied, transcription of IL-10 in 
pancreas was not increased in ventilated animals, and increases only after 3 hours of 
brain death. B) no change in IL-10 expression is observed in the pancreas of  esRAGE 
or HSA-transduced control mice. C) There is a reduction in the upregulation of IL-10 in 
esRAGE-treated mice compared to that in HSA group at 3 hours post brain death 
induction.   
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 Figure 5.19 A) Gene expression of IL-33 increases in response to instrumentation and 
prolonged mechanical ventilation, with or without the induction of brain death. B) 
Overexpression of esRAGE or HSA has no effect on IL-33 expression in the pancreas 
at baseline. C) IL-33 mRNA level is increased in esRAGE-transduced mice compred 
with that in the HSA-expressing group at three hours following induction of BD. 
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 Figure 5.20 A) Both ventilation and brain death induction can increase IL-6 expression 
in pancreas; the most dramatic change was detected at three hours after brain death 
induction, where IL-6 mRNA had increased almost 10,000-fold from baseline. B) 
Transduction of the animals with esRAGE or HSA per se does not affect IL-6 
expression in mouse pancreas. C) A minor decrease in IL-6 expression in pancreas was 
noted in the esRAGE-treated mice compared with HSA controls following brain death. 
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Stress ligands: 
Expression of the NKG2D ligand RAE-1 (retinoic acid early inducible gene 1) 
expression is strictly regulated in normal cells; therefore, little is expressed on healthy 
adult tissues, including normal pancreas [352]. It has been reported to be induced by 
retinoic acid, transcription factor AP-1 and MyD-88-dependant-TLR4-signalling [353]. 
Ischemia/reperfusion injury induces expression of RAE-1 and MULT-1 (another mouse 
NKG2D ligand) in renal tubular cells, and this effect was abolished in the absence of 
TLR4 signalling [208] In this model, the mRNA level for RAE-1 in mouse pancreas 
increases about threefold within one hour post BD, but this increase is not sustained. A 
comparable increase was observed in the pancreas of mice transduced with HAS, but 
not otherwise subjected to any experimental manipulations. Unexpectedly, we observed 
a significant increase in RAE-1 transduction in the pancreas of brain-dead mice treated 
with esRAGE, when compared with control animals transduced with the HSA vector. 
Possible reasons for this are discussed later in the chapter. Increased stress ligand 
expression can render the tissue prone to immune attack by NK cells and activated 
CD8+ cells (Figure 5.21).  
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 Figure 5.21 A) There is a threefold elevation in RAE-1 gene expression in mouse 
pancreas at 1 hour post induction of brain death, which is not maintained thereafter. B) 
Of interest, baseline pancreatic RAE-1 mRNA level was elevated to a comparable 
degree to that of the BD mice (1 hr group) in HSA-expressing mice (d7 post-
inoculation) but not in mice transduced with esRAGE. C) Unexpectedly, RAE-1 gene 
expression was significantly increased in the esRAGE-transduced animals after brain 
death compared to expression in all of the controls.  
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Protective molecule A20: 
This protective molecule is induced as part of the endogenous regulation of 
inflammatory responses mediated by TLR or TNFα signalling. Feedback mechanisms 
controlling the expression of A20 are complex; A20 transcription is promoted by NF-
κB, yet A20 prevents NF-κB nuclear translocation, thus becoming subject to self-
regulation. Similarly, upstream blockade of TNFα signalling has been shown to reduce 
the gene expression of this anti-inflammatory product [350]. In parallel with the 
changes in TNFα expression, A20 gene expression in this model increased in the 
pancreas of mice subjected to instrumentation and mechanical ventilation, whether or 
not BD was also induced. Transduction with esRAGE or HSA per se do not result in 
changes to the baseline expression of A20 in the pancreas. However, levels of A20 
mRNA in the pancreas of esRAGE-transduced animals following brain death were 
reduced compared to those in HSA-transduced mice (Figure 5.22). This trend was also 
in accordance with the pattern of TNFα expression in this study, and may also reflect a 
reduction in NF-κB signalling as a result inhibition of RAGE and/or TLR downstream 
pathways. Whether the net effect of these changes in A20 and other gene expression is 
harmful or protective is not possible to determine without further information.  
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Figure 5.22 A) Ventilation and brain death induction can both increase the level of 
A20 gene in mouse pancreas as early as 1 hour after commencement. B) Expression of 
A20 is not altered by esRAGE-overexpression in the pancreatic tissue before 
manipulation. C) Animals expressing esRAGE exhibit a lower level of A20 after BD 
when compared with mice transduced with HSA; this is concordant with TNFα gene 
expression.  
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Complement Component 3 measurement: 
Total RNA extraction, cDNA synthesis and real time RT-PCR for C3 were performed 
as described in chapter 2. The results were normalized to histone H3 values and 
analyzed using One-way ANOVA and t test.  
 
Gene expression of C3 in pancreas rises slightly due to anaesthesia and mechanical 
ventilation. However, contrary to our expectations, C3 mRNA levels were, if anything, 
suppressed following brain death induction in this model. Further slight downregulation 
of complement component-3 mRNA transcription in pancreas was observed in brain-
dead animals expressing esRAGE compared with the HSA controls, although this 
difference did not reach statistical significance (Figure 5.23). 
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Figure 5.23 A) C3 mRNA levels in mouse pancreas fall following brain death 
induction, contrary to our expectations. B) Baseline expression of complement 
component-3 in pancreas is not affected by esRAGE transduction. C) Further slight 
downregulation of pancreatic C3 mRNA level was noted in brain-dead animals 
expressing esRAGE compared with HSA controls, although this difference did not 
reach statistical significance. 
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5.5  Insulin protein and gene expression in pancreas post 
brain death 
 
Pancreatic insulin content is frequently employed as a marker of pancreatic integrity 
and endocrine function. We studied both insulin gene expression and the insulin protein 
content of pancreatic islets to determine how these indices were affected by brain death 
and by systemic esRAGE over-expression. 
 
5.5.1 Insulin gene expression 
  
Insulin gene expression is normally tightly regulated in order to maintain glucose 
homeostasis. After three hours of anaesthesia and mechanical ventilation, increased 
insulin gene transcription was evident in mice whether or not they had also been 
subjected to the induction of brain death. Anaesthesia and surgical procedures are 
commonly accompanied by a decline in IGF-1 production with concomitant 
hyperglycaemia [354]. The liver plays a role in glucose homeostasis, and disturbances 
of hepatic glucose metabolism occur in viral hepatitis, possibly secondary to 
endoplasmic reticulum stress [355]. At d7 post-inoculation, transduction of mouse liver 
with either esRAGE or HSA vectors was associated with a small increase in Insulin 
mRNA, suggesting that overexpression of the transgene in liver may cause a modest 
metabolic perturbation. Conversely, at 3 hours after the induction of BD, the animals 
expressing esRAGE manifested a reduced level of insulin gene expression compared to 
that of the controls (Figure 5.24). 
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 Figure 5.24 A) Gene expression of insulin increases in mice exposed to prolonged 
anaesthesia and mechanical ventilation whether or not they are subjected to brain death.  
B) A slight increase in insulin gene transcription was noted in mice transduced with 
either esRAGE or HSA vectors suggesting the possibility of mild perturbation of 
hepatic glucose homeostasis when large amounts of transgene product are synthesised. 
C) Conversely, at three hours after the induction of brain death, insulin mRNA levels 
were lower in esRAGE-transduced mice in comparison to those in the ventilated or 
HSA-transduced brain dead control groups. There were 4 animals in each group of the 
study, and results were analysed using One-way ANOVA. 
 
 
 
5.5.2 Anti-Insulin immunohistostaining 
 
5μm sections from the paraffin-embedded pancreatic tissue were subjected to anti-
Insulin immunohistostaining as described in chapter 2 (Figure 5.25). The slides were 
then examined by light microscopy, and all the islets throughout the sections were 
photographed to be analysed. The images were subsequently assessed using Image Pro-
Premier 9.1 image analysis software (Media Cybernetics, Rockville, MD). The 
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numerical value of staining intensity from each islet was generated by dividing the 
Integrated Optical Density (OD) by an Area factor. The mean intensity value for the 
islets in each mouse pancreas was calculated and used in further analysis (Figure 5.26). 
 
Insulin mRNA levels are increased in response to ventilation and brain-death 
manipulations, and in general, the insulin protein content increased in parallel with the 
changes in gene transcription. However, brain dead mice transduced with either HSA 
or esRAGE exhibited the highest islet insulin content of all groups (Figure 5.27). This 
may represent a synergistic effect of high-level transgene expression in the liver with 
surgical stress. 
 
 
 
 
 
 
 
Figure 5.25 Anti-insulin immunostaining on mouse pancreas. The scoring system is 
based on the intensity of anti-insulin immunostaining which correlates with protein 
content (400x magnification). 
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 244 
 Figure 5.26 Example of the insulin staining intensity values from one islet generated 
by the Image Pro-Premier 9.1 image analysis software. The OD/Area is inversely 
correlated with the immunostaining intensity. 
 
 
 
Figure 5.27 Analysis of anti-insulin immunostaining in mouse pancreas. Both 
prolonged anaesthesia/ventilation and brain-death induction can increase the insulin 
protein content; the increase is greatest in the brain-dead HSA and RAGE-transduced 
animals, suggesting possible synergism between the effects of surgery/anaesthesia and 
those of high-level hepatic transgene expression.   
 
 
5.6  Detection of apoptosis in brain-dead mouse pancreatic 
tissue 
  
Interruption of RAGE signalling through the administration of soluble RAGE has been 
reported to prevent apoptosis and promote regeneration of liver and kidney 
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parenchymal cells following ischemia/reperfusion injury. We examined apoptosis 
within the pancreas of mice subjected to brain death and mechanical ventilation with 
and without systemic overexpression of esRAGE or the control transgene HSA. 
 
5.6.1 TUNEL assay 
 
TUNEL assay (Terminal deoxynucleotidyl transferase dUTP Nick End Labelling) is 
used to detect apoptosis (programmed cell death) by tagging the cleavage of genomic 
DNA to single strand breaks (nicks) with labelled dUTPs. These breaks in DNA occur 
during apoptosis or severe damage. The procedure was performed as described in 
chapter 2 on all 7 groups of study, each including specimens from 4 mice. However, as 
outlined in chapter 4, we concluded that TUNEL assay on either murine or porcine 
pancreas might be prone to high rates of false positivity (Figure 5.28, showing 3 normal 
pancreas sections) and we employed the alternative method of specific immunostaining 
for cleaved caspase-3 activity to detect apoptosis in situ.  
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Figure 5.28 Normal C57BL/6 paraffin-embedded pancreatic tissue sections 
immunostained for Cleaved-Caspase3 (column A) and TUNEL (column B) assays to 
detect apoptosis. A significant number of cells are positive for TUNEL in the normal 
tissue (200x magnification). 
 
  
  
  
 
Mouse pancreatic islet 
stained with TUNEL 
 
Mouse pancreatic islet 
stained for Cleaved-
Caspase 3 
A B 
100 µm 100 µm  
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5.6.2 Cleaved Caspase-3 activity 
 
A reliable technique for investigating apoptosis is anti cleaved caspase-3 
immunostaining. This assay was performed on paraffin-embedded pancreas sections 
from brain-dead mice from different experimental groups, using rabbit anti human 
cleaved caspase-3 (ASP175) (Cell Signalling) and following the protocol described in 
chapter 2. After the completion of staining, the slides were photographed using an 
Olympus microscope and camera. Pictures were taken with x10 magnification, and the 
number of positive cells per 16mm2 of the tissue were counted with ImageJ software. 
Results were analysed using One-way ANOVA and t test. Data are shown as scatter 
plots with the mean value indicated (Figure 5.29).  
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 Figure 5.29 Evaluation of Cleaved Caspase 3 activity in murine pancreas by 
immunostaining. A) Overexpression of esRAGE in otherwise unmanipulated mice does 
not alter the C-Casp3 activity, when compared to the activity level in the normal 
pancreas. B) ventilation or brain death induction resulted in a modest increase of the C-
Casp3 activity. C) There is a trend towards reduced C-Casp3 in esRAGE-treated mice 
after brain death, compared with that in HSA-transduced controls. 
 
 
Cleaved Caspase3 activity can be used as a consistent method to evaluate apoptosis in 
mouse pancreas as well it was for pig pancreas. 
The analysis shows that C-Casp3 activity rises due to mechanical ventilation and brain 
death induction, reaching the peak at 3 hours. The BD-esRAGE-treated pancreas 
expresses lesser C-Casp3 level compared to others, although the difference doesn’t 
reach significance level. 
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5.6.3 Neutrophil infiltration assessment 
 
Neutrophils are amongst the vanguard of innate immune cells, migrating to sites of 
inflammation within 6 hours after the initiation of tissue damage. Lymphocyte Antigen 
6 Complex family (Ly6) including Ly-6B.2 are expressed prominently by murine 
neutrophils and are frequently used as surface markers for identification of this 
leukocyte subset. We detected the presence of neutrophils in mouse pancreas by 
immunostaining for Ly-6B.2 antigen (using a rat anti-mouse primary antibody (AbD 
Serotec, Raleigh, NC). Immunostaining was performed as described in chapter 2 
(Figure 5.30). The slides were then examined under an Olympus DP72 microscope. 8 
random fields at 20x magnification were captured for each specimen, containing 
vessels, islets and areas of exocrine pancreas. The number of positively-stained cells 
was counted in the tissue interstitium as well as in the lumen of the microvasculature 
using ImageJ. Values were analysed with One-way ANOVA and t test, data sets are 
shown as scatterplots with the mean indicated (Figure 5.31). 
 
 
 
 
 
 
 
Figure 5.30 Anti-Ly-6B.2 immunostaining for neutrophils on mouse pancreas, 
conterstained with Harris Haematoxylin. The presence of neutrophils was evaluated by 
staining to determine the effect of esRAGE expression on neutrophil infiltration 
following brain death. A significant increase of marginating neutrophils within the 
pancreas is noticeable at 3 hours after induction of brain death, compared with the 
normal mice. This increase was inhibited in the esRAGE-expressing BD animals. 
   
BD+esRAGE 3hr BD 3hr Normal 
100x 200x 200x 
200 µm 100 µm 100 µm 
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Figure 5.31 Analysis of neutrophil presence evaluated by immunostaining. A) Brain 
death can isignificantly increase the presence of marginating neutrophils by 3 hrs after 
induction. B) A modest decline in the number of marginating neutrophils was noted in 
the BD animals expressing esRAGE when compared with the HSA-expressing 
controls, although this difference did not reach statistical significance. 
 
 
5.7 Discussion  
 
For these studies, we were able to develop a mouse model of brain death which 
recapitulates many of the features of the human condition, including haemodynamic 
instability and systemic inflammation. Using an AAV2/8 gene delivery system, we 
were able to achieve high-level expression of esRAGE in circulation and throughout 
the transplantable organs. Because mice can only be maintained reliably for three hours 
after brain-death induction, our examination of changes in gene expression or cellular 
infiltration was necessarily confined to this early period. Similar to published reports, it 
is likely that damage to the pancreas and islets which is initiated during brain death will 
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be amplified by islet isolation and/or transplantation. In subsequent studies, this model 
will be extended to incorporate those later processes. 
 
Only the earliest stages of neutrophil infiltration are apparent within three hours of BD 
induction. The effect of esRAGE in reducing the number of marginating neutrophils 
detected within the pancreas at this time may be mediated through a reduction in 
expression of neutrophil chemokines such as KC (the murine equivalent of IL-8) and 
MCP1, but also through a direct effect on adhesion, as RAGE is a known binding 
partner for the leucocyte integrin Mac-1 [143] and esRAGE could disrupt this 
interaction, preventing neutrophils from binding to the endothelium. 
 
Release of DAMPs such as HMGB1 follows a biphasic pattern. Whilst pre-formed 
HMGB1 is released into the circulation within three hours of the induction of brain 
death, upregulation of HMGB1 gene synthesis has typically been reported to occur over 
several days after an acute ischemic insult, and TLR4 upregulation is seen over a 
similar timecourse [205]. In contrast, upregulation of cytokine and chemokine gene 
expression in pancreas was noted by three hours post-BD. esRAGE overexpression was 
generally associated with modest reductions in cytokine and chemokine expression, 
though these differences usually did not reach statistical significance. esRAGE can 
prevent RAGE signalling almost completely via sequestration of RAGE ligands or 
prevention of RAGE homodimerisation at the cell surface. However, the extent to 
which esRAGE inhibits signalling through other pattern-recognition receptors depends 
upon the extent to which these receptors are engaged by ligands which are shared with 
RAGE. Whilst HMGB1 is paramount amongst these, other ligands for TLRs will be 
unaffected by esRAGE overexpression, as will ligands for other PRRs such as RIG and 
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NOD-like receptors. Regulation of expression by alternative PRRs may explain why 
IL-33 expression in the pancreas appears to be increased in mice transduced with 
esRAGE. 
 
Complement and TLR signalling are activated by common ligands and there is 
synergistic yet complex crosstalk between the two systems in shaping the innate 
immune response. For instance, C3 expression and deposition and serum C5a are 
increased in wide type mouse intestine after IRI, but not in TLR4 knockout animals, 
whilst treatment with a local inhibitor of complement can reduce TLR4 expression 
following IRI, indicating the close interaction of these systems [356].  
 
Following brain death, increased C3a serum levels, local and systematic complement 
activity and deposition have been reported. Moreover, clinical transplant biopsies show 
an even greater extent of complement deposition compared to those from animals [229, 
357]. Higher levels of C3 activity in the brain-dead donor are correlated to increased 
expression of the proinflammatory cytokines TNFα and IL-1β, as well as to endothelial 
activation and expression of the adhesion molecules VCAM-1 and E-selectin. Given 
the intimate link between complement expression and TLR signalling, it was surprising 
that complement levels in BD mice should be reduced in comparison to mice subjected 
to anaesthsesia and prolonged mechanical ventilation alone.  
 
Both esRAGE and HSA vectors increased pancreatic insulin mRNA expression in the 
steady state and significantly increased pancreatic islet insulin content was evident in 
the BD mice transduced with either of these vectors. Although the mechanisms 
contributing to this increase are unclear, it is possible to postulate that complex effects 
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of high levels of transgene expression in the liver upon glucose homeostasis may be 
involved. In further studies, it would be possible to substitute administration of 
recombinant soluble esRAGE for use of an esRAGE-encoding vector to avoid any such 
effects. 
 
One striking and unexpected effect of esRAGE overexpression was increase in 
transcription of the NKG2D ligand RAE-1. RAE-1 expression often accompanies 
cellular proliferation [358]. The pancreas recovers from ischaemia-reperfusion injury 
through regeneration and proliferation of its parenchymal cells, and such cellular 
proliferation is promoted in situations where RAGE signalling is interrupted, such as in 
the presence of soluble RAGE [359]. Another possible factor contributing to the 
increased levels of RAE-1 in esRAGE-transduced mice, is the reported reciprocal 
relationship between RAE-1 and levels of various pro-inflammatory cytokines. 
Downregulation of RAE-1 protein expression by factors such as MCP1, MIP1, IL-1α, 
IL-1β, IL-33 and TNFα, has been described in salivary gland [360], another exocrine 
gland which may behave similarly to the pancreas in this regard. Expression of RAE-1 
or other “stress ligands” could potentially increase the susceptibility of the pancreas or 
islets to attack by CD8+ T cells and/or NK cells following transplantation. However, 
given that RAGE itself is also expressed by activated and memory T cells, suppressive 
effects of esRAGE on T cell activation and function may outweigh RAE-1 expression 
in determining the outcome of islet or pancreas grafting in the presence of esRAGE. 
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Type 1 diabetes mellitus is an autoimmune disease, with a growing global prevalence 
estimated at 0.2-0.5%. Short-term complications of T1DM include hypoglycaemia, 
ketoacidosis, and infections. Long-term complications comprise microvascular and 
macrovascular complications, leading to end-stage organ damage. Treatment of type I 
diabetes mellitus with exogenous insulin prevents ketoacidosis, but can contribute to the 
development of hypoglycaemic episodes, sometimes accompanied by hypoglycaemia 
unawareness, as insulin therapy cannot respond to the constant changes in blood 
glucose.   Pancreas, or alternatively, islet transplantation have the potential to restore 
normoglycaemia and reverse the long-term complications of diabetes mellitus, while 
preventing the life-threatening hypoglacaemic periods, even when unable to procure 
insulin-independence [14, 15].  
 
Currently, donor pancreata comes predominantly from deceased donors and their 
availability is extremely limited. Donor brain death has detrimental effects on pancreatic 
tissue, which is very sensitive to ischemia, release of proteolytic enzymes and nucleases 
from the exocrine pancreas amplifies the inflammation. Moreover, when pancreatic islet 
procurement is undertaken, the damaging effects of isolation compound the islet’s 
susceptibility to the deleterious consequences of brain death. Brain death in 
combination with exposure to enzymatic digestion and cold ischemia during 
purification, results in the expression of proinflammatory markers such as tissue factor 
(TF), MCP1 and IL-6 [213, 222, 267, 361, 362].  
  
Expression of tissue factor and monocyte chemoattractant protein (MCP)-1 by islets 
triggers the instant blood mediated immune reaction (IBMIR) following intraportal 
infusion. IBMIR consequent upon the exposure of islets to whole blood induces 
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coagulation, neutrophil infiltration, and extensive loss of islet mass with poor 
engraftment [363]. For the islets surviving the initial stages of IBMIR, the 
proinflammatory microenvironment which has been established within the graft after 
the successive insults of brain death, isolation and IBMIR contributes to the severity of 
subsequent rejection and opposes the development of immunological tolerance [72, 
222]. 
 
The present lack of a sustainable source for β cell replacement compels us to explore the 
possibilities of islet xenotransplantation. Porcine insulin is active in humans, and the 
relative compatibility between porcine and human glucose homeostasis suggests that 
porcine islets, and particularly porcine neonatal islet cell clusters (pNICCs) are a 
feasible alternative source for insulin replacement. IBMIR triggered by porcine islets is 
particularly intense due to pre-existing anti-Gal antibodies, although the severity of this 
reaction can be attenuated when islets are derived from genetically modified pigs 
lacking the Gal epitope. Various strategies to overcome the xenogeneic barrier are being 
proposed, such as immunomodulation, genetic engineering and immunosuppression. 
The ability of such strategies to promote the acceptance and function of pNICCs is 
being actively studied in a number of experimental models [99, 105].  
   
Interventions to reduce inflammation in donor pancreata and isolated islets are urgently 
required to increase organ availability and improve the outcomes of pancreas and islet 
transplantation. Anti-inflammatory treatments, optimised donor management protocols 
and immunoalteration techniques are amongst the strategies being vigorously pursued 
[89, 114].  
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 In this project, we evaluated the effect of three potential strategies for the attenuation of 
inflammation within donor pancreas or islets. These were:  
 
1. Treatment of porcine neonatal islet cell clusters in culture with recombinant human 
activated protein C. 
2. Use of a hormone resuscitation protocol instead of conventional pressor support with 
noradrenaline or other catecholamines in a porcine model of brain death. 
3. Overexpression of the natural soluble anti-inflammatory molecule esRAGE (a decoy 
receptor binding HMGB1 and other danger signals) in a mouse model of brain death. 
 
 
Treatment of porcine neonatal islet cell clusters with rHuAPC 
 
Recombinant human activated protein C has been reported to reduce IBMIR in vivo and 
in vitro through anti-coagulation, fibrinolysis and NF-B inhibition pathways [117] 
When human islets were exposed to ABO-incompatible blood, APC protected islet 
integrity in a dose-dependent manner [305]. Treatment of murine recipients with APC 
during intraportal transplant reduced endothelial activation in the recipient, increased 
engraftment and functionality, and reduced immunogenicity and apoptosis in biopsies 
[306].   
 
We studied pNICCs during a 14-day-culture period. They carry a considerable amount 
of exocrine tissue for the first few days, shedding this mostly by day 3 post–isolation. 
When the expression of a panel of genes was investigated using quantitative rt-PCR, 
maturation of the pNICCs during the 14 days in culture was accompanied by a gradual 
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increase in insulin mRNA levels. The expression of most proinflammatory mediators 
typically reached the peak by day 6 of culture followed by a reduction. However, stress-
induced ligands pULBP1 and MIC2 increased and remained elevated.  
 
Protein and mRNA sequence comparison of porcine and human protein C reveals a high 
level of similarity – the mRNA sequences are 83% identical, with 74% identity at the 
protein level. The thrombin cleavage site on protein C is completely homologous in pig 
and human. Endothelial protein C receptor demonstrated a high level of conservation.  
In particular, 7/10 of the residues recognised to be involved in APC binding to EPCR 
are identical between pig and human while the remaining 3 residues were from similar 
families. 
 
According to these findings and the literature, we proposed that rHuAPC should be 
active on porcine tissues. When porcine aortic endothelial cells were treated with 
rHuAPC in culture, they produced a small increase in IL-8 and MCP1 levels suggestive 
of possible APC activity [195, 196], although alterations in gene expression were 
modest when compared to those resulting from culture itself.  
 
Whilst EPCR is characteristically found on vascular endothelial cells, expression of this 
receptor in cells of non-endothelial lineage (e.g. keratinocytes, tenocytes, lymphocytes, 
monocytes) has been described [192] EPCR gene expression was detected in pNICCs. 
However, we could not identify expression of the receptor at a protein level, and it is 
possible that mRNA expression in pNICCs originated from vascular remnants, that 
mRNA transcription is not reflected by the presence of EPCR protein at the cell surface, 
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or that EPCR previously present at the cell surface has been cleaved by enzymes such as 
ADAM 17/TACE. 
Although APC has a half-life of 20-30 minutes in circulation due to inactivation by 
serum components, its biological effect has a much longer duration: twice-weekly 
dosing with rHuAPC protected NOD mice from the development of autoimmune 
diabetes over a 10 week period [308].  Distinct from the results obtained when PAECs 
were treated with rHuAPC, treatment of isolated pNICCs with rHuAPC in culture did 
not result in any change in the gene expression profile. The absence of detectable EPCR 
protein on the surface of islet cells along with these results suggests that the addition of 
rHuAPC to culture media is not likely to be a useful intervention for the reduction of 
inflammation in porcine islets. In contrast rHuAPC treatment of the recipients of 
pNICCs could potentially attenuate IBMIR and islet graft destruction and should be 
further investigated. Lack of penetration of rHuAPC into the islet clusters in addition to 
overshadowing of other pathways are some other propositions for our observations. 
 
Effects of hormone resuscitation on brain-dead pig pancreas 
 
Adult pigs were subjected to brain death and two different donor management 
protocols, hormone resuscitation (HR) and standard pressor support with noradrenaline 
(NA). 
Animals receiving HR maintained higher mean arterial pressure, lower heart rate and 
increased stroke work. HR was associated with better renal and pulmonary function and 
preservation of morphology in pancreas biopsies; although serum levels of the 
pancreatic enzymes amylase and lipase and various parameters of liver function were 
comparable between the two groups. Of note, amylase and lipase are late markers of 
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damage after pancreatic IRI. These features are indicative of superior haemodynamic 
status compared to the NA-receiving group.   
The pattern of gene expression for a number of inflammatory mediators was evaluated 
in whole pancreas specimens – these genes included danger signals, pattern recognition 
receptors, cytokines, chemokines and stress ligands downstream of TLR signalling, as 
well as the protective molecule A20. Expression of pro-inflammatory markers was, in 
general, upregulated in pigs receiving noradrenaline, whereas expression of these genes 
either showed a more limited increase or was downregulated in the HR group.  
 
Activation of the complement cascade contributes to inflammatory events following 
brain death and helps to trigger adaptive immune responses against the graft. The C3 
mRNA level in pancreas was measured by RT-PCR, showing reduced gene expression 
in pigs treated with hormone resuscitation compared with noradrenaline-treated 
animals. This result is in accordance with the overall reduction in proinflammatory 
gene expression in the pancreas of HR pigs. 
 
Whereas the islet content of insulin was less in the pigs receiving noradrenaline 6 hours 
following BD than at baseline, insulin mRNA expression was increased in this group, 
implying that insulin synthesis was increased in an attempt to maintain glucose 
homeostasis, potentially contributing to islet stress. In contrast, HR pigs receiving 
exogenous insulin as part of the hormonal cocktail maintained islet insulin content with 
reduced insulin synthesis. 
 
Given these results, it can be concluded that hormone resuscitation has beneficial effects 
on pancreatic inflammation and islet integrity. Possible mechanisms include: 
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 1. Improved haemodynamic status results in better perfusion of pancreata, less 
ischaemic damage and therefore less release of DAMPs. Therefore, the innate immune 
activation of the organ is diminished. 
 
2. The methylprednisolone within the HR cocktail exerts direct anti-inflammatory 
effects. Application of glucocorticoids, and commonly methylprednisolone as part of 
the invasive donor management protocol has been shown to support organ perfusion, 
recovery and possibly survival [348]. However, corticosteroids can suppress the 
inflammatory response in tissues as well; anti-inflammatory properties of these agents 
are propagated by the binding of the corticosteroid to glucocorticosteroid receptors 
(GRs) and translocation of this complex to the nucleus. This results in two subsequent 
events: downregulation of downstream proinflammatory molecules by suppression of 
co-activator molecules with intrinsic histone acetyltransferase (HAT) activity such as 
cyclic AMP response element binding (CREB) binding protein (CBP) which are 
induced by NF-κB (trans-repression); and upregulation of anti-inflammatory genes 
[such as NF-κB inhibitor IκB-α, Annexin-1, Antileukoproteinase Mitogen-activated 
protein kinase (MPK)-1, glucocorticoid-induced leucine zipper (GILZ),] through direct 
binding to glucocorticoid response elements [364] in regulatory regions, promoting 
transcription of these steroid-sensitive genes (trans-activation)[349]. 
 
3. The methylprednisolone component of the hormone cocktail induces A20 expression, 
which then mediates anti-inflammatory effects. As a negative feedback regulator of 
innate immunity, A20 is directly induced when signalling by any of the activators such 
as TNFα, TLR4/IL-1, NOD2 or IL-17 leads to NF-κB translocation [177, 180]. This 
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serine ubiquitinase mainly acts through deubiquitination to suppress inflammatory 
signalling, deactivating RIP1 in the TNFα, RIP2 in the NOD2, and TRAF6 in the 
TLR4/IL-1 and IL-17 pathways. It has been shown that corticosteroids selectively spare 
the expression of anti-inflammatory targets of TNF through context-dependent 
cooperation between GR and NF-κB [350]. This finding can explain our observations 
showing downregulation of multiple NF-κB-related proinflammatory regulators, and 
simultaneous increase in A20 gene expression in hormone-resuscitated animals. 
    
4. Low circulating insulin and hyperglycaemia caused by brain death is rectified by 
exogenous insulin in the hormone cocktail [270], this adjustment protects the endocrine 
pancreas from overload, preserves the insulin content while reducing insulin gene 
transcription in the HR group. Glucotoxicity and the related islet stress/exhaustion has 
deleterious effects on islets manifest as reduced glucose sensitivity, downregulation of 
metabolic genes, diminished proliferation and differentiation, increased inflammation 
and apoptosis [365] Hyperglycaemia also increases oxygen consumption, exacerbating 
the ischemic condition of islets [366]. While diminished islet graft outcome and survival 
is known to be accelerated by islet exhaustion - manifested by excessive release of 
insulin and C-peptide by dead β cells within the garft within 24 hrs - peritransplant 
exogenous insulin administration was shown to reduce islet exhaustion and substantially 
improve clinical transplant success[79] [342]. 
 
5. The increased proinflammatory status observed in the noradrenaline-receiving group 
could be related to the exogenous catecholamine.  Release of adrenaline and 
noradrenaline into the circulation following increased intracranial pressure or sudden 
hypovolemia induces a strong inflammatory response. Engagement of α2-adrenregic 
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receptors upregulates synthesis and release of TNFα and leads to translocation of NF-
κB, initiating production of downstream proinflammatory molecules including IL-8, IL-
1β, and IL-6. Release of TNFα, IL-1β, IL-2 and IL-8 into the circulation after 
reperfusion in human liver transplant recipients is correlated with increased levels of 
noradrenaline administered to the donor for blood pressure maintenance [346, 347, 
367]. 
  
Neither TUNEL nor cleaved caspase-3 staining was significantly increased at 6 hours 
after induction of BD in either treatment group compared with baseline. However, we 
did find that TUNEL staining of both porcine and murine pancreas substantially 
overestimated the numbers of apoptotic cells when the results were compared with 
detection of cleaved caspase-3. According to the literature, TUNEL assay may detect 
single-stranded DNA breaks with free 3’-OH ends that appear during DNA repair. High 
levels of false positive staining can also occur in tissues with high rates of protein 
synthesis and are ascribed to DNA strand breaks happening during RNA transcription. 
Moreover, tissue deoxyribonucleases can degrade genomic DNA within samples. Thus 
the TUNEL method should be accompanied and verified by other parallel detection 
methods including Annexin V, Caspase activity, single strand DNA, etc [344, 345]. We 
attempted to identify the extent of apoptosis in pancreas using a third method, DNA 
laddering. Detection of the typical cleavage pattern of genomic DNA by endonucleases 
upon agarose gel electrophoresis, yielded only smears of degraded DNA from pancreas 
samples, where the typical ladder pattern was observed in mouse splenocytes treated 
with etoposide. The exocrine pancreas contains high concentration of nucleases as well 
as proteases and degradation of genomic DNA by these enzymes during the extraction 
process make this technique unreliable for the detection of apoptosis in pancreas. Thus 
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we propose that apoptosis detection results from pancreas or islets should be interpreted 
with caution. 
 
 
Systemic overexpression of esRAGE 
 
Signalling through pattern recognition receptors is central to the inflammation which 
accompanies brain death and ischemia-repercussion injury. Endogenous soluble RAGE 
(esRAGE) acts in two ways to block this signalling. Firstly, esRAGE is a soluble decoy 
receptor which sequesters HMGB1, S100B and other ligands for the pattern recognition 
receptors TLR2, TLR4, TLR9 and RAGE – in addition, esRAGE forms heterodimers 
with transmembrane RAGE, thus preventing signal transduction [149].  
 
We have used an AAV system to achieve systemic overexpression of esRAGE in mice 
undergoing brain death in order to determine whether this could attenuate inflammation 
in pancreas and other transplantable organs. 
 
Overexpression of esRAGE was well-tolerated, without liver inflammation and could be 
manifested for at least 100 days after transduction of mice in-vivo with AAV-esRAGE.  
The mouse brain death model recapitulated features of brain death in a clinical setting 
with an initial spike in mean arterial pressure followed by a slow decline, and 
tachycardia which was sustained. Serum levels of proinflammatory cytokines and 
chemokines were upregulated up to thousands of folds within one hour after brain 
death, and both HMGB1 and S100B were released into the systemic circulation with the 
greatest levels being attained at 3 hours after the induction of brain death. These soluble 
mediators may originate from multiple sources. S100B is particularly abundant in the 
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CNS but can also be released by other damaged tissues. Cytokines and chemokines such 
as IL-6 and IL-8 can be synthesized by a variety of parenchymal cell types, while 
HMGB1 is ubiquitous, and is released either passively following necrosis or actively via 
a vesicle-mediated mechanism from stressed cells. Gene expression of proinflammatory 
mediators in the pancreas was examined in mice at 1 and 3 hours after the induction of 
brain death, in normal controls and in mice undergoing mechanical ventilation for 3 
hours but without the induction of brain death.  
 
Gene expression of inflammatory mediators was not influenced by esRAGE in animals 
without surgical manipulation.  Levels of proinflammatory molecules, including MCP1, 
MIP2, KC, IL-6, IL-1β, TNFα, and IL-33 were upregulated by brain death and generally 
also increased by instrumentation and prolonged mechanical ventilation over 3 hours. 
Expression of these proinflammatory genes in pancreas was modestly reduced in 
esRAGE-expressing animals compared to the control groups. esRAGE is thought to 
suppress both TLR and RAGE signalling through sequestration of RAGE ligands or 
prevention of RAGE homodimerisation at the cell surface, which downregulates 
proinflammatory cytokine and chemokine production. However, the extent to which 
esRAGE inhibits signalling through other pattern-recognition receptors depends upon 
the extent to which these receptors are engaged by ligands which are shared with 
RAGE. Whilst HMGB1 is paramount amongst these, other ligands for TLRs will be 
unaffected by esRAGE overexpression, as will ligands for other PRRs such as RIG and 
NOD-like receptors. Regulation of expression by alternative PRRs [368] may explain 
why IL-33 expression in the pancreas appears to be increased in mice transduced with 
esRAGE. 
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The protective molecule A20 was upregulated in response to brain death and also 
ventilation. Levels were lower in esRAGE-expressing BD animals compared to the 
controls; the mechanism might involve general suppression of NF-κB signalling by 
esRAGE overexpression.  
 
Interestingly, gene expression of retinoic acid early inducible gene 1 (RAE-1) was 
substantially greater in the esRAGE-expressing BD animals compared to the other 
groups. RAE-1 expression has been observed to accompany cellular proliferation [358]. 
The pancreas recovers from ischaemia-reperfusion injury through regeneration and 
proliferation of its parenchymal cells, and such cellular proliferation is promoted in 
situations where RAGE signalling is interrupted, such as in the presence of soluble 
RAGE [359]. Another explanation for RAE-1 upregulation might be provided by the 
reciprocal relationship between RAE-1 and levels of various pro-inflammatory 
cytokines. Upregulation of this ligand is shown to be independent of TNFα [353], 
distinguishing its pathway from TNFα-induced cytokines and chemokines. In fact, 
RAE-1 can be downregulated at a protein level by factors such as the proinflammatory 
chemokines and cytokines MCP1, MIP1, IL-1α, IL-1β, IL-33 and TNFα, in tissues such 
as salivary gland, another exocrine gland which might behave similarly to the pancreas 
[360]. NKG2D ligand gene expression in porcine neonatal islet clusters in vitro also 
persisted whilst islet cells were proliferating, despite the noticeable reduction in levels 
of other pro-inflammatory genes. Expression of RAE-1 or other “stress ligands” could 
potentially increase the susceptibility of the pancreas or islets to attack by CD8+ T cells 
and/or NK cells following transplantation. However, given that RAGE itself is also 
expressed by activated and memory T cells, suppressive effects of esRAGE on T cell 
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activation and function may outweigh RAE-1 expression in determining the outcome of 
islet or pancreas grafting in the presence of esRAGE. 
 
Overall, the most promising therapy for attenuation of inflammation in pancreas and 
islets would appear to be hormone resuscitation of the BD donor. This therapy is 
already in clinical usage, and while the rationale for its introduction was to improve the 
quality of hearts from potential donors with unacceptable haemodynamic parameters, 
beneficial effects in pancreas and other transplantable organs suggest that HR may find 
broader application in donor management. Over expression of esRAGE showed some 
promise in reducing inflammation in BD donor pancreas, with the caveat that a general 
reduction in pro-inflammatory cytokines was accompanied by an increase in expression 
of the NKG2D ligand RAE-1.   
 
More information about the ability of these two treatments to protect pancreas and islets 
would be obtained after isolation of islets from BD donors, subsequent functional 
testing and transplantation.  It is also possible that HR and administration of soluble 
recombinant esRAGE would have a synergistic effect if used in combination. 
Treatments aimed at reducing inflammation in isolated islets could also be combined 
with the donor treatments above. Although rHuAPC may not be useful in this context, 
other manipulations such as transfer of genes encoding protective molecules to islets 
[109, 111] may confer additional benefit, as may treatment of the islet recipient with 
rHuAPC. 
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APPENDIX : COMPOSITION OF BUFFERS, 
SOLUTIONS AND MEDIA 
 
1. 0.1% DEPC H20 
1 mM of DEPC (Sigma) was dissolved in 1L of double-distilled autoclaved water by 
shaking the solution and incubated for 3 hours at 37ºC. The solution was then 
autoclaved at 70ºC for 1 hour to deactivate the DEPC. 
 
2. 2M Sodium Acetate  
8.12 g of Sodium Acetate (Sigma) was dissolved in 44.2 ml of DEPC-treated/ 
autoclaved water. The pH was adjusted to 4.0 with 5.8 ml concentrated HCl (BDH 
AnalaR). After adding 0.1% DEPC (Sigma), the solution was incubated for 1 hour at 
room temperature, heated at 60ºC overnight, then filtered through an 0.22 μm filter and 
aliquoted into 5ml lots. 
 
3. 49:1 Chloroform: Isoamyl Alcohol 
2 ml of isoamyl alcohol (Sigma) was added to 98 ml of chloroform (BDH AnalaR) in a 
DEPC-treated glass container. 
 
4. 75% Ethanol 
37.5 ml of Ethanol (BDH AnalaR) was diluted with 12.5 ml of DEPC-treated/ 
autoclaved water and stored at -20ºC. 
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5. 50x Tris-acetate EDTA buffer (TAE) 
242 g of Tris.HCL (BDH AnalaR), 57.1 ml glacial acetic acid (Histolabs, Sydney, 
Australia) and 100 ml of 0.5M EDTA, pH 8.0 (Ajax Univar) was mixed and made up to 
1 L with triple-distilled water (50x stock solution). 1x TAE was made up by diluting 40 
mL of the 50x stock solution in 1.96 L of triple-distilled water. 
 
6. 1M Tris.HCl, pH 7.5 
121.1 g of Tris.HCl (BDH AnalaR) was dissolved in 800 mL DEPC- treated water and 
the pH was adjusted to 7.5 with concentrated HCl (BDH AnalaR). The solution was 
made up to 1 L with DEPC-treated water and autoclaved for 20 min at 121ºC.  
 
7. 0.5M EDTA, pH 8.0 
186.1 g of EDTA (Ajax Univar) was dissolved in 800 mL DEPC-treated water and pH 
adjusted to 8.0 with 15M NaOH. This solution was made up to 1L with DEPC-treated 
water and autoclaved for 20 min at 121ºC. 
 
8. 1x Tris EDTA buffer 
1 mL of 1 M Tris.HCl (pH 7.5) was mixed with 0.2 mL of 0.5 EDTA solution (pH 8.0). 
The solution was then made up to 1 L with 988 mL autoclaved double-distilled H2O. 
 
9. 7.5 M Ammonium Acetate (mw=77.08)  
57.81 g ammonium acetate (Ajax Univar) was dissolved in 45ml DEPC-treated water. 
The solution was made up to 100 ml with DEPC-treated water and filter sterilized 
through an 0.22 μm filter. 
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10. Hanks’ Buffered Salt Solution (HBBS) 1X 
To 100 mL of HBBS 10X , 20 mL of Pen/Strep solution (Invitrogen), 12.5 mL HEPES 
1M solution and 5 mL of NaHCO3  were added and was made up to 1L with double-
distilled water. 10% pig serum (10mL) was added prior to use. 
 
11. HAMS-F10 medium for PNICC culture 
After dissolving 9.8 g of HAMS-F10 powder in 750 mL of double-distilled Mili Q 
water and filtering through 0.22 μm plastic filter, following sterile material were added 
to the solution: 
20 mL Pen/Strep solution (Invitrogen), 20 mL L-Glutamin 200mM, 1 mL CaCl2 
236g/L, 14 mL D-glucose 50g/L, 10 mL Nicotinamide 1M, 10 mL IBMX 5mM, 12.5 
mL HEPES 1M, 16 mL 7.5% NaHCO3. The solution was then made up to 1 L with 
Mili Q water and 110 mL of heat inactivated porcine serum was added afterwards. 
 
12.  M199 complete medium 
M199 media (Gibco), 10% heat-deactivated FBS, 100 μg/ml L-glutamine, 100 U/ml 
Penicillin, 100 mg/ml Streptomycin, 10 mm HEPES (Sigma), 50 μg/ml ECGS (Sigma). 
The solution was filter-sterilised with an 0.22 μm filter, and stored at 4 °C. 
 
13.  Collagenase type I solution (0.26%) 
Just before use, 780 μg of Collagenase type I (Sigma) powder was dissolved in 3 ml of 
enzyme buffer and sterilised by passing through and 0.22 μm filter. 
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14.  1% w/v Gelatine (for coating culture flasks) 
1g of bovine gelatine (Sigma) was dissolved in 1L of hot autoclaved distilled water. The 
solution was poured at 1ml/cm2 into culture flasks, covering the surface thoroughly, 
allowed to set for 5 min at room temperature, then the excess liquid was discarded. The 
flasks were stored at 4°C for up to a week. 
 
15.  LB-Agar  
In a 2 liter flask 10g bacto-tryptone (BD, Franklin Lakes, NJ), 5g bacto-yeast (BD, 
Franklin Lakes, NJ), 5g sodium chloride and 15g of bacto-agar (BD, Franklin Lakes, 
NJ), was placed. Distilled water was added to the mixture until the volume was about 
500 ml. The flask was covered with foil and autoclaved for 20 minutes at 121°C, then 
allowed to cool. The LB-agar was again heated and dissolved before use for bacterial 
culture. 
 
16.  Phosphate Buffered Saline (PBS) 
1 sachet of PBS powder (Invitrogen) was dissolved in 1L of d H20. 
 
17.  Tris Buffered Saline (TBS x10) 
To 1L dH2O, 24.2 g Trizma base (Sigma) and 80g sodium chloride (Sigma) were 
added. pH wasadjusted to 7.6 with concentrated HCl. 
 
18.  Tris Buffered Saline (TBS x1) 
100ml of 10x TBS was added to 900 ml dH2O. 
 
 272 
19.  Tris Buffered Saline+Tween-20 TBST: 
100 ml of 10x TBS was added to 900 ml dH2O. Add 1 ml Tween-20(Amresco, Solon, 
OH) and mix. 
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